var title_f6_48_6912="Placement of precordial leads";
var content_f6_48_6912=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Placement of precordial leads",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 302px; height: 281px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The horizontal plane (chest or precordial) leads are placed with electrodes in the designated locations.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_48_6912=[""].join("\n");
var outline_f6_48_6912=null;
var title_f6_48_6913="AC joint palpation";
var content_f6_48_6913=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62599&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62599&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    AC joint palpation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 301px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Careful, systematic palpation of the clavicle, acromioclavicular joint, and acromion can help to identify the source of pain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott Koehler, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_48_6913=[""].join("\n");
var outline_f6_48_6913=null;
var title_f6_48_6914="Colposcopy";
var content_f6_48_6914=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Colposcopy (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?6/48/6914/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/48/6914/contributors\" id=\"au6904\">",
"       Colleen M Feltmate, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/48/6914/contributors\" id=\"au6580\">",
"       Sarah Feldman, MD, MPH",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?6/48/6914/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/48/6914/contributors\" id=\"se5145\">",
"       William J Mann, Jr, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?6/48/6914/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/48/6914/contributors\" id=\"de1930\">",
"       Sandy J Falk, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?6/48/6914?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      COLPOSCOPY OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Having a regular screening test for cervical cancer (Pap smear",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     human papillomavirus testing) is an important part of staying healthy and avoiding cervical cancer. If the results of your screening test are abnormal, further testing is needed to confirm the result and determine the severity of the abnormality. Colposcopy is the test that is usually recommended in this case. It allows your healthcare provider to look at your cervix using magnification. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/53/8019?source=see_link\">",
"      \"Patient information: Cervical cancer screening (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Not all women with an abnormal cervical screening test will need treatment. Colposcopy can help to determine if and when treatment of the abnormality is needed.",
"    </p>",
"    <p>",
"     More detailed information about colposcopy is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24808?source=see_link\">",
"      \"Colposcopy\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHY DO I NEED COLPOSCOPY?",
"     </span>",
"    </p>",
"    <p>",
"     Colposcopy is used to follow up abnormal cervical cancer screening tests (eg, Pap smear, human papilloma virus (HPV) testing) or abnormal areas seen on the cervix, vagina, or vulva. Your Pap smear may be abnormal if you have cervical pre-cancer or cancer, often caused by HPV infection of the cervix. HPV is explained in detailed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/53/8019?source=see_link\">",
"      \"Patient information: Cervical cancer screening (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The colposcope magnifies the appearance of the cervix (",
"     <a class=\"graphic graphic_picture graphicRef77157 \" href=\"UTD.htm?42/63/44019\">",
"      picture 1",
"     </a>",
"     and",
"     <a class=\"graphic graphic_figure graphicRef80271 \" href=\"UTD.htm?14/52/15171\">",
"      figure 1",
"     </a>",
"     ). This allows the clinician to better see where the abnormal cells are located and the size of any abnormal areas. The size and location of abnormal cells helps to determine how severe the abnormality is and also helps to determine what treatment, if any, is needed. When monitored and treated early, pre-cancerous areas usually do not develop into cervical cancer.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      PREPARING FOR COLPOSCOPY",
"     </span>",
"    </p>",
"    <p>",
"     Before your colposcopy appointment, you should not put anything in the vagina (eg, creams).",
"    </p>",
"    <p>",
"     Colposcopy can be done at any time during your menstrual cycle, but if you have heavy vaginal bleeding on the day of your appointment, call your healthcare provider to ask if you should reschedule.",
"    </p>",
"    <p>",
"     If you take any medication to prevent blood clots (aspirin, warfarin, heparin, clopidogrel), notify your healthcare provider in advance. These medications can increase bleeding if you have a biopsy during the colposcopy.",
"    </p>",
"    <p>",
"     If you know or think you could be pregnant, let your healthcare provider know. Colposcopy is safe during pregnancy, although healthcare providers usually do not perform biopsies of the cervix when you are pregnant.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      COLPOSCOPY PROCEDURE",
"     </span>",
"    </p>",
"    <p>",
"     Colposcopy can be performed by a physician, nurse practitioner, or physician assistant who has had specialized training. Colposcopy takes approximately 5 to 10 minutes, can be performed during an office visit, and causes minimal discomfort.",
"    </p>",
"    <p>",
"     Colposcopy is performed similar to a routine pelvic examination, while you lie on an exam table. The healthcare provider will use an instrument called a speculum to open your vagina and look at your cervix (",
"     <a class=\"graphic graphic_picture graphicRef77157 \" href=\"UTD.htm?42/63/44019\">",
"      picture 1",
"     </a>",
"     and",
"     <a class=\"graphic graphic_figure graphicRef80271 \" href=\"UTD.htm?14/52/15171\">",
"      figure 1",
"     </a>",
"     ). The provider will usually repeat a Pap smear, then will look at your cervix using the colposcope. The colposcope is like a microscope on a stand, and it does not touch you.",
"    </p>",
"    <p>",
"     The provider will apply a solution called acetic acid (vinegar) to your cervix. This solution helps to highlight any abnormal areas, making them easier to see with the colposcope. When this solution is used, you may feel a cold or slight burning sensation, but it does not hurt.",
"    </p>",
"    <p>",
"     During colposcopy, your healthcare provider may remove a small piece of abnormal tissue (a biopsy) from the cervix or vagina. Having a biopsy does not mean that you have precancerous cells. Anesthesia (numbing medicine) is not usually used before the biopsy because the biopsy causes only mild discomfort or cramping. The tissue sample will be sent to a laboratory and examined with a microscope.",
"    </p>",
"    <p>",
"     Some women also need to have a biopsy of the inner cervix during colposcopy; this is called endocervical curettage (ECC). Pregnant women should not have ECC because it may disturb the pregnancy. The ECC may cause crampy pain, although this resolves quickly in most women.",
"    </p>",
"    <p>",
"     If you have a biopsy, your provider may apply a yellow-brown solution to your cervix. This acts as a liquid bandage.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      AFTER COLPOSCOPY",
"     </span>",
"    </p>",
"    <p>",
"     If you have a biopsy of your cervix, you may have some vaginal bleeding after the colposcopy. If your provider used the liquid bandage solution, you may have brown or black vaginal discharge that looks like coffee grounds. This should resolve within a few days.",
"    </p>",
"    <p>",
"     Most women are able to return to work or school immediately after having a colposcopy. Some women have mild pain or cramping, but this usually goes away within one to two hours.",
"    </p>",
"    <p>",
"     Do not put anything in the vagina (creams, douches, tampons) and do not have sex for one week after having a biopsy.",
"    </p>",
"    <p>",
"     If you have a biopsy, ask your healthcare provider when your results will be available (usually within 14 days). In most cases, further testing and treatment will depend on the results of the biopsy. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/29/2515?source=see_link\">",
"      \"Patient information: Management of atypical squamous cells (ASC-US and ASC-H) and low grade cervical squamous intraepithelial lesions (LSIL) (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/44/17092?source=see_link\">",
"      \"Patient information: Management of high grade cervical squamous intraepithelial lesions (HSIL) and glandular abnormalities (AGC) (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/57/14227?source=see_link\">",
"      \"Patient information: Treatment of precancerous cells of the cervix (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Do not assume that the biopsy results are normal if you do not hear from your healthcare provider &mdash; call and inquire about the results. Most women will need a follow up test (repeat cervical cancer screening (Pap smear)",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     colposcopy) within 6 months.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      When to seek help after colposcopy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Call your healthcare provider if you have any of the following after colposcopy:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Heavy vaginal bleeding (soaking through a large menstrual pad in an hour for two hours)",
"      </li>",
"      <li>",
"       Vaginal bleeding for more than 7 days",
"      </li>",
"      <li>",
"       Foul smelling vaginal discharge; remember that the",
"       <span class=\"nowrap\">",
"        brown/black,",
"       </span>",
"       coffee-ground discharge is normal for the first few days",
"      </li>",
"      <li>",
"       Pelvic pain or cramps that do not improve with ibuprofen (Advil&reg;, Motrin&reg;)",
"      </li>",
"      <li>",
"       Temperature greater than 100.4&ordm;F or 38&ordm;C",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1784865651\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H94723864\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/32/28163?source=see_link\">",
"      Patient information: Cervical cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/8/15491?source=see_link\">",
"      Patient information: Pap tests (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/40/33411?source=see_link\">",
"      Patient information: Vaginal cancer (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H94723871\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/53/8019?source=see_link\">",
"      Patient information: Cervical cancer screening (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/29/2515?source=see_link\">",
"      Patient information: Management of atypical squamous cells (ASC-US and ASC-H) and low grade cervical squamous intraepithelial lesions (LSIL) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/44/17092?source=see_link\">",
"      Patient information: Management of high grade cervical squamous intraepithelial lesions (HSIL) and glandular abnormalities (AGC) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/57/14227?source=see_link\">",
"      Patient information: Treatment of precancerous cells of the cervix (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37736?source=see_link\">",
"      Cervical adenocarcinoma in situ",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/42/6826?source=see_link\">",
"      Cervical cancer in pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=see_link\">",
"      Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9624?source=see_link\">",
"      Cervical cytology: Evaluation of atypical and malignant glandular cells",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33895?source=see_link\">",
"      Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28517?source=see_link\">",
"      Cervical cytology: Evaluation of high grade squamous intraepithelial lesions",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6086?source=see_link\">",
"      Cervical cytology: Evaluation of low grade squamous intraepithelial lesions",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44343?source=see_link\">",
"      Cervical intraepithelial neoplasia: Ablative therapies",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31065?source=see_link\">",
"      Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30762?source=see_link\">",
"      Cervical intraepithelial neoplasia: Management",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/17/33048?source=see_link\">",
"      Cervical intraepithelial neoplasia: Procedures for cervical conization",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24808?source=see_link\">",
"      Colposcopy",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/ency/article/003913.htm\">",
"      www.nlm.nih.gov/medlineplus/ency/article/003913.htm",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Society for Colposcopy and Cervical Pathology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.asccp.org/patient_edu.shtml\">",
"      www.asccp.org/patient_edu.shtml",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American College of Obstetricians and Gynecologists",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.acog.org/for_patients\">",
"      file://www.acog.org/For_Patients",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?6/48/6914/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 9, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?6/48/6914?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6914/abstract/1\">",
"      Wright TC Jr, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007; 197:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6914/abstract/2\">",
"      Galaal KA, Deane K, Sangal S, Lopes AD. Interventions for reducing anxiety in women undergoing colposcopy. Cochrane Database Syst Rev 2007; :CD006013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6914/abstract/3\">",
"      Cantor SB, C&aacute;rdenas-Turanzas M, Cox DD, et al. Accuracy of colposcopy in the diagnostic setting compared with the screening setting. Obstet Gynecol 2008; 111:7.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f6_48_6914=[""].join("\n");
var outline_f6_48_6914=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           COLPOSCOPY OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHY DO I NEED COLPOSCOPY?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           PREPARING FOR COLPOSCOPY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           COLPOSCOPY PROCEDURE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           AFTER COLPOSCOPY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\" title=\"figure 1\">",
"           Female anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/63/44019\" title=\"picture 1\">",
"           Normal cervix PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f6_48_6915="Gottron sign";
var content_f6_48_6915=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F75246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F75246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gottron's sign in dermatomyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5k/QGigZx6GioNw7GjtilA96MetCAMfTmk7YNLjgAYpQvpzQA3vx1pQABzRjJ7UvI9KLgJt5NGPl4H6Ue1L35NNsYmPpRilxik70twsIfoKUY3Hpz7UUY5xTYgxjmgDtSng0d+etCATApMdhS0duKSAMYoNL+NIRmi4CHgcUYzxS/UUYoATAzxR/OlxmlxRYBvvRS460lFwFAAPTj0pKXjuRig9B0+tNMBOCRR3oI4wKXFMBMfSjv0xgUHrilA70AJ160q9eetA4NKelADSMfWl2+nWjuMfrS4qWAZ4+v616d8PdfF1Zrp9w3+kwD5Cf44/8AEfyrzHvU9pPLbXEc9u5jmjO5WHY1E48ysb0KrpSufRFnJuVeAeO9a9q68vwT646VwPhHxBHrFqGyEuEGJ4geh9R7GuytW3IGBwP88VxtNaM9uFRSV0b0E4XaMAlf1q7E6s284PoMVkW3OMNz2q3AWUjJ49RU7Gl7mrF8wY4GTgepqzCcAdvTHf61n27ELkDBPepw+w7SeD15yaalZitcvrCRIHIiBwTlhnHsBWdNbqNxdsrzjirIZmXpjjvyalUbFByo459TWilczcbGDc2zAZO0nr0rKuLRmO4BnPoBxXUXDAFcrktz6VUMIdQzAAA8c/zqtCdbHA6ppcGoI0U8KlD1DrkV5r4k8GPaPJJprmWIZPksMMPoe9e7X1vtUHGBnB2jBFYV3p4kBYIPm5+c4x71cZWdmYzpRmtUfOLoQxUqQRwQRgj8KjK8EYNes+JvDNtdMXeHyrj/AJ7RNnP1HevOtZ0q50uVY5wCjZ2yL0b/AA+lbJnnVcO6evQyCMdqSpGWmEVVzAMUoWu2Hw+vyuUu7Vm9CjAfnV3Tfh1I7H+0NVjtiFyAsBbJ9M/1qOZGnsJ9jzwqfoKUoT2NepQ/DW2dSV1MvhSzEOoAx+Gah/4V7DyVkvHT+GQEBG+hxT5kWsNNnmRU5FOVDjoa9D/4QW03bWvLuNwcHcFI/lV2x+HdlNu8y9vWIHRAgzS5kP6rUPMBG3PHal8s4717Fa/D7QQ6CU3jqR98zY7emOKjbwRog3KbSVcdG85s0nNIpYSZ5Bs9qbtOcHr616xL4D0hgSi3KNjgLPn+YrNuvAVu0RNne3Ebjn98oPHp2NCqJieFmjzojANJtOPautuPBepRjMT28/qASh/Ws268N6rbs3mWErAd4/nH6VSdzJ0ZR3RiY+tJgZ56VYlgaIlZVeJh13qV/nTBGD0K/nQRZkRHPB4z1oI5zU3lDBywzSeXnowP40xWIgOaCMHrU3lsDwMijy2oAhI5xRjBqTyzjNIVPFADPxpMYpxU4o2n0oCw3tRjr7U4rijGM4zQA2ilIyOeKXbjGeMjIzQKwh4NJSmkHJoQWCig0Y96GwsJilpcYApMH/61CCwUh6Ggj86cPeqCwlFGKCDUjAUtA4FA5oGW9MvbjTruO6tH2Sp27MO4PtXtHhXX4dTs0miIUniSM9Y37j/69eGjoe1aeh6rPpF6txbnKniSPOBIvoayqQ5kdOHr+zeux9G2852nYQTVoTYUkenWuO8Pa1BqVnFPbvujJwQeqn0PvXQxO0zLGOmMt7CuKSa0PZg01dG9ZSFsEsQvYDtW5bxL5edvzNzkjoK560kCKF7eprftHZo1yww2B7iiHZlNkqLhs5JB7j+VTLs+Ubh9SO9R3AEQCKcFRyO30quDls79vvWi0JdmrliWGNuWB457ZqssQZGkCDaQTjOBUss8Kx43FvYVVkvW2gCFiOwPTA7VojJ7DZYvMUk4Cgdcfd/+vWPf24QrtZTn+9ySKu3Wp3SoQbeMJ6M+efWsO5uLq4JdnWTzO6jgfSh2CMWyO9WAIY2VdxPQDnNc3rOkw3cclvPBG6sPmz2PaukltZBD5ZdzuGDhTz9apTwzKAPn2sAuQvTHTNNOwOC2PItf8IXFtGZrLMyDrE3+sAHp/erkXhIU92zt54IPUjFe+XizKqYBfGQM4rm9Y0C21hHE8HkXW0hZkXkHtkdxW0Zo4a2F6xO5ihRVwAfypXjVRkKKUS7VyeuOtN80OM56Vha5qkVZY1ZgSi59TTR+5cGInjquTg+vFSyY2kmm28e+Reox045Jq1GxqkS3T4s/JVFMOFKyMuWxz1P6VRsQ/wA5dAkRJCnHf0FXNWQwq4Z/nB8tlzwuP/11X06J5IvL34Bb5SegIFK5vSilEtyRMpRlGPMXeVbt7iqrAu78AqpwTj2zWlOwFvblTu3LnPXocVRtpFS5ljdPMWUEHd1yAdv64oNI6oIgr7UfghSQw54qaRDHDkn5dv8AEKrhDDeWwlBRypd89hnGP0rViT7R8pj4JAPHA7j+VQ1qKSW5gtaq8gVU2j0P86uT6d5aso2juMjvV37P/powBjP6Cp7kfvABzuAwalNohwTaMaTS0usJOiS7R0dAwH51A/h3S2Rlm0myYMOSYQMflXQ20SyAk8DPT0pixv5wBB3dODxT5mQ6UWYCeGNHihO3SrLjr+5BJ9qdL4b0mXHmabZlgAMeUBx6V0MKtJuH905Az3qVIAshd15x3o5mL2UUce/hDRA+59LtCR1XaRxUbeD9CbIXTYSp5HBB+mc9K7JoFaAT7jtYkKpGM47+4qOUYU9Ap6dqfO0CoxfQ8+uvBOhuz/6JJHxgeXKRzVOD4dafLz9uu1DNgABSU+vrXocluJdqpuL9wRVFrd4ZuenfB7+tNVJIiWGg+hw9/wDC50j32mqB1HXzof8AA1iXHw91WHOZrN/TDEA/Q4r2rTmW4sysrfPGSp46+lVVQi4MSgsApIBGeKv2juZfVIPoeJyeCNaQt+4ibBx/rAM8ds1SPhbWQrt/ZtxiM4bgfpzzXud5GWu9sm4vj7q1ThtFWaRo2JCYPlsThj61SmxvAxPD20S+UrusrkBjgAxnk+nHFV5LOeASLdW0yDG7JQ8H617ozPGWELtGxBBKEKffHpWdNE/2WNc785YE/wAQz0PqRT57E/UV3PEjHgckH6U0KQf06V7TLodje+U1zaxMjE7MqBk9+n86xbzwFZlA0M1xAHBIxhlBz3zzTU0YTwclszy/HXNIV7jpXXap4K1O18swKl3GwO10+Ukjtg1jJomouqsun3RDDI/d9apNM5nSkt0ZWM9aAvqce9aZ0i+U4axuwcZOYWqNtPulGWtrgD3iYf0p3FyMz9v40uOOlX0sLltu22nOeB+6Y/0qKS3eJisiMjLwVZSCKVw5GVMHPNBHPsKm2gngrj60bR/eH50CsyHHHuKXHpUu0ZI3A49xRsz0INA7MjHcnFOGR3/CniM4IxzSqm0/MVXtyaBpGn4e1m40W9E0HzxtgSwk4Dj/AB969v8ACV/DqWnR3sJZklyBu4IwcEH3rw+x0e/vebPT7y494oGIH44r034baZr+lG4tb/SLyGykPmxvKAAj9COvesKsOZXR24WpKD5XsegwSbbjg8da3oLoALggZPQdc1hQ2awy+ZcPIT2RFwPzNX473yUYxxBQP4iK54wdz0Oc1ZpGZfl+QdBmoFeOMZLFiPXvWUdWjuOSTjpgAmni4QsfKRt2Ou3ArUl3NE3GRxHhTx702W4yhHHAzxxis4zNj5pAD9P50yJkYuZHiZCeB3NTqgSQk4jZ8osjbuM4602cxIgUALgjOFHFFwwGQUcxt0IbmqwWM7lDJljkhvapdzWxoA4jBi8pi3AO0Z+lVbiS5j4KquThtnGaieVmwoijYNxw2SDVK6gmDKQm3b2znr/Wr5gUV1FvC0xzPGcE/M0keCPxqExQmNhFvdBwcHd/9eprdmhUrlmxnG5ug/PmnpHBiR5IgjdRg8/jzmrTIkiiJAy9qaGIUkD9a5y11dHVfmzkdc1dXUF2gBue4pRt3OXVGpJKSgwOTwMdK19ICrHLc4Ui3QMAeQXJwP8AGuZW7DgY5NakNx51tFao+I428+fHU4IJ/wAK1ei0Bu6sRaomy42JcCRWG58YwTnkD1xVmQC2tY0YbZpME7uPx/GsU3ay3UoVBs3kqcc4Ld63VkiufJIRWZJBuyPv5P3cDr2xU26HXskmXpId8DI4VGhX5ucZ9D+VSQW1uYYp4hsuUyJIhn5gQcnPpxj8apzXDmAPKwbDuvzdePbtUujXri7DRY3Irbw2cOCORx0+tO1mTrbQhkt1nkha5d8wxuY22Fi+eQD+JxmtPTkYHzGYKmdjL/tkZP4AYH402xmSPTnn3sqPE3kQk9i2AD9T39quFViuLe1UrkbVeT+82csf5j8KnRag5t6DFt4nlknG0PgxAerc5P8AKqd1buyx4kAyv3l6VdV0+zfKwRQWyc8sxJ5/Him3uCqRkgIVxxyFPUfoalpWCLsVYYfJUhOVBwBnPNOMRa5AiHrnJ/KtM28cVqojCu2GZyCdxOcZPp07etMlhUSBScMsmJGXncQOMe2MUONg57kNpEsUjlQC2M+2MVHNJiORBnfyKtmMyW5mGF2yIGYDoGbH6GqyJ++2yHjkFsdaLDhrqWhbR+QyA5aJByenTJGO3NQy2tu8DyDeTGQGjY4Bz6GpYJfLilVwGZnEeQeuB60ydGExWVgrZGQOuTV2TQ9SuYVWN9pK7PmCltw9KyLlV3vFyxyBkdRWnqMyo+Y84B5LHPPpWMrSs5nBwXfCt79z9BSaSY4odoxf7bcpnBaNQwHGcEnH5U+S4MGqW8sEpHzbGYLkhW4p+mqA11/GodUBxwcA9PXk0l3buNTtDtwHmTbkcMM/5/KpaskVZXZan+S8OQWIbr+nNU7mF4yY8gRqxX2KjNa96ivK+7OM4OVxg+1U7qMbP3rB2OMA8fiKrZjWxl31lHBdSQJy0QCkMeT3/Lmq3k7JoyVDfvdqrj5QmOfzP8q0JoGP79HLso5HX8CfpTVcT3A3jAI2qo9elPoOxnXiSM0JaNUWJRCqjgbR6fmTVhMSRhZFCnv3H/66u6rHuZI8DpjI7VVNurSNHk5Ug49KhuwnDmQ+GHdG0MqhocblyfukdxVNIY0n3nhXJ3ZH8Xb6VtRwFIGlYliQBtPT3rNMbGQFyQpGRuHSktDNU7q5LHFbu+18qw+UkkkE0+aw8w/Ic9znnFSquF3s5YcAAjDflRvILbt4OOcHJX2NVzD5GhkFuwB6qM/UCopoFdgQoznY5Kg/StOIKsDqwJ3dM+tNSCOMBmdg3cgZ20XuxqBzlzotm7P5tjbSE9P3Y/Xipo9As9qqbK0RGIwoiUKB+Wa3JYw0Zb5nAAztHT6mm+ZuYbgA7/ezzx/niquV7NdihHpFiFbZa26xsMBRCpBHqeKzbvwzpBQyNpdnJGrYyEA5NdQ6xEAR7g2Ody8Csa4ePziWJ2ZxgHGT64oegKkpdDA/4Rjw/GxLaTbEk4w24j9DW3p1jotgq/Z9GtbduQJoow7N+JqUWYMRXBLAFgcjp61Hpty3/HtKvysd23pzRsRKjHsdDbSNdRsbe/VlAxtY7eKZcSS2qKblCobkHOQfxrL8ryb4OiPsyGZUOGI9j0qW31RsCKQHYeCMBh9f/wBVSyfZW9C0JY5VIR5Vfvu55+lQzJNICivtQcbo2PP0FWp1jkEZjVWXbkSr1PsfSm2tsryBHKxrjCs5yCfr2pFWSV0UUjnZlJkbkHlQACatxSsj/vCR6Ecc1aJQNsfhyc5Pf8aiIQk7W3PjhD1PNS1cTuyUSts3SqxjA5JANMjCTKrRyJtPcrwKYZiuUki+de69Pzqp9oDysIpCBj7pFFgUWTzqysQ64x3Q1XS3Vi5AY56ENg57/nQ08sQ6YHYg8ipEvEKDzlxt5yowc+9IrVC29qIfniDR5HzHYGJqUSF3JSXcc4w0dDXJEYKumw88nBpRIHOVUyDGcjpT0Wwr3GyLKrDyhH5ZGWwvH4g1UniR/lKk7fTir5hSSNhCXVsfdJyM+lQyxbS5CHd1IA4/A0BoeK6HqOlXrKWhUP8AxoWK9e49a1YhEpzHNKsfOCGDA/nzXlwOGBBIPUEdqvwavdRgCQ+aB0LcH866HT7HlUsWtpnqmnwRzOFOopGT0Mq1auphYXHlWjGU7NpldtvJ6nA7e1eYwa9hfn3L7GtK21lX2ssh46ZNZyj5HXTqQk7qVzuLWQRv8u0Ec5zkH/GtaG8EQ3I21ieMHGDjqK4SHVgR97BrQg1PIB3ClzWOjmUmdQk4jnbzfn7Zzn6VLFfkBhHIyttK5Bxweormo7zcDjknsOwq7byo2G39e3pS5rl9Dq9OujLPDFkeXHg59h0FX3mMlw+WIZiTntzXKW999nDndksfyxU1vqhVg4bLFSOtS30Mzq2uFOVfGFHX14xT7ecb/wB4oCkgjHfA71z63ytGTU32lWVgvTBApBc6GC7VUY53Z7Hvz0qeKVGmkfftdjuUH1PX9K5mG5GMyHIArRFyMMwHGapS7iaRotef8S+5iOQWxgg9g2TVq2kR5FwiLhsoQegxySax0IYKjEkNuX6ZpZLkQoFwBlOmepHaq5tLsaepc0grLLPDIMRwgsxHPU8Yq4Z7dTK0rO8h4Lbd2ff61jaXdpH50vADIFC/3c9efWp7e5V5XZ+OSAMfdpKVki7XuVr64Zx5MKeWmSwLD5snj8vakiAmIZo1RYl2qiDIGO59TV65gjkaJIuXP7xncYC+g96jt0HmOG+UJk5HeizuNtWLlhbi2s0eRcC3TzpM4PzevuSSOKksbQx3el+YSxiR7hiDkqQDge3JqDzTNcW9ki78ETzDHQL2+mSK1zOlrIZpArIoAxnqAOn50731MnJrQzb9G8wbiVZnEbE/3iR/jVa+jEsphkjbZArIzDuBnmrEm++KnayNPMGY56LjOasQSxtc6kvE1vPEVjeXr6An04zSTuaKXKZD2v2d1ihUh5YsDLZDZAw31welNSOOe5t5LdX2xw72U9d3Qc+nBPtVzLJDbSNiRoY2iXrkejfSrEULWySoFVZGRsqO4I/lVbg6lmZFzDsihbcCo3ZAPOf60yNAtyM4yCGwP5VckUs0IAxEUUkHv3PPpToYEjvYlIATeGDeinsTUSNOZWLlujxpNb7hJC7FwhXBX8ff+lZcFuXnaNVJI4UVv3ZjMMs4Y4kXcF79cL9QAP1qkHe0lBPFweSMdOMY/Cm1d2JhqtDLNssZ2yxkOORz0/xq3DaK5DTEZboR6+578UkiFHC7hHhs7mz+dOjvFdnMR2qnyxg9z6ntQuxq02ILTzXPl/dQ4yOpP0pJIERrh45PN8mRSGxkSLnB/Co47p8PHGSP4Tg9QKhWU7WRQyxhduFGRtPWnokPlZJDERcZUsHkbEaqRgk9iO4omtlFw22IQSKNrbMlG/3c/wBKEkhSMhlDsigRkdWY8c/hT0do2V0YSAHAw2QuP/r09kLqQ3IbiNRJ5rfdGOfpiqT2rGD5gPMRiM9Tj0NatzcjfEXkLGMbcY9+/p1pCrTyvKq7yOuOOKL2Gm0c8JihCYwwPbqRVa5dfPBjYfvAGwOcVtXJhmYDywoAyWU4OP6VjXNu3nu0Y+RflGeq0mFtTZsp94RXb5lGFOfXt7ippbOOWzcBNskT7g6n+E+317ismwiZoFRXXzA2VOe1aVrcPGxiKFZScMSeo9TUqXQze+hWUvaOqXGQOokHce470Nfs3+rnQxdMfeU/4VoXkaXdjKqMu+L5xnqR7fSsG3XyBlBtcfex93ntStqTcurclZCkpUxuceu0+3tVlpo9x43Rgcg8kH69x3rBZo7lvLXdA6n8DV/S18puccHG4n9D/Q1NmmLU1YXadBsKhc5yVxTBapPNvDgSA9MfpSJGI1UQlsDll7/UipIZRIwVlAb+8OlV6jfkJPbtCpeaNmU9SORUb2qSAGPkMASrd61DKzELIQ8eMbgOfpVJ1UlVjbypcnbjkEe9NqxF29CA2DGFPIMfPJAfkYpLRvLmYQrsKn7pbGPwqVZwVMbINx4O1eagkKtJtQEDPJP8qLoVmXJ74bSs42Pk7XjPAqrDJ5SO7Ssyk5JXr9KsxyRSOMoHjIxiM+g9/pQ8EcrMUdl77SMUnq7oVj5T9qPx/CjP8qABXcfPCg8Hv9aBjjA5pB05pc98jNKwEsc0iD5ZGHtmrMOp3MbDkMPcVRPWgemeKXKnuXGpOOzOhtdfC/6yNlPqDmtW38QWzf8ALTaffj864oE5z2oPPXFZujE6I4yot9T0CPVInHNwGPoKmi1LaOJQR1rzoADpx6VIlxNGfkkce2c1Loo1WO7o9Qh1oABWIB9a0YdTDA4IOfevJ49RuVwCVYe4q7DrsiY3Bx9DmodKS2NY4uDPVVv8gEVfttRwoUnI/lXl9t4kUECQgfpWpb6/C33ZBj61HIzZVYy2Z6KuoMUwCSV546jHpT7m9jnRQcEqdwOOxri7bVYHIKybW9jWpBOrZ2t8pORtPAo1NE0aztNHCwiKyRMc5PVfpRYajPASkx+X1OearwyGFyBIWiPUdxU6iN127t/cA9qViuextnV42Clic4ytNl1IbcljkDOAaxRZvvHlqxPotaFtYxwASXrBsciPtn39aXvAnE3NCcw2810+VkuVAGeojHI/M8/lRdStMfmbPYEVlfbTcPuGAg4q5Zuu7Lt26ZpN9CvM2JmkRBGpOxgAwz2qBZjEcCPzU6ruOOapSXpdyACue9JHJ5rAtjAHaq5uwWNyyZDFN5gP73KkfXnj8ailkBkhYADcnl8+1VbOTMyK2AuMDHHFTSq+SAfuvn8Krn0M+WzJI1HkWuQGZXMeG7ClvRzPmPduiKrjjB9aLkkSIuMqGXkcdqsXSqXjUMVGNx4z3p3uCk0QXqtNbQxxMdxdevsP8RUsVq1y/wC8GZdpZj0z9KktsSXyFlKxR53/APAun8iavIob/VjHmNuz/dTPT29aEle5XtGtDL+zPdXwZkzFGoyqnOcD/wDVmqdlaKzlGQMz/IuOgHqPc10MqeURsyCh3KRxiqU6NGqumNyMrNnggnkH9KVrGsKjaMaaFIJJoWjJkU4KMCChz3qlKRCFdvvZJ244/EV0utiO6uRcQlnKjG/qWJPU1li4e2cSqFdgSV+Xrn271UjaM21coIpnEabvJ2NlZDx1pkNwkE0Sxw/JnhyflyDyT61eaNHjJkU4YZyenr/kVQuL23jDAEEZ5HQfhxSuNSvoWEkaRvl24J544696kWJtx3ZCE53DgH2qETwTGMh+nzBD90fl1qaESTeZ8/mJnseB9fahy00JZTaNgrrAA2Tz3zVK3h3SBH/dn+6Dya0XgMEgMZbaWwuznn0qvKxdgxUbQMDA5xUyu9Sk7kps2gnOFwxxlAefwqxdtsMJUHKptmz1z3qG2umEeH5jJxu6sKsi3CyFeAGHGDkPSdraENK+om8jypI0UTLlX9G/D6VQaIJDJt4LjBB5wQejVagUIVT5sOcAmp5dnyhcmQcNx1I9aSk2TboZKxQSupRAVU8ZGOPamspSRxHgqRgrjK1qbWYhkCsvQjHIqsVYuW/jB4K9/Yim2LlKsLXCTK7jMLfdYdfwq/HMspYuRG5GDgcN70y5tndVkUEjqQOin0qtNuiP70AsPlwOR9Kq1thWuXYpyinBBA9OuKVXjbDP95uOv61TiuImUeXIpbptHUVNG24LmPJHOVFSmFi1LBhFZcSLyCR1WqfkiKTcFZ0P8W6pYbgW9xujb5WOGz2q8UE2ZEZYiOmOQT602ri2KNkLeR2SDckvfDfeq0TGXJmCuTxhkxVV1kiO9o2ILZD7evryKn+0RyZEoCMRlWHTPvSXmDXY+UegNFHbFJjBHtXefNC0Dg0UfhQAp+tIMHNL1FGOvvQAUtJ9BRk+lACgnNHeg4xxRntSAUDJ4oHFIMYpeM0DD2NOyM4wQRTaUDngYosBMk0qcrKwPsavWms3tu3yybh6Gsw5zwPxoOQfQ5qXGLLVSUdmdbZ+MJYRiaJ/qpzW1B4stZ8cMr+1eddOaT09qzdKJ0RxU1vqes2/iInCxXGzPrwam+3vK2ZJGf6NxXlEd1NCBtc49G5q9basyEebGR7of6Vm6T6HTDFwe+h6xbXiKflfZ7ZrRjuwfuk8nk15ba6zGcbbnB9H4rZs9RkIyjq49mzWbi1udKnGWzPQklBYgscH3q4lwiEcjpiuHt9XKY3rIB9K07XWIZPlLDJ9eKku51kV4IpVYEKK00nElw4ySduRXJJMtxGQjJjGeD0qSO6lgmi3NnacB/Ue9LVD3OumlDOXXOcBuvpVv7RG07ZPJAA9s1z8U5aVt3AYdGHUH3rS023Msbtn5mIAOOwp8zFZWNLSIzLDNIFYNPLwc8BRxn+dbwRIWXCnaFwOM4qrZoF2r2UDHGABU0z5cgHIwRx0z9a1WiIluVrtQZW3k59PWqXmNcqN5IWP5dw5yueh9SO1X5txZXbG5lGcnpVGeIRNuVwodskk9fT8KUjSGwk0Sy6e0YwhHyowJHBOTn2rKWVYZxAq7TCcFTzk/Wr6ySHkhWhUEZBz+OKhvjHPKsjqFkK4Jzyx6Um+ppG60ZS1K3d3E9vMFI7E8E/41hXq7ywuE+X/AGW4AJ71v+YQNqMR2wRkEe9V7hMHkjJPbvRZPU0g2ita20aw7ly4x0xg49fephA23egBBwTj0qVAYsOFyxGOvI+gqT5WIYMVkLY9gaVgk2UZJFSQOWbcnGQevvVe88toxLu2MOCRxnPX8Per0sGN8cikheR3xmoBal5FXy/K4GCeQf8A9dV6DTRSwyIrjcCeCexrV0+6UjyySQTt3KOh+npVKKMZkXdtkB2+We5z1pkcckbkqrHGQfQGpsyW7mltw5OQJDxgdj3pyu9y42Eq4UjDDggelZ967xoZE6gD7pGT9KjsdSd0YvEyMjAxuejDpj60aJ6jW10asaq4PAEqjBAPHtSiJTGZQxDjjB4x7VUlEs06hG2xAnHPUe9X7mZDNuV1UkKMAcHiq3HLyGou1zhv3b9ecc1VvoTIy/wjcG46j0q0jlkbkRlcg5HH1qD7UIyDIAA3ytu7Hr+XvRtuZvQptbfvYmwAiZICjnJ6mraxKSFB+Y85HXFMuZj5kcaoPm6KR0/Gn28EgOSQOefUfh6UtE7IXNceEVFZZFwG4JH86izLbvgDv95OeasgEgxFx7ZFOhVSzKdw7EkYBNN2YhFYSRlWZi3fsQfUD0qnNCFO0EHaf4uDVi5jZFBUbV789/amfaFYFJFywGQWOKh+ZSXY+UsetB9qKOpFegfMB1+tA4NLjFLQAhz+FLRj06UYoAP0o6UpHOP6UAZ+tAxADj3FKOBSgdaXbQA3HpTiM0oX604LgcnFK4DMfjSjpzTlwxAU5J7DmtSw8P6xqCB7LS72ZD0ZYjj8zSbKUW9kZJ6UAdj69a6WHwR4knHyaROp9HKqf1NTW/gLxHPKyHTvJ29WmkVV/OlzJdS/Yz/lOVHWl/lXfxfCrxE6Ak6cinubjP8AIVKPhTr2MST6fFMODG8jc/QgYqedFrD1Ox53jnpS7fyr0e3+FGquD9p1CyhbGQqhn/XAq7bfCkNj7TrBHHWKAEfqaTqxRawtR9DywD1pyblb5SVPscV61/wqiyBUnWrrn/pgv+NOX4aaPGSJdQ1GXHPARf6UnWiVHCVbnmNvql/B/qrl8ejYb+dbFp4puI+Lyzt7gccrlGr0Oz+Hvh5TmSG7lH/TS4I/kBVs+DPDMDMy6Ssozzvmc4/Ws3OD6HTHDVo7MwfDuqaTqsyRW0z2d2ekUvG4+3Y11iI4cRziNycDcvcfSmxeF/DUMiOui2isCCD8+AR/wLrXU2r2qIMRImBjcBmsm09jojTqL4inp1tuCbiwwNvrxXRW2xDjy9pHCj0FU7G4UXZCgbWBXcO5/pT5Lgq/mbxgMB0qVpqVym1FNv4DABvXipC24upDBhxms8OgkAYssT/xAfcbsal8xzmN9xc/Ky5+8PTPr6GtExNDnlARXbhVO04+mc1VvpRM8Uc5YxkKu8HO0Z7U25CpDtDkoVDBv0/OqE+ZPKmgfduyJF7Ag/rx3ol2NYw1uTqpjuLqHaoe36MONwz0/EVX1GVmliCsqnBOVPT2qxlZLjcH8ozL8xH98c1C0Xm+YZDtkQZGB19TTSurGsUr3ZSkiKrvEuGHT0zUAfc6+YFdue3f/wCtWgqRknc25geAB69fxqOa3RLvaoPHBbHGKXK+haetiIrvIZQUYc7s8ik2yP8AO2M5zwMcirSARAZKjJwGpzBWkTLBsctx0NVy6CuV7SYKXguiGLqArHjp2NMkX5Crkg7iqEc8+gqzeLGIzvAwBx3warWsxjZYpX2bz8so5/D2NLZ2ZmldXIoIWUqrtg5OWJ+7+HeoLjek5VXBHQk96sXGSxwzOwwdw/nSpaiWMpktvIOV/nT8hbamfHErlowQyFsKh4Jz6VJDCscvlt99fuAjBP8Asn3pfJjVyCv75eQTzUjTRcP5WwnI2j5imT6nqKXQOZ2JbOAyM6bgGXPy56cHP48dKdCsTuwZ8sOeRwfektl2Sl3JZGGAe+TTnhO8Ko2djjv9KaQczITJtZlJIIPDAZGaRh5jxSSSAMo+6ec9qZPIscZ6lh0Un7ueM1RgnMRMTSIQGHyk46jrn0qGtbESbNIxv5wBHBORgZ21pWcIDgShixzhyevt7VhTXR3MsT7+eMfdIqa11GaLermNx3B4I+hpqOtyUm1Y6P7Iu070DKBu3J95c/zpsqqYfmI+Xvjp9ar6Zqw2FVdwxBDYGcj0+lWUaPcuCCD0PQ+49xS06Ds1uVntXkiAeJ3VmKxsP4j6Cq1zawxTFVjeORRhg/UHv/8AqrdIW5giRHlh8tNrARF1HPUY7+tQXhS5lCIJQ8SBCZBhmwOppNK5UJO58bYJPFOwcD+tdJZ+DdUuMeYYLcdTvfJ5+la0fgIBVMuoM+eMRxdPxJrtc4ngxw1WXQ4QDnNOAJFeiW/gawLYM07465fb/IVqw+BNLTy2e3MgbON0zEH8qn2qNvqNTrY8nx6kfjQu3ONwz6Zr3PT/AAfpIBMWnWqFRk+Yu4/hmtm30W0t48x2sC467I1GP0qXVSKWBfVnz5BaXNxjyba4k7DZET/StC38Na1O37vSrvB4+ZNo/Wvf7a3DKduQOxPAP0xUyQqp2nJ981Dr9jVYBdWeG2/gTxBN/wAukcef+ekyitex+GGrTEG5u7SAH+6GkP8AICvZYYgMfuwvPHPUf0qyhHbB781PtpFrBwR5pY/CjT4yv26/u7hsZ2IFjBP15NbVl4N0C0lCR6VCzr1efdJj8z1rspf3nyc5bOMUttAh3qpBwMZPU1PPJnRCjTitjJg062hZUtLeGEHkFIwMfpVqSFtxSSQscDAB+6fTNbENqyqGi8tSeADj07e9U7hRuGCCGBGAu1h9felbuaRSb0MloFDMfMdTn7u7rSS3U0DLIcPGG79f93dUxjO7aSfcEVXkjL71L7QaFfcvlOgs/Inha4sS8e7IKN1A7Aj3qGCQ3bG2ePbdLnac5EgA/mOawre8kt7uzhAwrOYuO4PQfgf51o3rusEd1CCJbdhIBjqQeR+WaNWKNO24XlwIHUH5gwznuCKqyaistusscafLwQCTnnHIrQ1cRriaF0ZJE80D0DDtWGsMgumxtHmr1PcY6fnT5bM3hBNalmO6ZLqSBctlcrnuMZFVGEmWkkJIyFxzxn1p8SyS3gbg7R8hzjPHf9auzR7trKVZpF3MCcc/0pqN0PRbFFTJC2OecMB1b8BSTvH5fmxqDubbzxhuvSpJonW6UMQGxw568ds08YImGwbWw5Yj07D86TiBXW4LRh1AJzgZ6jsRVhysccbkMy4GMDJB70wwqYThuc557Gp4XJKoOpO08cAipa0E9S3CygRyq2WDBuT29CK0bny45yrKTEeD9KwGdkIA6E4wexzyTWlMfMJOSpGBnPoKVnqQ4amzE7NaKSdzfcJA4I7U9ZXlthuZhLGwCEenQflisfR7p1LW8hB/5aLx94DPH9amjvHDkqMc4z2q49xOmWYXWeUxFgMqSw6ncP6ZqCRvLVoyclWzlTnOeMVWsWMF3FK4+6+1m9m9auXUOy5ZSQqhsZPp9KcVc0sloQI5spIZ8DMbCQDOcjP/AOurutEi5lOAqSODg+mM9qpQqHbBVpdwIznHFSQJNMsIl58pmjbB4JB6H8DzVqLeg2upFF8jbniJDdCrc898elTbl3FTtySFADfrTbovK7L5W1S2Fx/D7VHbK63LziHzWhOZIycFlHp70JWFuTy4WSS2Rf4uB3FMm320XlSKFlBG7j/PNJHcjDsWKvMu3nqeeh/xqK/Ek8P7qRSzMRg9QPU1Vrg0yaW4UmMPyR/f71l3cazP+5cIrdBnofWtGNUWLYEYzI33s/wgUtuI00ufKqy7shwMn/dFTy30JWhXsH3JtbKzLxhR1zxUqxotvJHnDqwCSE8BT6n9Kja3ZdpB+d2CsQeUY/07VPuCud0YX5grk9iPQVm3bRilG4wxwkCRm+bHz4/hqN7AxTLLIYj50e9FD7sdhn0z6U+ZWinZ0yec4I6fUVYtoldgFVV3Dcq5OD7e1Cl0MZJoqwpKJQjESOASvOe3P8qguXGTkvu6jGP8itGNVik8xGxJvyFP+NVJkT5hGcoSeT+lX0GpXZmxIJJyS4bGOo4rJnt5C8jldjE7T3B+lbqJ5HmgHaZBt3dwOtNlZDjJyOcZ6ipSHYxArxRqM/KMY28k/WrsLwMvzEbuy98f41JdxHYA0alXA+gNMexZmDxARcZGTxmrWgmi1p6+RIrbj8xBAYg1u28McwVEZsnJwO3visG0Qkq+5Qy8NgferTWe4tpllhiUuhJywzUPYLs6DT5pZrOAC9igKoQYw+08E8/yqnNDI07GW4Fy2MB1Ynt0z61Zg1VJ7ZJkhgVsYYGMcGo0vDOXDxoEb5fkXbgiiSRMLp3seTw/K77cBVwM46Zq2IVeF3XBZT8474PQ1BYSCRbiILguo57MVOfz61K8rI0cpJ2Sl4QxHBAFW1pcq2thoxGqMhw/97NaNjKJrQsSBIj4YYwc9j755FZkMsYb5mCHHJJ7ZHIrZTT7m0u4zIr/AGSf92sqjqcZx9aTgDslqW0lVJEZUGHA3flmryMeFZcluPXis3ChSGJzGSgz/CM5APr1q7A4aMvKWAUYHuf6VFhaEkSgDnCrnHHX609ogpQtnPXjjimM+ZWLYzxtC9BUhBIUjkkd6fKFySMgTKJRlHJGR16cH86TaTCWcgccDuTSKX8wc8DvipsLKQJDhPvcjoaOW4r2Cyb/AE+BWOBu2k49RVvTh/p0isQp2Bj9M44zWcoljulbkBWG4Z9Oc1dt5DFq9uy/dmDxgn36VOwSd9i5uMIzjLISox6+orKlL+YxY5bJJPtV27LbNiudhGcd/T+lZMlsS+CvUgAZ5Oa05dSoWHyZSHcwOJOhI6+9UJZVOI4sszPt6559Kt3MiyTIkU8mxMCRyMqB6KKp3BUSKVZpEVv3aAbcn396bKuS6jbiKzTywxuYSskh5/dndwtaisGs1kCyRxSKDh8EsQSGx6DNZrQMInKsxLZ8xix+cnqa0LArLoW7Z84ncflgfh1oswXQjs0WTSbmPr9jkxjGTsbkD8MkVnJEEkbdHksNpB/hGeufrVqzYQ61MjJlJ4GBjPGdo4NSIIyquUztOQpHX2HtUx1N72v5lIQLBOsYUht+CD1PsfepyjFGjnOxovl2HGc9adAYhdsZlVojJ8odudwFM3M2pXhbYfPBJ9Fx6e2KuxLGCAKzuCWBAaME8r25qKHllUKctJ5ZYHncemauSzIt1aMU+7CI2I7kE8/rUKLEXQ8LJjgjs3976CixNxtrCEuZYWLYVuAeoUEgmpbGJmkuoixGxyUyMZBGc+1ULW5EurbWYMvllyT0Azk4Prya0ftcQu93+rSSPCKUznaSfm9znrTSTQ22iG58uNZlkB+ZgFUc/Uk9qvWYQRqJAPmzj5O5PBNZGssy/LH87lQWZTnODx+NWkuhHbRyOxVoxnbnJODxUaczHrYVEMWHGVkgkw/zcFc4NaItWVzCd5I5Ckc/SqN1MRbOI9rRzsWPqTkdfzNaU19FCWklDMcDGOC5A4z+VJJLcpt20IJgIYWhbJkJztYcjFX7tA9vCz828gGWU85xwD7ZNYX72Rry5uwxJ2BmPcsw/pzWzfTrCqQCTmLcGIHDY4GP5013Bp3SKx4kVgrYBxnPA9Kks3eK/njhw0hXeA5656jP4dabE8cluDvGGAP1Aqvcs2+G4Vir58s4HIPUU30HvoycTQu5cSMP7qk/MrGprYxW6MkgPmuwGc8e5zVO9j892CRjzkUHzgep68jvTV8yVAs3zbh8ybc4+lP0E4lm8QOxMci+XKflDY25/wAeKjgZkV3OCwGQG6f/AK6jnLedGqDCMgK45wV6mp4nB3hog0eMOOf3g7D2x7UW1E00ieax8t182RHEi5YxPkfQ+1KIl3W8jhJG3+WEHygsOQMD2qDLOFdtvyN5fyAcDHGaYJGWSFJGO5WV9w6EDj+RNO5Nn1ItSlY3VmYGRVl3MxboSrc4FWW3hPMMaoW5ZOpNZ1wQXW5EaogmIQfeAGRj8K2YkEiHLlWyeP6ioS5m7jlokV45EkC7h90EE+3an7vLVDKCF5OR94VFcwpbI0mANhBYHOCO5q/fz2VkB5e7ypIC6CQZZG6/lRy2vczaV9Cpcr5iRvgfPztBwSOtRySAIY1ViueSOoqD7QNqcqS6nCEfdHqKsysrRCZ3H7xdrbfXvkfSmrMmUbGWZZGLiUZJ5XB6fWnJLHsXfj345/CrJiUhyBlSqg+uBzmq1xbCSRGikJ5wD65o5WtRppiJmYAo2Yw3tVm4hiKrEVwx64PH401LIxBMk+YWBKRjPHercaspk8kZSQkZIyfSjbRjsVLa08oFio/P3qW4QsryMzZA7H+dW44j5bdTzySOB9KdMWyyhceoJ6+lGyFbUp2dvcER+WH3sSqAD7x/+tWldTYLQeS0MqjD5Y5PFXrbBsxKkcjOsfkEhcooJ5bPriszVZM3WwRuqxoEAY4bAGMmhqyM4y5pWaPMLRduxgTgDdjPXsa37mFJPCro+RJE4MUgGRuHI59SDisS1+S2knIMiGTZ6AEr1rYeeF9HZ1YmCOVsRKBwCuMk+3YVoloQ5NtGDHF/pMPm7TG/8XYA+/t3roIp3UmG8Z2khDouMN84wAfYYyc1zsE6ZMfzMU+5z0yeTjvWpJODcwscqCm0/UVneyuXLU3CyjZJuy0kKSsMfdYk8fp+tF+yxgMgwocpjv0yCfqapRt8wynzFVG7+8ec1J+8kLF5NyZVyO2RxzQxpouvIFMeQyvtBZT2I61cilSSLc8oA3Lj8Tj9BzWJM29mzIWQncD357VPG5KqDjnge1TezB7G4kkBkdFwxVSQ6j8/w71ZEMk8jhVzhS6r3dB6f57Vgm4AZCoG9RwO5HerkVy6FGLt8nAPfFVzdGZPQ1IhCLyzZmxDdxfM3IC/NjOfyNRSL+4j3sPOhlZRj19fpkVReYmBVI+WJiV56A9R/WntcL5Uy5BaQLIeO4Pb8KTsxJl+7kyhkUYVW2tj0bp+GR+tZdxclFbhlDdz6jgc1JdTFYzGT8zrgY9un9Ky7i8WWJG2grnaVzzST1Nqb7k6nesaQrvOCTVeFZI7i3VslfMAbI7nODn0pbe5SKUKwLRuMKT1Iz0H0qxfpmBri3KiOBVcA4+YZ4+verauro0vYtxo7LFgqxIOM9vyo05WEEy7ely6ncemQpxTNPkk82R4sYxuX16/rTriRoUmwQ3mN5pI68gdPyq7pWYJ9CnqLbNQhlZdgjYDk8kHIrSOwZV2TbIAAW4xxzzXOXcxlUyKc5YDHphh0q3eXLCDyeyncMdvWsIyV2zSXYn1a4HmRtblVG8FMHJXAxz9arPcNN5aydldA/qGrPMk0rAEhVPIIqzCw2kE/MTyCecUOd9hN2GEuFK78FB8gHXnr+ooknmJ3SksCuFGcYqUv86hj8wyDgdqgeJhJJguWccZ6Yo5iXMgJYTRyK+1s449Mcg1cRnSI7mJCEgA/wAIPaoQpKsGA4wxz1qwhDI4ZSTwSex+lCZDkQwhFkhdiShdSy5469KmQtJPCgCZztJH1pzxqsacHqMY7c1SLOuqqsLAkZYkjt6VMxKozeeA5giQgZkGBjoM5NWorc3FxvIJ5IUdi2f6dazbeVhcKifNMQVHfk10boLWBY48NOf3bYOMZ6gf1NDV9QjUexQ1p8WjWyBeW8wsvJZuMmk1JdxSQ/KqKoGOoznr61cNqGtWIfLquR2B9vaopIWlk8kKHHBHOMGqu92bQl+BWgcWwkjePMqAljnaD3HFR2IO1jJwXbzS7txu/wAO1X3hRRi4nMlwfkVnGAE68fQ8Vms0isQ0YbcOx6U73NYvmLkWHbCcZy554OfepJYo4C0kBYuq7CD1fPXNUFeB0jUSFS7EEnIAPbFXoxKdpj2NhsZDckY9D/Omn3E1YlWON7GNV+QxudmAScHGefQU8sAgaEFTnaQP5/yqOYZCXFuWXJ+dNvH1FNt3Vky6yKWfDHaePXIqnO+5G45lcxtxjKYOV6ConkN1cq5AIYYBQD5gOPypXuF80q6lIU4KAElxnv61HI3mSh2jfcHG1CeAvYcdOaXMnsMXUI1g0iSOEBhGMlyOSc849qb9rCJGyvlg20jrg9sireuXVzqFo1mII7VFj/efNvYk+/YcVizNMzRzTgZkGxyDn5x3qZySehKd1qa73MT2lwrly/GxQuQwyMnntVK8DSYbcXEcPf8AujkfrUaXBCopzgngH3549qsTOs1o6LCAyKRvBxwO2O55/SpcuZEleC0E5JBcsE3hj2YDkD68051Wby5UTZlBuOTyelXLOMJLECWDKd2ccHI61HMJsBSNkY+UjHB5Iz9OvNaKyQPew63UbgJWKxkkE9cDHGanulWK5guF27GBwTxk/wCR+tVre9S3kcucnYUPA5H0/KoriQCFU3qUIzhhyvNaJqxnytM2oig+yXEkcsQ80q2P4kPQ49qW0VXvbhYxvjjOFBGcZ6E1QS48u3bklo9pC5ycY4/D2p0M+2FvlZHCjoTnPUEf4UNoSJ7wMGIwVAGCCcd+cCkjilluXMe1R0xKeoFQySy7FkkO+WRM4PO0k9RUk21UnJPmIyKFckgjuSB9ag1i+hf0y4gm0zZJOkRWJotshI+bP3h6+9V7yWKeZzHIsrR26r5h/wCWhHBNaFrJcrpllFYokgjQl/lDMDyTnP4VBfkS2VxIwizFGpVo8DMh+8o9R/WqasjnXxHiplRSdpDKcY3DH1pzjZDh5UbeA3yZI/GsmKcOuQ+T1INBl+fC52t2J6ZqHIImjZTrHdZUEnZ8xxmtLzhLLAcg7STzxnNYHmKXjbZt2qEIAxux3PvVuKcmLK8kdTUt6WKlbc6ZrpVQ/wCyRxUkVwrJjsOgFc6tySmejAYp/wBoJUEcMB69aTZmbzTIDzxz0FKHO4FT8o6Z9KxFuznJ5FTJcYUEccdjSfcNTcEynbwOnPqKkjnI4PrWIt0No7n1p63JGDu4NLUm5trc44PQ1I04JUjkjgisP7Rx1yM9alSbGCGww/zmjYaZpvKQvJzt5H0rMupws7Y+QSHnI4Lf/XqX7RuBJ6jtVG5QSqysfoQaoqMmNS4YXIYMA/TDf0rWtrh5wsdw+Isbfl4/GuYnRpCVkTEn6Gqq6jd2Z2P+8jXp6ilzNbmjlzHa+cYIQVY4Qna54+hxUF3qe9AuB50nTnpXLnWfMj+ZsL/d6UxLxpZC7ZA9+p/+tSctAVzp4SHMMZG5AwYn6VLdyoWwmcjpisxLmMoCWGcYwKUXCOSXI56DNHoF31LUZOI5Fw3PIqztXczq3J6HrxWWJUTAVsY96lS6TaFBA/GptYTkzQlkxsIXnH5VIrggFs7gKyvtIBJLbj0BFMbUI4s73VSeDlsUxGnHIrFiR9Kcp2hz1IrBl122SQK88IB5yGHWga7buQPNUoepDUXCzN+OVCGBPA5+lZcM6tdz3BO1R8o96yX12MIyxnczHaMVc0G1a8kV5j+7Q5CH19TRe7CzW51vh6ByDeyZErkBB3Qev1P6V0EUagFs7jx8x647iqlohkUJg8DgLyK0Y4vs4w37xQwyo4A9vetEieboKsbupMWAP4mb7o/+vTsqtuBGSEOFDnozjuT7Ul0rGX5tpRedqn5TTGmScqkjKmflBwcA+w9P509NjSJWvZYorRCQZZ2TaAR0UcYPvnms+SPcAoBWXALKP4T3I/SlupJQw+bDk4yo5AA/rUbot0Ek8x4ioBHP55FK9zpjohLZijqJXVlB2gjoa00AjZmjjxGcJuB+c5649cD+dZsjRJESJEZwNoYd/c+9CXZMWVDblAXluneq2B3kbl9cm4uWygTI2og5wB7+vFV4A07yLErMvV3AOAPXNZouxI+5fuqgYqrc7j/SrNrqgtji63x26sFfBA/EjoeOKFZvUzceVFuwikmmVVC7WPzsy52r6/nVG+tvsdzIJHTyUyFZT9/0I9s5qR9TtmAFvcyBgMrIUGWz1XIOAvFZk5Ls8smXKguXJ6//AFzSm0lZAm76l23WaY/6wrFjaC3QfT6UyZoxDJDMqMJMfMhORgdQKnikP2GPEYEOfk/ugnGfxq1Fch4p3UOYwAo3nnryf/rUlAzcjAST99ACG3DI5HB44x6VeFzuZEZdoC7AM9hUj2RWJbkMu2clfLPO3HIzmtBYkeTMix9AMhQMe9KMW9BOoESsYUXksqNs3fyrPnleTUXSHJifCZbnaMdPwNbccCKY5EdlOSGO48VFPp0bI06xMzIplkI7DiqabJjUUWc1c2wihRWVm5OTnnmrflBETfyHG05HBGP51oPbefPaLEpxjcQDnsf8CahneKWdpVJZDngjGfQ+lSla5rzORWltl8uMo5dQMbx/Ce2D3xU4hmgtg74w7g4B53D1+tWEb7LGyACSOVCjYHT/ADmmzqp05AjF2BLNxyAOBWqWhnJtEaR7C7bhtf5QD+uKlkeMiUqVGxcKM+vH596hRGeF9sKpt2q0hz8voB9e9RPD/rA42kttPHJ9AKm99hRd2bUESW0AijtluJZLd3DyE/Mw6g47Y7VW1dlM8cUUKw7o0ZQB/qww6foTU0CRxWsM+y5dlHMkUhCq3Ixx34FVJo2a6aVYZdhA3CQ7izYPU1VyofFc+chdHqG6d81ajvgFxI/H4VwmT6n6UdRzn86fsjy/rz7Hc/b41fLzKQOxalTWII+DMn1LYrhAB+NKce2aPZIPr8ux3q6/bqf9anPq2alHiG1HPmrj2YV59xwKDz+NHsV3F9el2PQ/+Elsh/y2U0f8JTZL/wAtRXnoOKWn7FC+uy7I9C/4S6yA/wBZ/wCOmg+MLMfxsR/umvPgcDg8dKBn0o9ig+uT7I9BHjKzHQyc9fkNL/wm1qpztlPb7leej606j2KF9cn2R6D/AMJxal8+XOD/ALvWkk8bWbYIS4yPRcVwAHHX60DPNHsUH1ufkdbeeM3kOILU49ZH7/QVlT+ILybltoPpk1jmlxVKlEl4qq+poHWLs/xKPwoXWL0EHzlB/wB2s87QOSKVEZzhFZv90Zpezj2Eq9V/aZrx+ItSXGJYz9Up58T6mR/rYh9ErPj0+6kIKwkD1OBWjZ+G7q4PzOqjvgZqWqa3NovES2bAeJdUPSdB/wAAFMfxFqhGPtmz2VRXSWPglGwZDJL7ZwK2rLwjZxkbbePI6grk1DlTWyNVSrP4pWPOX1PUbnrd3UnshP8ASkWxv5ycW10+e7A/1r2aDQYYVUxooXvgY4q6mkgcKu6j2nZFfVr/ABSbPG7Tw9qjgbIUUejsK2rTw1fLt86REDHooJ4+temvpuJ4mVVGc7qluLJCsYC9T2qZTbNqdGMNjkbXws6MrLKcj+8K6rw7YSqvlyq21DnK9VHuK6C1stzIoA5XuM1bitXtblZImXzM9Oze1Ty2dzRu6sy1YF4VMLBSnbZ0P1q4qccDHp6n60QhLmziEWFnDkupX7vP8Pt61E26M5XkYOQDwT7VRNrsZLKY0CY2vgknHb0rPa8jyPkEjluDjjj0p91KkitvBDqow2eGPcfWsyWYQ7djBFZd+9uOfSpu7m8IrqWJ44XkWRi4lwB5e7v/AFrOuyJE+WYRyHjB46evpTLqeO5g82XO3plT8y+/4frWVcK0AJWQ4bGGAyp+vofanY2joT3QltVQlcRv/FnIz7VJaXAS2VVw7PnzEPb0NMs9TjO+NisaEZaORcoT9e3NOj80pJPYwK8J+YruA2eoFVZW0HKb6hE6K+UDbuy9RipYLuScMsccTzOOd4H9arSTRkLIY0OTwdu0ip5Le3EhiaSeKbG4Kq5yMZBwcUJGXOX0toIpUj8sicDdIySDaB/jVmOI28jJI28phvlOVUnpVHTkkiiLMmVJxnoGPfFOt7oOrrHJukkfLDP5U+VMm7ZtFrdVAUCBGUOAzcMfXH1plqzsGT5SrSM+VIIOeaiuLJ7pvJiiDhANm043nr1/pVOBJraNTcIIlYkqB8wYf0IokmJJNaM20iMbNKy+asa5VSMAE1EWmV1VVBLYJ9vamxzNexqlpGJHJ6g9h2OT+NRmW5glZSpZjjDZHH+NEn2CMX1Ni7iJxhjkDkk8Yxk1NazxpBOjyFWcADPrWWZdtisjE+bJJtDZ42gZP5nj8KV52NqMPgu+c4yOv/16lSs7gqd1YngCRq0sjADYY1K8c9P5VmRxLLbXi5/1CCUEc5OQB+HNTSTM1om0M3zFSMdjxnFNtolSGZSxDqjBuxCDsanmuzVRshZPM8kImRwWRh6d+KlthI8rxRsgVlLFgMgAgVVWRxsVDuKEMq98en4irtuTBeRf6to94jYKeMnnn25rRdxSgQb/ALUWijZli3fOR90eh/Ko7YPIWdgNyOV65H3c1M0YiM2CEYEZQD7wJP8AhUcUy2HltIEc72bBHBJHGR+NGzI5dPdOignH2e1RbxYQi5eNc8t6kjvzVS9iSW5j/wBIM+SwJDHONvB9yKhi1gSW6hYbYNuII8rjjvT53zcuzCNfk2EIMZ4zwOxq3qYQTT1PjEDilx6UlKM1ueCH86CKTqeRSjHagBRxQOlKBxSbTQAY5FLzn2oxS465xQMBjvS+/wCFAHdeT7c1at7C7n/1dtK3/AcUm0txqLeyKvWnYres/Cuoz43qkSnu3J/Kt2y8CZAM8ksmeyjaKh1Y9zaOGqS6HCED1qeG1uLjHkwSP9Bx+derad4KgiYBbZc44JXJrorTw1H90IB26Vm63Y6Y4P8AmZ5LpvhO8uWX7QywqeeBuauosPBenxrukheUf3pG6/hXpsGhRxq5AwQMcip5NMV5BGUCqq7h/nvWblKR1U6EFsjz/wD4RvSYlDLZ24YDqyVJoXh1b273Nb5gAIVI1wGPv7V2r6AGMmFOduecjcKm05BbwlDsRlGdwB6e9Di+ptGklsZsPhTTrh1hitwl1jhQuCxz2qxD4egikETKQB90nqD6Vfurg5DISsiH5HB5B96si9jvoY54CN5z5oPBVs85qbdDRQZVTTUij+VAccnIwPY0sdgkitP5e1ogWdR1Zehx9OtTQ3ZDbO2drMP4Se306VHc3qW6oSOnUr+RzQl3KcHsSyacVCqgDI2NpHQg9DUpt44RG0hbDkqCvfHX6GtJyn2W1KEOjxd+w/zg1Snj3pH5pzGOuBgg9/rVcttjFa7lB0R7i3wcAsRz7ippoUWMggFg+CR1Aq1NGhsYpIVHy8BsZxUVu5liZUO5iAScdv8AGi3fqUtdUXYUSO3B3bpoxvIHfsc+hHB9xUTzef5jMPmyCCo5NZxnl+c7s/LgHpnAxn8qox6iYpmSQFTjjsAPX1z3puV0VGnc6JrjIDwPmVQM44L/AP16it78pFiVecZbI689KpRXShGkhZWyvzL689R9Kq3sjPGohck5IYdx70n3FydGWr64bKywLvGckEfMR/jXP6hdB3UElsdCBkD04q1DfTWn+sUMMg525pl3Gk+YosmUAsAo5x3we/0pWfQ2S5WZXmq6YEYLDgHPT8KcY5EhZ0fzY9uJVIwfy7/zFMWNUAcuNpP3gMc+vt9KfGdxZkfKqNwY1SVy2VjGrhXgljULyVJw2P6irrxvayRrcRrJHKN6S27hlf8ALpTooIb65+QQpKRlecK5HY/3frTGjlS6eCaHyHBKCPAGfbj+dFrCavoA8yNAzNvhc5Uqw+UgdDT72aMWyPcMTt+7KnBI9D6U2xRyCHdIwR5bRSrkMB6+mKQWc+3MAXYR88LYbA9cHqp9aa2FyCtd/bFyZtpjAKRkYBHZRUE8sdpevCZNzIANyYZfUj6jv71ItlI0g2QmJQATHuypPbB6iozp0k5YjyRtyHy2G56/nTbdhcqNqx1NooMyvlHYFdvXj0+ta15fpMyNHCjDOAQvBB9e1ch5Eu1fLDYBx0z+AqxFezW4ZAjBiDuRwVH601LTUylCzujoo3km1FCgMZYbE2jHvT5Wd4pvPcExOHX6ng4P0rN0yUXFlZvJJGl+APNSLIXfzyuexFaUsECuFjkYQsBvyhBX1B9eaLJ7E860KV5PNMkJclAsgK5IwAM96ne4McMQQMY89SOOarvJayXPlpDlOixuT+Jz/SpLxzJbYhdVRCoII6jpms0t2WpGjtkaFGiwdw4pLx3t4jIP3hKsuQOo75rPaaeB1iYttRcqetMa/V5pI4G3cAfpyfai0TRRe5JDIjWrbnHlD5kOMkEdKsWkjy7nDRiM/Iy4xgHvjtisqZ5ZIreKKLyxGpQnP32zkn8jUyrKFEu0pJIM++B04/Whdi7aXL0c3lwyNuLNuKbieSB6UJO73ESPArRzKXVGbhiB0J7VEELKW25WMDf65PekgQ3Ei7ApKIxAXrnr+lNMnRmxpgaeONhZWMEDnd+8kYEAcbsZ6Z4rTvXFnfM08Vs7srBI4mPyyEYDfkc1hweb5ljdyQypH5bWpYHiRW6EDsQau6iCbt1Hmp5ESqA4+bgY5NaLQ5JQvK58d9Pxo/CuhtvCOpzYLm3iz/efJ/QVtWngB5D++1Ie4ii/qTWnPE8VYep2OGwe3SjgHHWvVrT4f6XBHvuTPdOP4XfaD+ArXg0mztAEtrSGID+7GB/+uk6nY6IYKct3Y8bt7G7uiBbWs8hPHyxnH51r2/hTVJADMsVuP+mj5P5CvW47WSZQseACeT6UDS967sORuIBPfFZurJ7G8MDFfEzzi28Fg48+5kdvSNQo/Otqz8D2pIJhLe7sTmuzgstrLsxkA4GOprftrbMSzKAicZB6LUOUtrm/1aEdkcbZ+EookwkKKPZcVuWfhuMEEIAK6cQBoFkBGN21sH8auxRqFUsBgnj8qkrlsc7DpEMZIPGOmRWnHYW8YA2DJq9LCqj5j1z2HaprdAdueMrx7YqbMqyKwtVjAYADI4NSQw4UuV+VV3Z9icc/nU6fvEkzgBTjPpTEmGFQnA/1LZ/3sjiqsLbQluIgLebDZKkdscY7VW1Y+XcJKAGXheOnK5FOv5nVflwAZCGGfTihtk8DoB84wQxPQjpmqSCOmpj3eqTxo4bJBGCoHJHsfSqEN8hdXlkK9BjbkHsP61e1NA0fmEkhuox8yN6D1rLSQxhhJbiV9uFWQfd55Iqk+5vFq2hcuLk/ZGRdncq6jk+gNUrZ5YJFeLi0vOGGM+XIPX0zyKvadZCS7e4nK2+njhSTkj1Azz+JrNvlBvLuyjMka7POgCNxn7yk+vI/WlJManZ2NmBNyzEKMoclTyHHQflmtax0KSe0Quv2lnXLqMLgqfmU+2KwbC7BVLwn5ZoxhSOzDn8q2LTWzt379k7Es4U/ebGDuHuO9KHK9WOq5fZLOk3CSaTFbcAQM8RY9Qu7r+RH5VJOyFRGwPTcox827H/1qwFu4otWvrc5ERYHYp5wVB49cGon1CWYZfh0AJIOMY6GhT0sYezdzRjlcRyLG7eVuGQD0ycjP61SeSS3hm8oE+TIpY/3Ubow+lQpcxkzIz4JUBdp+9g9T+dV5bho7kGJt3yEfiD/APXqEzWOhbvpVtYjgrIobCnPTJyM+xzWbK8siZZ3eVP3Xz87R2x6jFQQgAssm545OOTjA9KdaruiZd21h1OfSrK5rFi3jKpvQkOOSD0P+Faq7XIkXKSF+R2/D/CqG9XhZ1BAPBI9aLYD7VAsTYLvwSfzo6Gcp31LN1alwzqcMB8yDow9R/hU8CRq3nSqSVKlWAySOnA71PNGGyi5IJxtxjaT3FWLlI42SMKTIox9fT8ab0JVRmPqNmJ8ybFAfhg317j09x0qmmmx7ZAFmiXJypOcew9RXWRRIlsWm3MzqA2RgfQVUuniBKKuQRhccZPb6UWW5pCpcyLPRm6ecI4wdxf8cVPDbBZ1imG+BMsiklSvv7VbD3Ck28aRvApDkk4JHHB/wqW4mDzROwVU5VuMjOc4zQrMvmdzHksrZpn4ZQTkEHn6fWn/AGKNI9n7wNC20hiTx6j07UrspALuoyDkY5yOn0ptxcssgaRf3jcMyvuD+4x0xRzJaspu5MtskCO5jaWAx8kk5iOeG9x2pt9aW72TqIT51vsaR1PJVuDn1GcEU+S6uXjWSO2Jt2YFoicK5A/i7nqSB0qNt53Ou+MyLtbfyGHbNKU10JKaq1gBIiq0gbkI3+q/D1p63hfMkv7yXJIfPb0qfT9PvUfcpXLDcCwByKstCzhkmt7U5X/lnDjp3yDSTkTKzM+eZZFSWLYWztAGAR74p5nuxH8m526kdj9RV4adbxiN5WVFUBsDGSo7D3qdYGKIWUAn5gC2eBT1e5i7LYzVhYukijyyVwRtyQe/51oXCweS6Wzq2I1Gxjg545x+dW/MVY3JOC/IOwjb/jVeG0ju5Q1srHeecHJB7ke1OyRndkCCF5ZYJEIDKRv/AA4FVItNiiAeFkKMM5XjJ9DW5FaBr5vJ/hON7DBA78e1KLSBo3eBcxhuC3p60crZoqriZ0MMKowdxuVd2CerZ6e9VZJTLOBCPMcnaCfX1PsKt6vKbK3KosW7gyMFyV9hVexjHmLLtO58Ft5yQOw/rUPsP2nUvCYoDGgwqDYxB5ckYJPtmoBbeXesIlkXcchVHU9wMVPIyNM0qKPmHygjGAO9RRCX7UhLEOr7iVPKgDp7VRcZaaG0bZNQtLV1+0xKiGPCRF1b3+tVrhwdSMTJLtVFjUNwzADhj/ntVmSaG1tbZ0nvQZF+7E4CpyfmFS3NvGXkngeeSVYo2JkwcoeMj0+lX1MFLl3PIfsfyll4RepFWLQbGAPBHJqdW8qYMqs0ZPOQMZ7j/CkuYxDOhQYhPKqex+tZQd9GOErmvAI5U2Nt5HXoaZPAhji4IBXcCTnj/GqsdwqRpkqJD8wJ7YqeWdUgtCrksykuTwOSTgf571rYtaCW22F1LD92eDz1/wA9atxXqpbpBJkSKxKfLxIrcg/TtWS9wqsSr7mbg8c49KuXbQfZbZ87pA+1sEY8tvp0w386TVtUVfuXLJFlUYwQG5Cnp9BV+2nO2aAALG/UdDx0xVGNxExI5Dxhhg49qnX5Z1fA44Ptx2rOV9xcyZryzKYUcYywTco6ZVcVVa7ZACDx90rnOM96riTA8tsqxBYK3X3zVfzkRkAx83UevtUtsqKVtTelYN5cjMFLJjCnuO340F90Dcg7FJZR1Qg4rJNzhxz+7Uj71C3CEyY6sM5Bp36kNWN5Hi+z3MQAQyqqo6HI3DB6+/SqV9cxtbyGMHlwfU8Djn8azluyI9qseuR25/8A1VHv3SOdx2sc+1U5KxCRfnuN5lYjPIlAHQg8Gq0N0ySZXkuoyrd8VVDYVcnjBjI9KqJceXHH8xWWJv5VKbNYpNWNyaRjpu9EEc0c6F2z8wIbjB9KrucQCOTcZy5yxPv0/wA8VlRSu++IkYdwSPxzVy8uQIBgI0quCcD5j/8AWq1Irls7DlUMTJJLmTdhgxJyeg/IVj6zLJ9ojmZtrofLyg6r7/jVprpljKow3LkZxkqCf5Vmai0ptJi6knAcMe5HaqvdDtYtwBZ9DtWRWzEWBwc5YMefaolkZGBUgZOH9/apNFSSXQePumRzknHfP41CYil0zDGOvTjNYX7G0WralyNgL+GVQd5XbyfxFTTwsyEghmyAQTzVCa4QQN5jbSh3K49ajXVoNkTGQB5EUk5zyOtUpW0Od76Fx40JjkQcKCv0pZFKsGTDbznPoazrbUHNzIkMM0kLfMG8s4609f7SngeNLKVUPzROSBt9jUti1LsjBCkmAY+mAOgpAkf2kkAYYdKrpp2sywnMESBhzls06PStYWHgWxcDGdxp87C1ya1fCTR8/fyM+hotstqcKdSMtntVWPTdahjC+VCz/wB7fg06IX2nXAnurGRQU270IcCldk2sdM95FYASzSZHO1RUFnftJ5ly0LGQ8Bc9B71zhaSXUfM1OGW3iICxh1LAjPXI710VrqWknckIWQINoVcgs3qR1wKad+omkuhZDaldsQsQhU52lu4pw0uYj97MFXnle9Nn8SDOxLWSUr95gCQv/wBanxa2rb98Tc8cDoPp6Ue63uNcy2Q9bd4ovK82RYQd+SPvnHU+tUZLTb+9UsyOfu57e4q5davbpkrIFH93HIrJGowsvlhi5HJcHg+lNxRpC+5owRRNcR74sxDkn1HpU5ijU/u419fl461ztxrqQui2yu5RSc7sc+tYs2ryMC6Od5OSQfu1a0QOLep1urQzSaey6ddpaXWR+8YAhO/A6H0quL62hmZ2ckg5K8MOlcu15JOo3SrvK9emaqqtxIWR+VU7mdedvuaJego6HfJqVujjzJTJGDldnBXPWrt9cxefERj7MQVHIGeMH88iuBsfmX53O7PO3kn3+lXxcXEajawMI6gdiPr0pXaQ7K50K3Mjy28LxooiQD134z+g/pWrFG5eEFlyvydM59MiuZivoUiikld3nU7gMYUegz9KW41USDKSMMnt1NNSs9SXDmOoub8SXKW0jvtHCZOQfX6CrESr5H7uMDaxZnBxt/H+lcFDeKlwSZc7wcc9BV576VrfyU3+Xuywz1HXNL2j3B0NNDrDcIpmjWQGPIRe3GOSfrWZe61HCzKhEjjqoHFZMKTSv9qYeXGThSTgk+1WxpZR3lPJYZVB1bnAGfelebQuSK3Ehja/mG/zBG4wWAznHoKth47eUxLhYgCOORn1q3G8dpB+6dXkUBSB0Dd8ewzWVkefu3ZKHnAzux607WBJNsuxskaL5mCQQSAO38OKhilyrLIoL7ty+nI6H1+tV7JHkGQflLH5mPX/AOtUxukiyCVDONo29VI9PSnYaj0R0UBSy06CK7kQqw3ANEH2j1yTxz2qvqUtxEroZ1cSYdnAxuB+7+HtWZbavbzWscdzb/aGQFU+YqyjPIJ7iprqVzcbrkxktErJGh4VCOB+FU2jn5GpanCB1edopQQhQsMHpj2onlWSzO3G4DIB5x61kxXPmXkO1vmIIx6DHNNS7xCdx+XB5zyazatIiOjLaymQjcSwTp7VanmimiRgP9VgEAc+pI9q5+G43SZD9uuen1qwZmADM2cnoO3/ANatE9DqZblm8wsEXOeOew7VPFcLbjcr5lXncBwD/WssXDkv8/zHuBgflSNMVCYPAPT1qHKxajc6+MvFDblsBvK3DHzZHFSRTuXbeV6cAVzqXsogVWfKAkqPrwfw9qvJdR8AnnGT7H0pSZHJY0ZLgsPmcl1JJP8AhTHlPDx8ZPJHWqrSbQSzAd/rSLKC3zY21mWTPcvIpT+HOamgfGWYnaBhQeKrAqxLjAyMgDoKf5ibdxI96LieqLLyKJApBIHT6+1SGUAIeQAeayZL+NDy6ADpzTTqCu2EV5M9lQmkmTym1JIrgngbuM9gaqzKGwy42tww9DVSOW8kUpHY3LI3qnT86esGql8iyIBPzBpABVAk1sJHfLbXGy8BUdQccGm32qQSZaNwGz3NNutK1K6Uq0UIB5y0nSoE8I6lKMfaIE9wpY4ofkaRfVjhf72VQQcnIIpL65eWJYUBYEbQ3YDPWtCy8FzouJr5z2JSMLitSz8FWkKKrSXEmP78h/pTV7ClMybW8gtLWK2QNJKucIg3HmnWun6tfHzHjFtGSduTk/j6V2+n6PZ2CEW8EaHqWxyTViRBGcgBgozxU8vcSld2Rx9t4PjnlRbySSVF5OT1NbVj4e062jxDHEm0jCsOW+laMspRSpBAPOCMg0yEl0LfKV7gHJ/KqS6FNOxPHaRxKoMe0HoynqKdHD8uYGVjyCMc8e1Qm7Vd6qBgDBiPII9fasiS9kjuUkt2KkHh+efr7ihuwowbNstGo81QAQdjDoCaaVT7yDA96gmmSaFpwq7J4yCp/hcHPHvkfrWfcTSII9m0oOQCfzpjVO5cchHJ4OehzVyBEkRoH2uGX1zWMZQjDJLcbxj071at54yyN5hQhscHp6UluKcNNCcRtueMlWMXKnHUGor3SIbhhMuYp0JAkj4OCP1qxdzMhE5K7WOxuOlFvK6s+9ztYgHH8PPBA/Srir6Mx13MiK4nt3t0vlXY42pOnQ44wR2zUl5HAxOMbvYYFS3XkmW4srmMNHMN4I9c9v51zF41zYeYTKZ7X7octkx+mf8AGh3RajfUs38TiPKSQygjgOcEGuZup4wSqxMsnf2Per8UjF983zDcNoH92q15E11IWiiZl6dOR+PfimldaGq0KIkKsWbO0kZBNRsu1t6D5nPGO9WJLfyQZDBwOjMeD+FRw427GUnPKk9vWn5Bqyu6m3faFVwecDqKv27bU8xFJUjO7tj0qpdbtq7hyDkEdxRZvKgzbSuN2CR6ntSWjFa6LVttLM0e4MMYIzwCfT0rRtrsvGU8pGfkknnj0rNkumhSMkKhByWVcHB6gVbt/s0twpRzCSoHPOT7+maBFu4ukms48IhkDkb9uNwx0NV5EZ7eNI8qWwTjtVlAYwDGkbZU/MG3Y45OKkskN3BIsJXYpCtOxCgcEjOfxpNDWhRtrW5nJKKTGj/6zgAe/wD9atPTmVd0hcOj/u4wOrnv9AMUSoszwxoHmjXByG2oeOQBVlIGWa2wseWO7ZEcheckA9veixpzdy2l75rIzIoJyDt+6OOo/wAK0o5FmEcanHljDsTwMdOfXms63iht2kNzcCKNV8xdoyX9Auf5miKVpYDGUCRK3mbl5IPYnvmnsZStfQeiMZPLC7zjAOcfMTx9aZLOtv8AumCHBIwvIB96y57zbc7zGQycxqTwKY90kTM0USgY+6OQvHpQh7l26unGW3An+JQuOnamxqktxDJIjGAH5kQ7SR6A9qoLdSSSOUbe+MjHPXtV7TgZpI4EVSZSFAP8HqT+vFDVxvRG4JtJRC5tbnkA5+0eo+lRT3K3cqy2yGGFYxGBI2TgDHWqqnSmbC3F2wRdvmeWoXr1xnNJdFbR/J3pJGYxJG/TIPIOKZlZX6nmNvOqS5G0sVIUt0HHNRtIBbsyfMo4+XkCuT/tWISbgeR0Zmzj8KQ6rGSS0sefVVwf0qvZnnqor3udHHOicseCeatfa1C9QQR0Fcf/AGvEucEn8DTTrQJzhj7YpcjNvrUO52f2pTgnls9utSF1YBhIAO3vXD/22QSVRj9aG1yY/diA/HOfwpOm2X9dpxW53n2pPL4zgcnPb1q7ZySXTYtYpZ8/3F4/PpVjwt4P8q1jvPERLXDDetoPux56bv7ze3QV2qBBGFtoZW7AKgVVFYyaTs2dcZcyOZTTNRlA8xYoR6O2T+lWoNAnYfvL0A+ix5/nW/Hay7vmgmyR6gHFH9nykKyhieNwHUe1CVx+73MyPw1B/wAtr64b/cIFXE8N6aD+9WSQdt8pqWW0ubY5mJBPQYqWCZiR5mOB2PQetFugct1dMI9MsovktrKJGPC4Qc1pQWzRHD4UY6DFEe18RqSO5bGDn1+lVrm7WMjYcKvA/wBo1ThYF72iNAxMqlwAw6FRUYjG3cUBB6jP3akhuCsqTgBYP9W6scEAj9efypqsgnlSIlo88A/e55Bot1IHpZ5KAKDkZHvVlIFC9qe53RxLGQHj6kc5HY0W42RgMexII5wcHj86aWpm5NoFAUg9u2O9TDDEHHUZ6VXSVQrHjLOBj881PG3T5fX6HGB1qkJhM3Em1TwMg44x/jTZ4d8V6TgLHtQHOCQT2pLhSUJRcB1dxnjIHb8qq3NwJFhZiCk+zJPAHGP5U7DgMcI9pasrqGYbWUnoQdufpxVWaDypY/Pk8oMNo2DJcjqMjoPrUcTspELkhllIwR1x6/zp1whubUwov3VYs+ce+R+FNJG17GdNHKZN8LFg33UznI9DiptLn+0QtBMC+TxtXLKT3qlbOIlZYv3ZUBRtPJHqaknkuNNf7VEWBHUBsHH8WcVDj1RXM3oXQDF58Azt/wBaFHPI+8B+FV5ILiBvPgk32xAxJ1GTyPz5H1rRtiLvyJFwEDBd47BuhPtmqa3kX2R7Kdf9WzFGXgEZ6H2yMiiKEp9CBUWWOMIjq7MWwOSwPYe1Xk2Rm4jt0LoOCT1BKhs49sHNZ5vGUW4R2Jh5RyOAf8iktdTaG+fzEI812kYdsFSM/Xk1bSYO7Nm5/daflxmVmBBz1U8L/jmoXux5Cttzsk27m7hv8mqAufMXaz7iAI1z1wDn9KoyTSNmNgCjAnOcdOTj86l+Rmo9y9q90DFb3KcyWzlHwvVehPvzg1ny30MrYeJSJAEYheCB7etV2umW1ZQwkWQ4ZfUj0+tZ9tcmKXyjhZEOGGMg+nP9acdy1oOS3+yPKhWR4FbLsw/1WT8pP+yT+VX4pE8otDGiLjDYzkkHufT6VTSR/OkiZkUxoyleDuB6g+tZ9ndYbyzINyghc9/eq2C9zauBAbfnBXI/dtyT9KyZ4Y0lIkwjHJUjvRNN5QVlJZsAqfemO/mNtZssBuVuw9qLgVZIleJgBumUZVfX6UwBBFuwUB+6c1px28s6R7AAckAscY9RSQ6W4eaO+kMUcR7jls9OKXUSktiJbb7SvlOEVXbAycAH61OqR2qeXIBJvypJ4Jx39q2YorZbTzZIwxYbLcb8bSOpb1zWc8jzqixxlrlnAEeMnp2NNoa1KWxYSwHmEY7jOfpU6qDFDD5aCYKDkcfWroeO2KLNJmYfJ8nIUHOefakSVQrGIyqjdSQDkdM/WkkO4thGGeWNN3lochV6Z71pSTx21sEt4wS3Dyfd79K56a/aMFIGZC4CbtuMDPJqgbt1bZ5jspJBIOeKTaE9TYkuHnklO0ShDwem3HcU77WzzxkzqhOPlY4/E+tZUc7JH5Y/dx9OD60ebFEo8s+ZIHYFm9MAjjv3osS5GjO4N2xumyu8jGOgzVYMSzmQqsYPQ8Z/Cqj3cygbwgdhu3dSB2przlVV5BuJHJP8XNCBM0I5WQuIioG0AN0PXP8A9apop5YblPsjSfa8/IsQ3MzVmB44slHBHBAx0NK928k8YgAR0AVTGCGJ7dOc5p2DmudNBLfuhaTw/C0rt9427cn1IBxVDVpLmS7Ju1kW6wMgoUAGOAB2AFOvbfWLlzK6rDM4UNGLkKWOOu3dwT6VkTz3cDyw3ZfzEbBEhOV4pkRfax4Xk/jS5Pak/wA5pe2K6D50Ac0UDrRk49qAHDHHrXafCTRxrXjS1R8eVbKbhtwyuR93P481xXevTvgayx3uuSk8i2jRT/vP/wDWqJ6I2w6vUR65KIXn3IG2/wAJbv7mtK1RNg+UsfaubiuCZcjgfTitiG4+Xjr71xxetz2Zu0UacixsuUh5HYt1qJpDGm9EAZew6ioFvSoPHbr61Xe73KxIXH1zXQmmYk984uELZfBBYKT0PcfnWNpE6W91/pMSyRg7xC3SVgPlz/sjOcVYS+CtKoG5QoJX1rCu54luY/J+U9XDevtUPe500ZaOJ1ttK3lMzugkYbzx3J/x7VhXEgffGTg5yoPUn2p6Xq4XnJJ5z/hSIIjOzlTkcbscj6VUtdioysbGmg3MUtu+PNdWI3dj1H41FFdEyWszEE8REnsV6fpmozc28LRlSDJsMj+xz0/LFUZ9Qt2jucSRnd86EHBVgc9PzqOXSwk2dOmRG7K+GRsHA4KnoaWW5QTIV43bTtHY45IrIt7zNozgZDDn+Ypl1cCAg7xt4xnr+FTclG8JF85wE/iYD2yM0lxdBM8fIuU4PfANYEV6MBhnk5Jz+YprXqSRllIHIb8qtMlx1OgluBFG7Fg3lEd8kBsHP5cViCVo3mt5clYm2qfoeD+VVzdAuwZsKwPWqc1yzXG/ruUD6Y4ob1LhobV3dbLy68ko28BwR0ORz+tVxeb4x5hUbuOD29/asuSdfN6sF5BI9D/9fFJM8iwI2+JISCCeMsRx070RepXkbNm0C/aJmZGlhAZEboR/EB781Q1KcSu0eQd4yecYPr+VZy3Yj2iIYcEMS3OOMU2a6UxSE8biGxtycg8AHsK0urWDZlzQr1oYjHgOyqU2NyMZ4z+lMiulnuJEZlKgAqW4rCEpS/cg9QCfTJ71KkvlXpQEENwX7dM1j6DvqaFzM7B49+5CASQMYA7VnG6kAYO6gjgH+L25phus4Rgeed3tVX7UTLnghRn5hVNDUjbtHdnRieBn5j61FelsoRIQ4B/4DVKO8zGWLEoR8w6VFe3KzMoUgFuQPQdKSRm52epN5xCyxRjgjPPU+9Q38jFo2OCxQLzxjHes6e/j8zKttXbzz0qrLqSzRbgSZQMD3FFhe0NVruUzFgVyRg8YB45qOdHZVkSMFlHOOM1Sgc48wkgkcKTVq0YvL+8zyOSKq3MU52J4r0yKQF5HBH93/Grdlao7hpW2nqEH9TRb/ZYgHZdx7AnoKmhukP3VVSTzx0os+pm6jexMg8qfzFlw+egqyLeMSSTXVyAoAZhyzSEdh/iaqidW2BAoH3mBFOvdRtowg8xN207hjI+v5UxRepNNcwtLiOFVhJ+RSfuj0J79alknFqxaBUw4PmPuwxGOn0FcnNqixtIImTY2D8wz09DVWTV45AuZm4OcKDSTNm0dFaTCMPdBQ+CcBugx0qjf6rK7sJJtzP1wcVkXOuSTKsJwI0GAvce1UGukZsEtgfhQ12IVVdTYlvAZMFizAYBzwBUUl0JFKRAgDk85xxWSXaMbUGQe9J5kkYG0rk9h/KhEurc0mImKrEzsWGfnGPwx+dXHuoWZ9qf61yyqDwgxjGaoxsyWhmCkPKfKiAGSR/E3tjoPXNQESMuFTac9CO+KdrEKomaMkuUD5AQHZ6npmmPIGUYc7F6A8mqbwyF8EYGc4HNTPA28kZ3HnIpWLVRFn7Sx2ncF2j86s6XqL2GowS/fWFwxQHGQOOv0qhbWheaMtkoCMk+laOkxQWer2813jy0m3P8ALkKOxI74PNOzIlWitCe5g0cD95f3kSn94RNZkvz7k4P1qDWL0XVyjIkqQJEkcfmj52VVwGY+p61cmu3kmubDXboXlo54uFbeYWPIdD1x6rUPiRA2oxR20sc6raQoZEOVJVcUWuSqtmjxD60A0UfX9K6DxQ+lKPWk/DFGcUAOHWu3+FWqJZa/NZyOEj1GHyQScDzFO5B+PI/GuIp0bYPp3BHUe9Jq6sVCTi7o91e7cTnMjDn7uMYrSg1H5R8/615PaeMZGgCalE0kygYuI+r/AO8PX3FWYvGcacCGXHqQK5PZSi9j1frMJx31PVDfDI5yKZJe/Kc88V55a+K4pnA86OIHu+eKmHiFZBhixPbacirSa1Fzp7HYTXQCsWBAchUKnAz1OfbFZD3iyXMkigthshT2rn31QSIxO0Oe6k5xTVvtz7lKj2IxS1vc6aTSOwtb/cRk7WB6kVrW83zDG9pOoA7D/wCvXD2t+BEGBw44x1q19vwmwPz3Oaq91qW7N6HUTXSPKpDEEqRx/KqrlIIxydzZZs9VrE+2jMecEhshs8jjpUD6grSF2kLdzzUppDOr0y+H2GWLdyo4qW91ATwxHcSNnFcjFqCq0m1htPpVQaqBEBu5GQPcVNjLmszpn1BUUABiTyR7VHHqnmZGSq54Ga5WTUl7v096h/thEJy607MHVjY7mTUP3Rbf86dBQ2pKVjO7jPXtg9q4NvEMIbPmgA8EZqsNeRcx+aPLJyCOq1XKzL2se56DJfK6AvnbnaMHn61XuL9WUNwG6OPQ1wya8och5Y2X60yfXYCATKu4emSaHFsarRXU7BtT3EknAOM474oTUhMOCS3TmuBl1yIg7RKT2xUB16ZQRAm0dPmaqUJEzxkOh6N9pCMWZ/mI5I6CqL30fmOFfI657V59LrV5Jw0gC+gFQNqN0wx5zY9KPZMyWMSPRDfRsuFb5id3XOB7/wCFQXGqwwndO6o3UZ44+leeNcyuMNK+PrUZY9ckn3qvZkyxz6I7a/8AFUAjCxCSTjpjANY8viW5dyyooJ9+grny2SfyoyapQSOaWJnLqbKa244dMj2qymvJxhGTHp3rnOvajv2p8iEq8kdWviJCGYueeMYqe28SwxspZ2O3sBwK40nI4oyfypezRaxc0dzJ4rhJxFuwOvvTv+EthEQVImDA5zu61wuaQHr9KORA8VNnZyeKLqZdqERp7Gqp1KZ2yZMnPrXLD1oyexxRyIX1mR1pvHIw8gPtUsMoZDtYD3NcesjggByPxqRLmZM4kJz601BB9Zb3O1jWInLSEseoXvViNIVPAyfWuITUblRjcCPpUi6tcDg7fwpco/b33Z3DCMgA5/E8U+JoEGWXOPyriDrEw4ZQfxpw1qb+6Pzo5QVVHoIvYmByvOMcfpTopU3blABPbHSvPo9bnjO5QKmPiGfgY/EUWY/aR7nfm8TOc9OKZ9oiUlt4yepFefNrcj8ENj60g1p1HCn8TRZjVWKPQhdod3OT/OhrnzbhIbddzO4VAo5YnpXnx16fHC8/WrOj+Ing1a2luDtgyVdxklAyldw+mc/hT5WT7WJ6N5Vmj+U14xmALF0gLRADqd3UgdyBisy+ke1uHhuCFkTng8EEZBBHUEYOaoiXUP7TsrxPt7SW8aIsdvEGglCrgFZs7VjbGTnkZNcn4j1F5r6OKC58xLeBLcyRnCuyjkr7ZOAfQUcrJ9skYQ6fSjHzUUVZzgoGaQ9aKKAD+GlXvRRQBJk5x2pMnAoopAKCTn6U7+HIJB46GiikMVHcSEB2A9jUi3U8QBWZ/wATmiiiw4yd9y5b6hcFt24bgM5rZttRuXiUb8ISTtHTNFFZPY9KjJ9y8l1LgjNZ11cuobaFGDiiipgjSbZkXOqXStsVgoPPAqmbqeQ/NK/4GiitrI8+rJ33GM75ILsfqabnJFFFNGN29wbgcUMBjpRRTAbk0A80UUCFyaTqvNFFMApBRRSAKO1FFAB2oPSiigBo60ooopiQvY0lFFAB2/HFB+6friiigAHRj3GKO2aKKAA9T7Uh44oopAthc8Ui9KKKYDjyeaAM0UUANyc4pQeaKKQAetCnB4oopgHrSjkUUUALvcRmMO4jJ5QMdp/DpTRRRQB//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Macular violaceous erythema is present overlying the joints of the hand.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_48_6915=[""].join("\n");
var outline_f6_48_6915=null;
var title_f6_48_6916="Intermediate ECG test";
var content_f6_48_6916=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intermediate ECG test",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/48/6916/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/48/6916/contributors\">",
"     Ary L Goldberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/48/6916/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/48/6916/contributors\">",
"     David M Mirvis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/48/6916/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/48/6916/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/48/6916/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     CASE 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 53 year-old man presents with the acute onset of crushing chest pain. Physical examination reveals hypotension, elevated jugular venous pressure, but no evidence of pulmonary edema. The diagnosis is established from the electrocardiogram (",
"    <a class=\"graphic graphic_waveform graphicRef82184 \" href=\"UTD.htm?42/19/43322\">",
"     waveform 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef61237 \" href=\"UTD.htm?17/53/18265\">",
"     waveform 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CASE 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient has a history of recurrent syncope. What is the diagnosis (",
"    <a class=\"graphic graphic_waveform graphicRef72945 \" href=\"UTD.htm?37/7/38008\">",
"     waveform 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef64124 \" href=\"UTD.htm?19/60/20421\">",
"     waveform 4",
"    </a>",
"    )?",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CASE 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following electrocardiogram was obtained from a patient with which electrolyte abnormality (",
"    <a class=\"graphic graphic_waveform graphicRef75872 \" href=\"UTD.htm?23/62/24550\">",
"     waveform 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef56952 \" href=\"UTD.htm?21/37/22097\">",
"     waveform 6",
"    </a>",
"    )?",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hyponatremia",
"     </li>",
"     <li>",
"      Hypocalcemia",
"     </li>",
"     <li>",
"      Hypercalcemia",
"     </li>",
"     <li>",
"      Hypokalemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CASE 4",
"    </span>",
"    &nbsp;&mdash;&nbsp;What is the cause of the wide QRS complex (",
"    <a class=\"graphic graphic_waveform graphicRef64687 \" href=\"UTD.htm?40/62/41962\">",
"     waveform 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef78511 \" href=\"UTD.htm?29/12/29895\">",
"     figure 1",
"    </a>",
"    )?",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CASE 5",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following rhythm strip is obtained during exercise (",
"    <a class=\"graphic graphic_waveform graphicRef57553 \" href=\"UTD.htm?15/6/15463\">",
"     waveform 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef67255 \" href=\"UTD.htm?43/6/44130\">",
"     waveform 9",
"    </a>",
"    ). What abnormality is present?",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CASE 6",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    presents with the following arrhythmia (",
"    <a class=\"graphic graphic_waveform graphicRef76280 \" href=\"UTD.htm?37/55/38774\">",
"     waveform 10",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef55277 \" href=\"UTD.htm?2/33/2578\">",
"     waveform 11",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CASE 7",
"    </span>",
"    &nbsp;&mdash;&nbsp;What arrhythmia and conduction disturbance are present (",
"    <a class=\"graphic graphic_waveform graphicRef69112 \" href=\"UTD.htm?38/2/38951\">",
"     waveform 12",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef79090 \" href=\"UTD.htm?8/58/9124\">",
"     waveform 13",
"    </a>",
"    )?",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CASE 8",
"    </span>",
"    &nbsp;&mdash;&nbsp;What conduction abnormality is present (",
"    <a class=\"graphic graphic_waveform graphicRef61820 \" href=\"UTD.htm?29/25/30102\">",
"     waveform 14",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef69487 \" href=\"UTD.htm?28/53/29521\">",
"     waveform 15",
"    </a>",
"    )?",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CASE 9",
"    </span>",
"    &nbsp;&mdash;&nbsp;What arrhythmia is present (",
"    <a class=\"graphic graphic_waveform graphicRef81885 \" href=\"UTD.htm?13/28/13767\">",
"     waveform 16",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef58210 \" href=\"UTD.htm?43/2/44066\">",
"     waveform 17",
"    </a>",
"    )?",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CASE 10",
"    </span>",
"    &nbsp;&mdash;&nbsp;What arrhythmia is responsible for the tachycardia in this patient with underlying chronic lung disease (",
"    <a class=\"graphic graphic_waveform graphicRef61455 \" href=\"UTD.htm?11/41/11927\">",
"     waveform 18",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef70800 \" href=\"UTD.htm?38/63/39922\">",
"     waveform 19",
"    </a>",
"    )?",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CASE 11",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following electrocardiogram is most consistent with which electrolyte disorder (",
"    <a class=\"graphic graphic_waveform graphicRef51818 \" href=\"UTD.htm?40/12/41162\">",
"     waveform 20",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef63569 \" href=\"UTD.htm?17/18/17702\">",
"     waveform 21",
"    </a>",
"    )?",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CASE 12",
"    </span>",
"    &nbsp;&mdash;&nbsp;What dysrhythmia is causing this tachycardia (",
"    <a class=\"graphic graphic_waveform graphicRef73314 \" href=\"UTD.htm?42/25/43418\">",
"     waveform 22",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef52398 \" href=\"UTD.htm?23/50/24361\">",
"     waveform 23",
"    </a>",
"    )? What other abnormal finding is present?",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CASE 13",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following ECG is most consistent with which condition (",
"    <a class=\"graphic graphic_waveform graphicRef66243 \" href=\"UTD.htm?42/22/43370\">",
"     waveform 24",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef77992 \" href=\"UTD.htm?20/9/20633\">",
"     waveform 25",
"    </a>",
"    )?",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hyperkalemia",
"     </li>",
"     <li>",
"      Hypokalemia",
"     </li>",
"     <li>",
"      Hypercalcemia",
"     </li>",
"     <li>",
"      Hypocalcemia",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"       Quinidine",
"      </a>",
"      effect",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CASE 14",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 53 year-old man with congestive heart failure and negative cardiac enzymes who had the same electrocardiographic findings three months previously. What is the diagnosis (",
"    <a class=\"graphic graphic_waveform graphicRef54956 \" href=\"UTD.htm?41/18/42282\">",
"     waveform 26",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef62688 \" href=\"UTD.htm?0/36/584\">",
"     waveform 27",
"    </a>",
"    )?",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CASE 15",
"    </span>",
"    &nbsp;&mdash;&nbsp;What is the abnormal rhythm (",
"    <a class=\"graphic graphic_waveform graphicRef76503 \" href=\"UTD.htm?24/40/25222\">",
"     waveform 28",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef55573 \" href=\"UTD.htm?20/36/21057\">",
"     waveform 29",
"    </a>",
"    )?",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CASE 16",
"    </span>",
"    &nbsp;&mdash;&nbsp;What arrhythmia is present (",
"    <a class=\"graphic graphic_waveform graphicRef69388 \" href=\"UTD.htm?11/53/12119\">",
"     waveform 30",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef79008 \" href=\"UTD.htm?37/38/38498\">",
"     waveform 31",
"    </a>",
"    )?",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CASE 17",
"    </span>",
"    &nbsp;&mdash;&nbsp;What is the abnormal rhythm (",
"    <a class=\"graphic graphic_waveform graphicRef57726 \" href=\"UTD.htm?42/39/43642\">",
"     waveform 32",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef69478 \" href=\"UTD.htm?39/16/40201\">",
"     waveform 33",
"    </a>",
"    )?",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     CASE 18",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 61 year-old woman presents with &ldquo;flash&rdquo; pulmonary edema and negative cardiac enzymes. She is on no cardiac medications. What is the diagnosis (",
"    <a class=\"graphic graphic_waveform graphicRef82379 \" href=\"UTD.htm?41/48/42762\">",
"     waveform 34",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef58680 \" href=\"UTD.htm?30/16/30984\">",
"     waveform 35",
"    </a>",
"    )?",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     CASE 19",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following electrocardiogram is obtained from a 76 year-old man with a history of syncope. What is the diagnosis (",
"    <a class=\"graphic graphic_waveform graphicRef72532 \" href=\"UTD.htm?33/49/34582\">",
"     waveform 36",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef82608 \" href=\"UTD.htm?0/42/674\">",
"     figure 2",
"    </a>",
"    )?",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     CASE 20",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 66 year-old woman presents with the sudden onset of crushing chest pain. What is the diagnosis (",
"    <a class=\"graphic graphic_waveform graphicRef54006 \" href=\"UTD.htm?41/21/42330\">",
"     waveform 37",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef65779 \" href=\"UTD.htm?3/0/3080\">",
"     waveform 38",
"    </a>",
"    )?",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     CASE 21",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 57 year-old man has severe chest pain. What is the diagnosis (",
"    <a class=\"graphic graphic_waveform graphicRef71434 \" href=\"UTD.htm?41/41/42650\">",
"     waveform 39",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef50306 \" href=\"UTD.htm?24/28/25032\">",
"     waveform 40",
"    </a>",
"    )?",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2099 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-704953041C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_48_6916=[""].join("\n");
var outline_f6_48_6916=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      CASE 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CASE 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CASE 3",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CASE 4",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CASE 5",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CASE 6",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CASE 7",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CASE 8",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CASE 9",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CASE 10",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CASE 11",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CASE 12",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CASE 13",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CASE 14",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CASE 15",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CASE 16",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CASE 17",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CASE 18",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      CASE 19",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      CASE 20",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      CASE 21",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/2099\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/2099|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/12/29895\" title=\"figure 1\">",
"      Intermediate case 4 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/42/674\" title=\"figure 2\">",
"      Intermediate case 19 answer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/2099|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/19/43322\" title=\"waveform 1\">",
"      Intermediate case 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?17/53/18265\" title=\"waveform 2\">",
"      Intermediate case 1 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?37/7/38008\" title=\"waveform 3\">",
"      Intermediate case 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?19/60/20421\" title=\"waveform 4\">",
"      Intermediate case 2 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?23/62/24550\" title=\"waveform 5\">",
"      Intermediate case 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?21/37/22097\" title=\"waveform 6\">",
"      Intermediate case 3 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?40/62/41962\" title=\"waveform 7\">",
"      Intermediate case 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?15/6/15463\" title=\"waveform 8\">",
"      Intermediate case 5",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?43/6/44130\" title=\"waveform 9\">",
"      Intermediate case 5 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?37/55/38774\" title=\"waveform 10\">",
"      Intermediate case 6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?2/33/2578\" title=\"waveform 11\">",
"      Intermediate case 6 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?38/2/38951\" title=\"waveform 12\">",
"      Intermediate case 7",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?8/58/9124\" title=\"waveform 13\">",
"      Intermediate case 7 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?29/25/30102\" title=\"waveform 14\">",
"      Intermediate case 8",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?28/53/29521\" title=\"waveform 15\">",
"      Intermediate case 8 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?13/28/13767\" title=\"waveform 16\">",
"      Intermediate case 9",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?43/2/44066\" title=\"waveform 17\">",
"      Intermediate case 9 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?11/41/11927\" title=\"waveform 18\">",
"      Intermediate case 10",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?38/63/39922\" title=\"waveform 19\">",
"      Intermediate case 10 answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?40/12/41162\" title=\"waveform 20\">",
"      Intermediate case 11",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?17/18/17702\" title=\"waveform 21\">",
"      Intermediate case 11 answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/25/43418\" title=\"waveform 22\">",
"      Intermediate case 12",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?23/50/24361\" title=\"waveform 23\">",
"      Intermediate case 12 answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/22/43370\" title=\"waveform 24\">",
"      Intermediate case 13",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?20/9/20633\" title=\"waveform 25\">",
"      Intermediate case 13 answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?41/18/42282\" title=\"waveform 26\">",
"      Intermediate case 14",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?0/36/584\" title=\"waveform 27\">",
"      Intermediate case 14 answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?24/40/25222\" title=\"waveform 28\">",
"      Intermediate case 15",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?20/36/21057\" title=\"waveform 29\">",
"      Intermediate case 15 answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?11/53/12119\" title=\"waveform 30\">",
"      Intermediate case 16",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?37/38/38498\" title=\"waveform 31\">",
"      Intermediate case 16 answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/39/43642\" title=\"waveform 32\">",
"      Intermediate case 17",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?39/16/40201\" title=\"waveform 33\">",
"      Intermediate case 17 answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?41/48/42762\" title=\"waveform 34\">",
"      Intermediate case 18",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?30/16/30984\" title=\"waveform 35\">",
"      Intermediate case 18 answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?33/49/34582\" title=\"waveform 36\">",
"      Intermediate case 19",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?41/21/42330\" title=\"waveform 37\">",
"      Intermediate case 20",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?3/0/3080\" title=\"waveform 38\">",
"      Intermediate case 20 answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?41/41/42650\" title=\"waveform 39\">",
"      Intermediate case 21",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?24/28/25032\" title=\"waveform 40\">",
"      Intermediate case 21 answer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_48_6917="Nervus intermedius (geniculate) neuralgia";
var content_f6_48_6917=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nervus intermedius (geniculate) neuralgia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/48/6917/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/48/6917/contributors\">",
"     Ivan Garza, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/48/6917/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/48/6917/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/48/6917/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/48/6917/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/48/6917/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuralgia is a form of neuropathic pain that is characterized by the following features [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6917/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paroxysmal, brief (seconds to a few minutes), shock-like or lightning-like pain that follows a peripheral or cranial nerve distribution and can spread to adjacent areas in the course of the attack.",
"     </li>",
"     <li>",
"      By definition, no objective neurologic deficits are found in the distribution of the affected nerve. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11431?source=see_link\">",
"       \"Overview of craniofacial pain\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Attacks can be provoked by nonpainful stimulation (allodynia) of trigger points or zones.",
"     </li>",
"     <li>",
"      A refractory period follows attacks; the duration of the refractory period shortens as the disease progresses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nervus intermedius neuralgia is a rare disorder characterized by brief paroxysms of pain felt deeply in the auditory canal [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6917/abstract/4\">",
"     4",
"    </a>",
"    ]. Other terms used are geniculate neuralgia or Hunt neuralgia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6917/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review clinical aspects of nervus intermedius neuralgia. Other cranial neuralgias and central causes of facial pain are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11431?source=see_link\">",
"     \"Overview of craniofacial pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/8/32904?source=see_link\">",
"     \"Central craniofacial pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31090?source=see_link\">",
"     \"Cold stimulus headache\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16243?source=see_link\">",
"     \"Nummular headache\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31509?source=see_link\">",
"     \"Occipital neuralgia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34873?source=see_link\">",
"     \"Trigeminal neuralgia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intermediate nerve of Wrisberg (the nervus intermedius) is a small sensory branch of the facial nerve (cranial nerve VII) carrying general visceral efferent, special visceral afferent (taste), and general somatic afferent fibers (",
"    <a class=\"graphic graphic_figure graphicRef68923 \" href=\"UTD.htm?40/53/41814\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6917/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The cell bodies of the sensory afferents dwell in the geniculate ganglion, and their peripheral axons innervate the inner ear, the middle ear, the mastoid cells, the eustachian tube, and part of the pinna of the ear [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6917/abstract/5,7\">",
"     5,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no proven pathologic substrate for nervus intermedius neuralgia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6917/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, there is no indisputable evidence that the neuralgic pain originates in the geniculate ganglion or the nervus intermedius.",
"   </p>",
"   <p>",
"    Some investigators believe that compression of the nerve by a blood vessel is an important mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6917/abstract/8,9\">",
"     8,9",
"    </a>",
"    ], and relief of pain by vascular decompression of the intermediate nerve provides some support for this position [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6917/abstract/8\">",
"     8",
"    </a>",
"    ]. However, there are multiple cranial nerve afferents in the ear [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6917/abstract/10\">",
"     10",
"    </a>",
"    ], and otalgia in these cases could have resulted from a compromise to the nervus intermedius,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cranial nerves VII, VIII, and other cranial nerves. In different surgical reports, section or decompression of a combination of cranial nerves V, VII, VIII, IX, X,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    XI has been necessary to obtain relief [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6917/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. Thus, the role of vascular compression in the pathogenesis of geniculate and other neuralgias is disputed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6917/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The classification and pathophysiology of neuropathic pain is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11431?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of craniofacial pain\", section on 'Neuropathic pain'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nervus intermedius neuralgia is rare, and only limited data are available regarding the incidence, prevalence, and risk factors associated with this condition. Middle-aged adults, however, seem to be predominantly affected, women more than men [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6917/abstract/1,7\">",
"     1,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The syndrome consists of brief (usually lasting seconds, rarely minutes), severe paroxysmal pain, limited to the depths of the ear, associated with a trigger-zone in the posterior wall of the ear canal. The pain can be sharp or burning. Altered taste perception, such as a sense of bitter taste, can occur in some individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6917/abstract/1,4,7\">",
"     1,4,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of nervus intermedius neuralgia is made on clinical grounds and is based upon pain description. The diagnosis requires ruling out other neurologic and otolaryngologic causes of ear pain [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6917/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The current International Classification of Headache Disorders requires that both of the following diagnostic criteria are present and that symptoms are not attributed to another disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6917/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain paroxysms of intermittent occurrence, lasting for seconds or minutes, in the depth of the ear",
"     </li>",
"     <li>",
"      Presence of a trigger area in the posterior wall of the auditory canal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the condition must be extremely rare if one carefully adheres to these criteria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Differential",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients fitting into the above diagnostic criteria may have a variant of glossopharyngeal neuralgia with pain paroxysms restricted to the ear [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6917/abstract/4\">",
"     4",
"    </a>",
"    ]. This is the main disorder in the differential diagnosis. In such cases, the typical pharyngeal pain of glossopharyngeal neuralgia may not occur until years later [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6917/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11431?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of craniofacial pain\", section on 'Glossopharyngeal neuralgia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a few case reports, vascular compression of cranial nerve VII, the intermediate nerve, and cranial nerve VIII by a loop of the anterior inferior cerebellar artery was identified as the cause of intractable paroxysmal ear pain. One patient also had ipsilateral sensorineural hearing loss, tinnitus, and positional vertigo [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6917/abstract/8\">",
"     8",
"    </a>",
"    ]; another had hemifacial spasm [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6917/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, it is necessary to rule out other neurologic and otolaryngologic causes of ear pain in cases of suspected nervus intermedius neuralgia.",
"   </p>",
"   <p>",
"    The workup requires a contrast-enhanced MRI of the brain, focusing on the internal auditory meatus. Brain MRI is useful for identifying structural brain lesions (eg, demyelinating lesions or a mass lesion in the cerebellopontine angle). Magnetic resonance angiography (MRA) is useful for demonstrating an ectatic blood vessel compressing the nerve. However, the sensitivity and specificity of these imaging studies for identifying a secondary cause of ear pain in patients with suspected nervus intermedius neuralgia and a normal neurologic examination is unknown.",
"   </p>",
"   <p>",
"    We recommend a brain MRI (contrast-enhanced) and MRA for patients with suspected nervus intermedius neuralgia to rule out a structural lesion or vascular compression. Urgent brain imaging is warranted if there are neurologic deficits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rarity of nervus intermedius neuralgia has precluded accumulation of data that could guide therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6917/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]. Pharmacologic treatment is based largely upon extrapolation from treatments that are effective for other cranial neuralgias, mainly trigeminal neuralgia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34873?source=see_link&amp;anchor=H12#H12\">",
"     \"Trigeminal neuralgia\", section on 'Medical therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pharmacotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with trigeminal neuralgia, a trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    is reasonable for patients with nervus intermedius neuralgia. The usual starting dose of carbamazepine is 100 to 200 mg twice daily. The dose can be increased slowly over several weeks as needed for pain relief, with a typical maintenance dose of 600 to 1200 mg daily.",
"   </p>",
"   <p>",
"    Adverse effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    include drowsiness, dizziness, nausea, and vomiting; slow titration may minimize these effects. Carbamazepine-induced leukopenia is not uncommon, but it is usually benign. Aplastic anemia is a rare side effect. The Stevens-Johnson syndrome and toxic epidermal necrolysis are additional rare complications, particularly during the first eight weeks of therapy. They are significantly more common (estimated incidence of 5 percent) among patients with the HLA-B*1502 allele [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6917/abstract/12\">",
"     12",
"    </a>",
"    ]. This allele occurs almost exclusively in patients of Asian ancestry, including South Asian Indians. Screening for this allele is recommended in patients of these ethnic groups prior to starting carbamazepine [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6917/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who do not tolerate or respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , alternative drugs include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"     baclofen",
"    </a>",
"    . In addition, tricyclics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    ) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    are useful in other types of neuropathic pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurosurgery is considered as a last resort when pharmacotherapy fails.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most often, the procedure involves excision of the nervus intermedius and geniculate ganglion [",
"      <a class=\"abstract\" href=\"UTD.htm?6/48/6917/abstract/13\">",
"       13",
"      </a>",
"      ], with or without exploration",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      section of cranial nerves V, IX, and X [",
"      <a class=\"abstract\" href=\"UTD.htm?6/48/6917/abstract/14\">",
"       14",
"      </a>",
"      ]. The surgeon may elect to perform vascular decompression if a potential offending vessel is seen during exploration. One series of 64 patients who had excision of the nervus intermedius and geniculate ganglion reported \"excellent\" results in 63 patients, but outcomes were not objectively defined in this report [",
"      <a class=\"abstract\" href=\"UTD.htm?6/48/6917/abstract/13\">",
"       13",
"      </a>",
"      ]. Complications included a temporary partial facial paralysis in 11 patients (17 percent). In addition, permanent ipsilateral xerophthalmia is an expected outcome, due to sectioning of the greater petrosal nerve as part of the surgical approach to the geniculate ganglion.",
"     </li>",
"     <li>",
"      Microvascular decompression of cranial nerves V, IX, and X, with or without section of the nervus intermedius, is another option. In a series of 10 patients with nervus intermedius neuralgia treated with microvascular decompression who had long-term (&gt;12 months) follow-up, an \"excellent\" outcome was reported for three patients, and partial relief for six [",
"      <a class=\"abstract\" href=\"UTD.htm?6/48/6917/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nervus intermedius neuralgia is a rare disorder characterized by brief paroxysms of pain felt deeply in the auditory canal. Other terms used are geniculate neuralgia or Hunt neuralgia. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction and definition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The symptoms of nervus intermedius neuralgia consist of episodes of brief (seconds to minutes), severe paroxysmal pain, limited to the depths of the ear, associated with a trigger-zone in the posterior wall of the ear canal. Pain can be sharp or burning. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of nervus intermedius neuralgia is made on clinical grounds and is based upon pain description. The diagnosis requires ruling out other neurologic and otolaryngologic causes of ear pain. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis includes atypical presentations of glossopharyngeal neuralgia with pain paroxysms restricted to the ear, and vascular compression of cranial nerves VII, VIII, and the intermediate nerve. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Differential'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with suspected nervus intermedius neuralgia, we recommend a contrast-enhanced brain MRI and MRA to rule out a structural lesion or vascular compression. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with nervus intermedius neuralgia, we suggest initial treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Alternatives include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/25/40344?source=see_link\">",
"       oxcarbazepine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"       pregabalin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"       baclofen",
"      </a>",
"      , and tricyclic drugs such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      . Neurosurgical treatment is an option if pharmacotherapy fails. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6917/abstract/1\">",
"      Bruyn GW. Nervus intermedius neuralgia (Hunt). Cephalalgia 1984; 4:71.",
"     </a>",
"    </li>",
"    <li>",
"     Peter, C, Watson, N. Trigeminal neuropathy and neuralgia. In: Neurological therapeutics: Principles and practice, Noseworthy, JH (Ed), Martin Dunitz, London, New York 2003. p.1849.",
"    </li>",
"    <li>",
"     Goodwin, JG, Bajwa, ZH. Understanding the patient with chronic pain. In: Principles and practice of pain medicine, Warfield, CA, Bajwa, ZH (Eds), McGraw-Hill, USA 2004. p.55.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6917/abstract/4\">",
"      Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     Nurmikko, TJ, Jensen, TS. Trigeminal neuralgia and other facial neuralgias. In: The headaches, Olesen, J, Goadsby, PJ, et al (Eds), Lippincott Williams and Wilkins, Philadelphia, PA 2006. p.1053.",
"    </li>",
"    <li>",
"     Vytopil, M, Catalano, PJ, Jones, HR Jr. Cranial nerve VII: facial. In: Netter's Neurology, Jones, HR Jr (Ed), Icon Learning Systems, Teterboro, New Jersey 2005. p.112.",
"    </li>",
"    <li>",
"     Boes, CJ, Copobianco, DJ, Cutrer, FM, et al. Headache and other craniofacial pain. In: Neurology in clinical practice, Bradley, WG, Daroff, RB, Fenichel, GM, et al (Eds), Butterworth Heinemann, Philadelphia, PA 2004. p.2055.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6917/abstract/8\">",
"      Sakas DE, Panourias IG, Stranjalis G, et al. Paroxysmal otalgia due to compression of the intermediate nerve: a distinct syndrome of neurovascular conflict confirmed by neuroimaging. Case report. J Neurosurg 2007; 107:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6917/abstract/9\">",
"      Yeh HS, Tew JM Jr. Tic convulsif, the combination of geniculate neuralgia and hemifacial spasm relieved by vascular decompression. Neurology 1984; 34:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6917/abstract/10\">",
"      Shah RK, Blevins NH. Otalgia. Otolaryngol Clin North Am 2003; 36:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6917/abstract/11\">",
"      Monstad P. Microvascular decompression as a treatment for cranial nerve hyperactive dysfunction--a critical view. Acta Neurol Scand Suppl 2007; 187:30.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Alert. Information for healthcare professionals: Carbamazepine (marketed as Carbatrol, Equetro, Tegretol, and generics). Available at www.fda.gov/cder/drug/InfoSheets/HCP/carbamazepineHCP.htm/ (Accessed on April 4, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6917/abstract/13\">",
"      Pulec JL. Geniculate neuralgia: long-term results of surgical treatment. Ear Nose Throat J 2002; 81:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6917/abstract/14\">",
"      Rupa V, Saunders RL, Weider DJ. Geniculate neuralgia: the surgical management of primary otalgia. J Neurosurg 1991; 75:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6917/abstract/15\">",
"      Lovely TJ, Jannetta PJ. Surgical management of geniculate neuralgia. Am J Otol 1997; 18:512.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3331 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6F4C19BDB0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_48_6917=[""].join("\n");
var outline_f6_48_6917=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Differential",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/3331\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/3331|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/53/41814\" title=\"figure 1\">",
"      Nervus intermedius",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/8/32904?source=related_link\">",
"      Central craniofacial pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31090?source=related_link\">",
"      Cold stimulus headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16243?source=related_link\">",
"      Nummular headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31509?source=related_link\">",
"      Occipital neuralgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11431?source=related_link\">",
"      Overview of craniofacial pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34873?source=related_link\">",
"      Trigeminal neuralgia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_48_6918="Panitumumab: Drug information";
var content_f6_48_6918=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Panitumumab: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?25/26/26020?source=see_link\">",
"    see \"Panitumumab: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3343189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vectibix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F6826223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Vectibix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F3343193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Monoclonal Antibody;",
"     </li>",
"     <li>",
"      Epidermal Growth Factor Receptor (EGFR) Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F3343261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Colorectal cancer, metastatic,",
"      <i>",
"       KRAS",
"      </i>",
"      mutation-negative:",
"     </b>",
"     I.V.: 6 mg/kg every 14 days as a single agent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Colorectal cancer, metastatic (",
"      <i>",
"       KRAS",
"      </i>",
"      wild-type), in combination with FOLFIRI (unlabeled use):",
"     </b>",
"     I.V.: 6 mg/kg every 14 days in combination with fluorouracil, leucovorin, and irinotecan (Peeters, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3343262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F3343263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F3343264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F3343265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infusion reactions, mild-to-moderate (grade 1 or 2): Reduce the infusion rate by 50% for the duration of infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infusion reactions, severe (grade 3 or 4): Stop infusion; consider permanent discontinuation (depending on severity or persistence of reaction).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic toxicity (&ge;grade 3, or intolerable): Withhold treatment; if skin toxicity does not improve to &le;grade 2 within 1 month, permanently discontinue. If skin toxicity improves to &le;grade 2 within 1 month (with patient missing &le;2 doses), resume treatment at 50% of the original dose. Dose may be increased in increments of 25% of the original dose (up to 6 mg/kg) if skin toxicities do not recur. For recurrent skin toxicity, permanently discontinue.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ocular toxicity (acute or worsening keratitis): Interrupt or discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pulmonary toxicity:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Acute onset or worsening pulmonary symptoms: Interrupt treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Interstitial lung disease: Permanently discontinue treatment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3343274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vectibix&reg;: 20 mg/mL (5 mL, 10 mL [DSC], 20 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F3343191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3343266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Doses &le;1000 mg, infuse over 1 hour; doses &gt;1000 mg, infuse over 90 minutes (via infusion pump); do not administer I.V. push or as a bolus. Administer through a low protein-binding 0.2 or 0.22 micrometer in-line filter. Flush with NS before and after infusion. Reduce infusion rate by 50% for mild-to-moderate infusion reactions (grades 1 and 2); stop infusion for severe infusion reactions (grades 3 and 4) and consider permanent discontinuation.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F14642042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F3343195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monotherapy in treatment of EGFR-expressing refractory metastatic colorectal cancer with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Panitumumab is not indicated for the treatment of patients with",
"     <i>",
"      KRAS",
"     </i>",
"     mutation-positive metastatic colorectal cancer or patients in which",
"     <i>",
"      KRAS",
"     </i>",
"     mutation status is unknown. Subset analyses (retrospective) in metastatic colorectal cancer trials have not shown a benefit with EGFR inhibitor treatment in patients whose tumors have codon 12 or 13",
"     <i>",
"      KRAS",
"     </i>",
"     mutations.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F14642038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of metastatic colorectal cancer (KRAS wild-type) in combination with other chemotherapy agents",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14471958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Panitumumab may be confused with pertuzumab",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F3343246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Peripheral edema (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (26%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Skin toxicity (90%; grades 3/4: 14% to 16%), erythema (65%; grades 3/4: 5%), acneiform rash (57%; grades 3/4: 7%), pruritus (57%; grades 3/4: 2%), nail toxicity (29%; grades 3/4: 2%), exfoliation (25%; grades 3/4: 2%), paronychia (25%), rash (22%; grades 3/4: 1%), fissures (20%; grades 3/4: 1%), acne (13%; grades 3/4: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypomagnesemia (38%; grades 3/4: 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Abdominal pain (25%), nausea (23%), diarrhea (21%; grades 3/4: 2%), constipation (21%), vomiting (19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Ocular toxicity (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Cough (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Dry skin (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Stomatitis (7%), mucositis (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Eyelash growth (6%), conjunctivitis (4%), ocular hyperemia (3%), lacrimation increased (2%), eye/eye lid irritation (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Antibody formation (&le;5%), infusion reactions (3%; grades 3/4: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Abscess, allergic reaction, anaphylactoid reaction, angioedema, chills, dyspnea, fever, hypocalcemia, hypoxia, keratitis, keratitis ulcerative, pulmonary embolism, pulmonary fibrosis, pulmonary infiltrate, sepsis, septic death, skin necrosis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F3343241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3343242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic toxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Dermatologic toxicities have been reported in ~90% of patients receiving single agent panitumumab and were severe (grade 3 or higher) in ~12% of patients;",
"     </b>",
"     may include dermatitis acneiform, pruritus, erythema, rash, skin exfoliation, paronychia, dry skin and skin fissures. Severe skin toxicities may be complicated by infection, sepsis, or abscesses. The median time to development of skin (or ocular) toxicity was 2 weeks, with resolution ~12 weeks after discontinuation. The severity of dermatologic toxicity is predictive for response; grades 2-4 skin toxicity correlates with improved progression free survival and overall survival, compared to grade 1 skin toxicity (Peeters, 2009; Van Cutsem, 2007). Monitor all dermatologic toxicities for development of inflammation or infection. Withhold treatment for severe or life-threatening dermatologic toxicities; may require dose reduction or permanent discontinuation. Patients should minimize sunlight exposure; may exacerbate skin reactions. Nail toxicity has also been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diarrhea: May cause diarrhea; the incidence and severity of chemotherapy-induced diarrhea is increased with combination chemotherapy. Severe diarrhea and dehydration (which may lead to acute renal failure) has been observed with panitumumab in combination with chemotherapy.  Gastric mucosal toxicity has also been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte depletion: Magnesium and/or calcium depletion may occur during treatment (may be delayed; hypomagnesemia occurred &ge;6 weeks after panitumumab initiation) and after treatment is discontinued; electrolyte repletion may be necessary. Monitor for hypomagnesemia and hypocalcemia during treatment and for at least 8 weeks after completion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infusion reactions:",
"     <b>",
"      [U.S. Boxed Warning]: Severe infusion reactions (anaphylactic reaction, bronchospasm, fever, chills, and hypotension) have been reported in ~1% of patients; fatal infusion reactions have been reported with postmarketing surveillance.",
"     </b>",
"     Discontinue infusion for severe reactions; permanently discontinue in patients with persistent severe infusion reactions. Appropriate medical support for the management of infusion reactions should be readily available. Mild-to-moderate infusion reactions are managed by slowing the infusion rate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular toxicity: Keratitis and ulcerative keratitis (known risk factors for corneal perforation) have occurred.  Monitor for evidence of ocular toxicity; interrupt or discontinue treatment for acute or worsening keratitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary fibrosis: Has been observed (rarely) in clinical trials; fatalities have been reported. Interrupt treatment for acute onset or worsening of pulmonary symptoms; permanently discontinue treatment if interstitial lung disease is confirmed. Patients with a history of or evidence of interstitial pneumonitis or pulmonary fibrosis were excluded from most clinical trials.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Colorectal cancer and",
"     <i>",
"      KRAS",
"     </i>",
"     mutation status: Patients with a codon 12 or 13",
"     <i>",
"      KRAS",
"     </i>",
"     mutation are unlikely to benefit from EGFR inhibitor therapy. Panitumumab is not indicated patients with",
"     <i>",
"      KRAS",
"     </i>",
"     mutation-positive metastatic colorectal cancer or patients in which",
"     <i>",
"      KRAS",
"     </i>",
"     mutation status is unknown. In a study of FOLFOX4 (fluorouracil, leucovorin and oxaliplatin) &plusmn; panitumumab, patients with a",
"     <i>",
"      KRAS",
"     </i>",
"     mutation who received panitumumab with FOLFOX4 experienced a significantly shortened progression-free survival (Douillard, 2010); panitumumab should not be used in combination with oxaliplatin-based regimens in patients with",
"     <i>",
"      KRAS",
"     </i>",
"     mutation or if mutation status is unknown. Panitumumab is also reported to be ineffective in patients with BRAF V600E mutation (Di Nicolantonio, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; EGFR expression testing: According to the manufacturer, evidence of EGFR expression is necessary to determine patient selection (the Dako EGFR pharmDX&reg; kit has been used).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bevacizumab and combination chemotherapy: In a study of bevacizumab with combination chemotherapy &plusmn; panitumumab, the use of panitumumab resulted in decreased progression-free survival and significantly increased toxicity compared to regimens without panitumumab (Hecht, 2009). Toxicities included rash, diarrhea/dehydration, electrolyte disturbances, stomatitis, infection, and an increased incidence of pulmonary embolism.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F3343196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3343197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have demonstrated adverse fetal effects. Based on animal studies, panitumumab may disrupt normal menstrual cycles. IgG is known to cross the placenta; therefore, it is possible the developing fetus may be exposed to panitumumab. Because panitumumab inhibits epidermal growth factor (EGF), a component of fetal development, adverse effects on pregnancy would be expected. Panitumumab should only be given to a pregnant woman if the potential benefit justifies the potential risk to the fetus. Women of childbearing potential should use effective contraception during and for 6 months after treatment. Women who become pregnant during panitumumab treatment are encouraged to enroll in Amgen&rsquo;s Pregnancy Surveillance Program (1-800-772-6436).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F3343199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3343200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The decision to discontinue panitumumab or discontinue breast-feeding should take into account the benefits of treatment to the mother. If breast-feeding is interrupted for panitumumab treatment, based on the half-life, breast-feeding should not be resumed for at least 2 months following the last dose.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F5685563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Vectibix Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/5 mL (5 mL): $1069.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg/20 mL (20 mL): $4276.08",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3343269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <i>",
"      KRAS",
"     </i>",
"     genotyping of tumor tissue. Monitor serum electrolytes, including magnesium and calcium (periodically during and for at least 8 weeks after therapy). Monitor vital signs and temperature before, during, and after infusion. Monitor for skin toxicity, for evidence of ocular toxicity, and for acute onset or worsening pulmonary symptoms.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6875345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Vectibix (AT, AU, BE, CH, CZ, DE, DK, EE, FR, GB, GR, HN, IE, IL, IT, NO, PL, PT, RU, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3343255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recombinant human IgG2 monoclonal antibody which binds specifically to the epidermal growth factor receptor (EGFR, HER1, c-ErbB-1) and competitively inhibits the binding of epidermal growth factor (EGF) and other ligands. Binding to the EGFR blocks phosphorylation and activation of intracellular tyrosine kinases, resulting in inhibition of cell survival, growth, proliferation and transformation. EGFR signal transduction results in",
"     <i>",
"      KRAS",
"     </i>",
"     wild-type activation; cells with",
"     <i>",
"      KRAS",
"     </i>",
"     mutations appear to be unaffected by EGFR inhibition.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F3343257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Half-life elimination: ~7.5 days (range: 4-11 days)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Allegra CJ, Jessup JM, Somerfield MR, et al, &ldquo;American Society of Clinical Oncology Provisional Clinical Opinion: Testing for",
"      <i>",
"       KRAS",
"      </i>",
"      Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy, &rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(12):2091-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/48/6918/abstract-text/19188670/pubmed\" id=\"19188670\" target=\"_blank\">",
"        19188670",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Amado RG, Wolf M, Peeters M, et al, &ldquo;Wild-Type KRAS is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(10):1626-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/48/6918/abstract-text/18316791/pubmed\" id=\"18316791\" target=\"_blank\">",
"        18316791",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Di Nicolantonio F, Martini M, Molinari F, et al, &ldquo;Wild-type BRAF is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(35):5705-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/48/6918/abstract-text/19001320/pubmed\" id=\"19001320\" target=\"_blank\">",
"        19001320",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Douillard JY, Siena S, Cassidy J, et al, \"Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone as First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(31):4697-705.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/48/6918/abstract-text/20921465/pubmed\" id=\"20921465\" target=\"_blank\">",
"        20921465",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hecht JR, Mitchell E, Chidiac T, et al, &ldquo;A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(5):672-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/48/6918/abstract-text/19114685/pubmed\" id=\"19114685\" target=\"_blank\">",
"        19114685",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lynch DH and Yang XD, &ldquo;Therapeutic Potential of ABX-EGF: A Fully Human Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Cancer Treatment,&rdquo;",
"      <i>",
"       Sem Oncol",
"      </i>",
"      , 2002, 29(1 Suppl 4):47-50.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Colon Cancer,&rdquo; Version 3, 2012. Available at file://www.nccn.org/professionals/physician_gls/PDF/colon.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Peeters M, Price TJ, Cervantes A, et al, \"Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone as Second-Line Treatment in Patients With Metastatic Colorectal Cancer,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(31):4706-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/48/6918/abstract-text/20921462/pubmed\" id=\"20921462\" target=\"_blank\">",
"        20921462",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Peeters M, Siena S, Van Cutsem E, et al, &ldquo;Association of Progression-Free Survival, Overall Survival, and Patient-Reported Outcomes by Skin Toxicity and KRAS Status in Patients Receiving Panitumumab Monotherapy,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2009, 115(7):1544-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/48/6918/abstract-text/19189371/pubmed\" id=\"19189371\" target=\"_blank\">",
"        19189371",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rowinsky EK, Schwartz GH, Gollob JA, et al, &ldquo;Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti-Epidermal Growth Factor Receptor Monoclonal Antibody in Patients with Metastatic Renal Cell Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(15):3003-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/48/6918/abstract-text/15210739/pubmed\" id=\"15210739\" target=\"_blank\">",
"        15210739",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Segaert S and Van Cutsem E, &ldquo;Clinical Signs, Pathophysiology and Management of Skin Toxicity During Therapy with Epidermal Growth Factor Receptor Inhibitors,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2005, 16(9): 1425-33.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Cutsem E, Peeters M, Siena S, et al, &ldquo;Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(13):1658-64.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10336 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-24A2ECD58B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_48_6918=[""].join("\n");
var outline_f6_48_6918=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709195\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3343189\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6826223\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3343193\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3343261\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3343262\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3343263\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3343264\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3343265\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3343274\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3343191\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3343266\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14642042\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3343195\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14642038\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471958\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3343246\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3343241\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3343242\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299817\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222127\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3343196\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3343197\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3343199\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3343200\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5685563\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3343269\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6875345\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3343255\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3343257\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10336\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10336|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/26/26020?source=related_link\">",
"      Panitumumab: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_48_6919="Superior view female pelvis";
var content_f6_48_6919=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F82997&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F82997&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Superior view of the female pelvis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    View of female pelvis during laparotomy. Pelvic posterior cul-de-sac (pouch of Douglas) is well visualized.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_48_6919=[""].join("\n");
var outline_f6_48_6919=null;
var title_f6_48_6920="Advanced case 7 with answer";
var content_f6_48_6920=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Acute infero-postero-lateral myocardial infarction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electrocardiogram showing the major features of an inferior (Q waves, ST elevations, and T wave inversions in II, III, and aVF), posterior (tall R waves in V1 and V2), and lateral (T wave inversions in V4 to V6) myocardial infarction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_48_6920=[""].join("\n");
var outline_f6_48_6920=null;
var title_f6_48_6921="Clinical manifestations and diagnosis of the Raynaud phenomenon";
var content_f6_48_6921=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of the Raynaud phenomenon",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/48/6921/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/48/6921/contributors\">",
"     Fredrick M Wigley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/48/6921/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/48/6921/contributors\">",
"     John S Axford, DSc, MD, FRCP, FRCPCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/48/6921/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/48/6921/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/48/6921/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Raynaud phenomenon (RP) is an exaggerated vascular response to cold temperature or emotional stress. The phenomenon is manifested clinically by sharply demarcated color changes of the skin of the digits. Abnormal vasoconstriction of digital arteries and cutaneous arterioles due to a local defect in normal vascular responses is thought to underlie the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    RP is considered primary if these symptoms occur alone without evidence of any associated disorder. By comparison, secondary RP refers to the presence of the disorder in association with a related illness, such as systemic lupus erythematosus and scleroderma.",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of the Raynaud phenomenon are reviewed here. The pathogenesis and treatment of this disorder are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23719?source=see_link\">",
"     \"Pathogenesis of the Raynaud phenomenon\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28200?source=see_link\">",
"     \"Initial treatment of the Raynaud phenomenon\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28138?source=see_link\">",
"     \"Treatment of the Raynaud phenomenon resistant to initial therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Establishing the true prevalence of RP is hampered by the lack of a well-defined reproducible \"gold standard\" diagnostic test. Cold hands and feet are a normal physiological response to cold exposure that, to preserve heat, cools the surface skin and causes skin color changes. RP is an exaggerated vascular response to cold temperature or emotional stress. Although survey criteria vary, most investigators agree that a history of at least two color changes (pallor and cyanosis) after cold exposure is necessary for a definite diagnosis.",
"   </p>",
"   <p>",
"    Community-based surveys have been performed to estimate the prevalence of RP in the general population. In these surveys, estimates of the prevalence of RP have ranged from 3 to 20 percent in women and 3 to 14 percent in men.",
"   </p>",
"   <p>",
"    These relatively wide ranges reflect, in part, the populations that are studied:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      RP is more common in France (17 percent) than in the United States (5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Definite RP was noted in 2 and 5 percent of healthy males and females in Turkey [",
"      <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/3\">",
"       3",
"      </a>",
"      ], 0.9 and 6.4 percent of males and females in a survey in Greece [",
"      <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/4\">",
"       4",
"      </a>",
"      ], 3.3 and 2.5 percent of males and females in a Japanese population [",
"      <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/5\">",
"       5",
"      </a>",
"      ], and 4.9 and 18.8 percent of males and females in a small New Zealand survey [",
"      <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/6\">",
"       6",
"      </a>",
"      ], while the disorder was reported in 6 percent of Hungarians [",
"      <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A survey performed by the author in an African-American community found a prevalence of 3 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A survey of 720 children ages 12 to 15 found a prevalence of 15 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/9\">",
"       9",
"      </a>",
"      ]. Among children, it is more common in females with a mean age of onset of about 12 years [",
"      <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    RP is more common among young women, younger age groups, and family members of patients with RP [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/11\">",
"     11",
"    </a>",
"    ]. A review found a 0.1 to 1 percent prevalence of RP among individuals over the age of 60 years [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/12\">",
"     12",
"    </a>",
"    ]. RP often starts early in life, but the prevalence then appears to remain relatively constant throughout life [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/13\">",
"     13",
"    </a>",
"    ]. Additionally, the prevalence of RP found in a given population is influenced by the climate of the region studied [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Raynaud phenomenon most often affects the hand. Attacks also frequently occur in the toes, but patients are less likely to complain of lower extremity symptoms. A typical episode is characterized by the sudden onset of cold fingers (or toes) in association with sharply demarcated color changes of skin pallor (white attack)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cyanotic skin (blue attack) (",
"    <a class=\"graphic graphic_picture graphicRef66438 \" href=\"UTD.htm?15/41/16018\">",
"     picture 1",
"    </a>",
"    ). With rewarming, the ischemic phase (white or blue attack) usually lasts for 15 to 20 minutes. The skin subsequently blushes upon recovery, thereby resulting in the erythema of reperfusion.",
"   </p>",
"   <p>",
"    A Raynaud attack typically begins in a single finger and then spreads to other digits symmetrically in both hands. The index, middle, and ring finger are the most frequently involved digits, while the thumb is often spared entirely [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/15\">",
"     15",
"    </a>",
"    ]. Involvement of the thumb may indicate a secondary cause of RP [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/16\">",
"     16",
"    </a>",
"    ]. Cutaneous vasospasm is also common at other sites, including the skin of the ears, nose, face, knees, and nipples. A common pathophysiologic feature of affected areas is the presence of thermoregulatory vessels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17658?source=see_link&amp;anchor=H86655702#H86655702\">",
"     \"Common problems of breastfeeding and weaning\", section on 'Nipple vasoconstriction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Symptoms of low blood flow and ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms of RP may include complaints resulting from low blood flow or ischemia. As an example, mild RP may be associated with sensations of pins and needles, numbness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    clumsiness of the hand, and finger aching. The signs of uncomplicated RP should be completely reversible on rewarming or reduction of stress. In severe secondary RP, pain or ulceration of the skin (typically the tips of the fingers and toes) may result from critical tissue ischemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Livedo reticularis",
"    </span>",
"    &nbsp;&mdash;&nbsp;During a cold response, patients with RP may exhibit livedo reticularis; this is a violaceous mottling or reticular pattern of the skin of the arms and legs, sometimes with regular unbroken circles. In those with RP, this finding is benign and completely reversible with rewarming.",
"   </p>",
"   <p>",
"    By comparison, non-reversible livedo reticularis may be observed in patients with vasculitis, occlusive vascular disease (eg, due to atheroemboli or thrombosis), or antiphospholipid syndrome. These cutaneous changes may also be associated with irregular broken circles. Due to these differences, some experts advocate use of the term \"livedo racemosa\" rather than \"livedo reticularis\" for these cutaneous findings in patients with inflammatory or thrombotic vascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=see_link\">",
"     \"Mucocutaneous manifestations of systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Provoking factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients note that exposure to cold temperature triggers RP. More importantly, the provocation occurs during relative shifts from warmer to cooler temperatures. As a result, mild cold exposures such as air-conditioning or the cold of the refrigerated food section of the grocery store may cause an attack. Although attacks occur locally in the fingers, a general body chill will also trigger an episode, even if the hands or feet areas are kept warm. To avoid RP, therefore, patients must maintain whole body warmth.",
"   </p>",
"   <p>",
"    An attack of RP may also occur after stimulation of the sympathetic nervous system (such as emotional stress, sudden startling). It is not uncommon for the clinician to witness a typical attack during the first encounter with a frightened or nervous patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnosis of RP may be made if the patient provides a history of the sudden onset of symptoms characteristic of a Raynaud attack. Such a history alone must be accepted as diagnostic, since no simple office test consistently triggers an attack.",
"   </p>",
"   <p>",
"    Attempts to induce an attack, such as a cold water challenge, are NOT recommended since the responses are inconsistent even in those with definite RP. However, digital vascular responses to cooling, using complex instrumentation to measure digital blood pressure, digital blood flow, and skin temperature, may distinguish patients with primary RP from normal individuals and those with scleroderma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diagnostic tools used to assess the vascular responses in the digits and skin include nailfold capillaroscopy, videomicroscopy, thermography, angiography, laser Doppler imaging, and direct measures of skin temperature and local blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/19\">",
"     19",
"    </a>",
"    ]. Nailfold capillaroscopy, thermal imaging, and laser Doppler imaging each independently provide good discrimination between healthy controls and primary RP [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/20\">",
"     20",
"    </a>",
"    ]. The response of the digital systolic blood pressure to cooling is associated with the RP attack frequency and has been used in clinical trials as a measure of RP severity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Raynaud condition score is a clinical scale used to assess severity of the RP from the perspective of the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/22\">",
"     22",
"    </a>",
"    ]. The score is determined by asking patients how these attacks impact their quality of life when considering the number and duration of attacks each day; the associated symptoms such as numbness, tingling, and pain; and the disability it causes in daily activity. This score correlates with other scales of well-being and is used as a primary outcome in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Finger systolic pressure and response to cold challenge (digital artery closing temperature) can be measured in a laboratory setting [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/24\">",
"     24",
"    </a>",
"    ]. These laboratory-based tools are useful for studying the physiology of RP but may not predict response to therapy or severity of RP in an ambulatory setting.",
"   </p>",
"   <p>",
"    The complaint of cold hands or feet is very common in the general population and must be distinguished from RP, which involves both cool skin and cutaneous color changes. Normal individuals will cool the skin and may experience some skin mottling on cold exposure. However, unlike in RP, the recovery phase of vascular flow is not delayed and there is no prolonged sharp demarcation of color changes in skin.",
"   </p>",
"   <p>",
"    To aid in making a diagnosis, one investigator has introduced the use of a standard questionnaire and actual color photos of witnessed attacks that the patient must identify [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. This method has been used in epidemiologic studies investigating the prevalence of RP in the community [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/2,27\">",
"     2,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H342907650\">",
"    <span class=\"h2\">",
"     Clinical criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical criteria describing relative degrees of certainty in the diagnosis of RP have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Definite RP &mdash; Repeated episodes of biphasic color changes upon exposure to cold",
"     </li>",
"     <li>",
"      Possible RP &mdash; Uniphasic color changes plus numbness or paresthesia upon exposure to cold",
"     </li>",
"     <li>",
"      No RP &mdash; No color changes upon exposure to cold",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These criteria are used for the diagnosis of RP in the research setting. We make the diagnosis of RP in the clinical setting based upon a history of uniphasic color changes (blue or white events) or direct witnessing of an event during physical examination.",
"   </p>",
"   <p>",
"    Prior to discussing the evaluation of the patient with RP, it is helpful to first briefly review the definition and clinical characteristics of the primary and secondary forms of the disorder. The presence or absence of these findings helps direct patient assessment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H357333852\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several disorders that can mimic RP. Many individuals report excessive cold sensitivity of cold hands and feet when they are exposed to a cold environment, but they do not see skin color changes. In one study, 10 percent of those surveyed had cold sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/29\">",
"     29",
"    </a>",
"    ]. This common complaint of cold hands and feet may be a family trait [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/30\">",
"     30",
"    </a>",
"    ]. Cold sensitivity and decreased skin blood flow following cold exposure occurs more commonly in women and in the older population [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    External compression of the blood vessels (eg, sleeping with an arm under the body) can cause transient decrease in blood flow, and, as a consequence, a hand and fingers can be temporally numb, pale,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cold.",
"   </p>",
"   <p>",
"    Peripheral neuropathy can cause cold intolerance with numbness and skin color changes in the hands and feet, or it can be associated with altered cutaneous blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. In complex regional pain syndrome (CRPS), abnormal vasodilation and constriction of cutaneous vessels alter temperature tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occlusive vascular disease (emboli, thrombosis, vasculitis, atherosclerosis) either can cause a cold limb, hand, foot, or digit or can be associated tissue ischemia with secondary vasospasm that mimics true RP.",
"   </p>",
"   <p>",
"    Acrocyanosis is a disorder which causes symmetrical painless and persistent blue discoloration of the hands or feet without the sharp transient events of skin color changes (eg, pallor) seen in RP [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/35\">",
"     35",
"    </a>",
"    ]. It is aggravated by cold exposure and is often associated with hyperhidrosis of hands and feet. Acrocyanosis has also been divided into an idiopathic benign form and a long list of associated secondary causes (eg, medications, hypoxia, malignancy, anorexia nervosa) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/35\">",
"     35",
"    </a>",
"    ]. Unlike RP, acrocyanosis rarely responds to vasodilator therapy. Patients with RP may have associated features of acrocyanosis including damp palms and soles with excess sweating and some degree of persistent cyanosis. A benign &ldquo;blue finger syndrome&rdquo; is reported when a digit becomes cyanotic and then recovers without defined secondary cause [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Erythromelalgia (EM) is an exaggerated blushing of the skin that can mimic the recovery phase or hyperemic phase of RP [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/37\">",
"     37",
"    </a>",
"    ]. The vasodilatation associated with EM is triggered by a warm temperature and is improved with cold exposure. An idiopathic primary form of EM exists, and a variety of secondary forms are reported (eg, polycythemia vera, neuropathies, autoimmune disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PRIMARY AND SECONDARY RAYNAUD PHENOMENON",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with RP are considered to have either a primary or secondary process:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary RP &mdash; Primary RP or idiopathic Raynaud disease have become popular terms to describe those patients without a definable cause for their vascular events. In this setting, RP is considered to be an exaggeration of normal vasoconstriction to cold exposure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23719?source=see_link\">",
"       \"Pathogenesis of the Raynaud phenomenon\"",
"      </a>",
"      .) Most investigators feel the term \"disease\" is inappropriate and prefer using the term primary RP for otherwise healthy individuals.",
"     </li>",
"     <li>",
"      Secondary RP &mdash; Secondary RP refers to those patients with RP in whom an associated disease or cause may underlie the attacks [",
"      <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/27\">",
"       27",
"      </a>",
"      ]. Other investigators prefer the term Raynaud syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Primary RP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary RP has an age of onset between 15 and 30 years of age, is more common in women, and may occur in multiple family members [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/11\">",
"     11",
"    </a>",
"    ]. Specific criteria for the diagnosis were first proposed by Allen and Brown in 1932 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/39\">",
"     39",
"    </a>",
"    ]. These criteria have been revised to include modern laboratory measurements and nailfold capillary microscopy and to provide a diagnosis of primary RP without the previous requirement of two years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Current criteria for the diagnosis of primary Raynaud phenomenon include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Symmetric episodic attacks",
"     </li>",
"     <li>",
"      No evidence of peripheral vascular disease",
"     </li>",
"     <li>",
"      No tissue gangrene, digital pitting, or tissue injury",
"     </li>",
"     <li>",
"      Negative nailfold capillary examination",
"     </li>",
"     <li>",
"      Negative antinuclear antibody test and normal erythrocyte sedimentation rate (ESR)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although patients with primary RP are generally otherwise healthy, comorbid conditions can occur that may aggravate attacks. These include hypertension, atherosclerosis, cardiovascular disease, and diabetes mellitus.",
"   </p>",
"   <p>",
"    Spontaneous remission of primary RP may occur. This was illustrated in a prospective study that surveyed a middle-aged white population over a seven-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/40\">",
"     40",
"    </a>",
"    ]. For those who had, or who developed, primary RP during that time frame, remissions occurred in 64 percent of both women and men. However, some symptoms suggestive of RP continued in about 20 percent of the cases that were classified as a \"remission.\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Secondary RP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since a variety of possible insults can disrupt the normal complex regulation of regional blood flow to the digits and skin, the number of disorders associated with RP is extensive. The most common associated disorders are scleroderma, systemic lupus erythematosus, other connective tissue diseases, occlusive vascular disease, drug effects, hematologic abnormalities, and use of vibrating tools:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other connective tissue diseases (mixed connective tissue disease, overlap syndromes, polymyositis, dermatomyositis, rheumatoid arthritis, Sj&ouml;gren's syndrome, undifferentiated connective tissue disease, and vasculitis)",
"     </li>",
"     <li>",
"      Occlusive vascular disease (arteriosclerosis, atheroemboli, and thromboangiitis obliterans) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/62/8170?source=see_link\">",
"       \"Thromboangiitis obliterans (Buerger's disease)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Drug-induced (amphetamines, beta blockers,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      , cocaine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , ergot, interferon-alpha, methysergide, nicotine, vinyl chloride, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20250?source=see_link&amp;anchor=H20#H20\">",
"       \"Treatment-related toxicity in men with testicular germ cell tumors\", section on 'Raynaud's phenomenon'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hemorrheologic (Cold agglutinin disease, cryofibrinogenemia, cryoglobulinemia, paraproteinemia, and polycythemia)",
"     </li>",
"     <li>",
"      Vibration-induced (eg, pneumatic drills and hammers) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/41-43\">",
"       41-43",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Vascular trauma (eg, injury to the distal ulnar artery in the hypothenar hammer syndrome) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/44-47\">",
"       44-47",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Frostbite [",
"      <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/48\">",
"       48",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, since primary RP is common in the general population, some reported associations of RP have not been proven. As an example, the prevalence of RP in rheumatoid arthritis is controversial. Some surveys suggest no increase in risk [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/49,50\">",
"     49,50",
"    </a>",
"    ], but other studies have found that 17 to 22 percent of patients with rheumatoid arthritis had RP [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Those with RP were more likely to have vasculitis or severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypothyroidism may predispose to RP, and improvement of cold induce vasospasm may occur with thyroid hormone replacement. Vasculitis may cause ischemic digits, but the absence of preceding cold-induced and reversible color changes help distinguish this from true RP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although extensive special testing is not always necessary, every patient with a diagnosis of RP should be carefully evaluated, beginning with an attempt to identify a secondary cause (",
"    <a class=\"graphic graphic_table graphicRef77253 \" href=\"UTD.htm?30/50/31532\">",
"     table 1",
"    </a>",
"    ). Clinical clues to suggest secondary RP include (",
"    <a class=\"graphic graphic_algorithm graphicRef62965 \" href=\"UTD.htm?21/28/21952\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Later age of onset (greater than 40 years)",
"     </li>",
"     <li>",
"      Male gender",
"     </li>",
"     <li>",
"      Painful severe events with tissue sign of ischemia (ulceration)",
"     </li>",
"     <li>",
"      Asymmetric attacks",
"     </li>",
"     <li>",
"      RP associated with signs or symptoms of another disease",
"     </li>",
"     <li>",
"      Abnormal laboratory parameters suggesting vascular disease or an autoimmune disorder",
"     </li>",
"     <li>",
"      RP associated with ischemic signs or symptoms proximal to the fingers (such as the hand or arm) or toes (foot or limb)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Nailfold capillary microscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nailfold capillary microscopy is performed by dropping oil on the periungual area and examining with an ophthalmoscope set at diopter 40 or with a dissecting microscope. Enlarged or distorted capillary loops and a relative paucity of loops suggest an underlying (or an increased likelihood of developing a) connective tissue disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/55-59\">",
"     55-59",
"    </a>",
"    ]. If the enlargement is associated with loss of capillaries, then the patient is more likely to have or develop systemic sclerosis (",
"    <a class=\"graphic graphic_picture graphicRef79285 \" href=\"UTD.htm?19/15/19701\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/57,60-62\">",
"     57,60-62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29224?source=see_link\">",
"     \"Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Primary Raynaud phenomenon",
"    </span>",
"    &nbsp;&mdash;&nbsp;If, after a thorough history and physical examination including nailfold capillary microscopy, there is a low suspicion for secondary RP, a clinical diagnosis of primary RP may be made, and there is no need for further specialized testing.",
"   </p>",
"   <p>",
"    If the primary care physician has a low suspicion of a secondary cause and cannot perform nailfold capillary microscopy, then careful clinical follow-up of the patient to assure that no new signs or symptoms occur is most important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Secondary Raynaud phenomenon",
"    </span>",
"    &nbsp;&mdash;&nbsp;If there is a moderate or high clinical suspicion of a secondary cause of RP, such as onset after age 25 to 30 or multiple severe uncomfortable events (",
"    <a class=\"graphic graphic_algorithm graphicRef62965 \" href=\"UTD.htm?21/28/21952\">",
"     algorithm 1",
"    </a>",
"    ), then special testing including an antinuclear antibody (ANA), specific autoantibodies (eg, anticentromere) or other laboratory testing guided by the history and physical examination are appropriate. Referral to a rheumatologist or other vascular specialist may be appropriate.",
"   </p>",
"   <p>",
"    The frequency and rate of development of a secondary disorder among patients initially diagnosed with primary RP are unclear. A meta-analysis of 10 articles involving approximately 640 patients diagnosed with primary RP found that 81 (13 percent) eventually developed a connective tissue disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/56\">",
"     56",
"    </a>",
"    ]. An abnormal nailfold capillary pattern was the best predictor of an eventual disease transition, which occurred approximately 10.4 years (a range of 0.6 to 27.9 years) after the onset of RP. Approximately 1 percent of patients initially diagnosed with primary disease may transition to secondary RP each year [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of specific autoantibodies targeting autoantigens also raises the suspicion of a secondary connective tissue disease or an overlap syndrome. A positive ANA screening test raises the possibility of an underlying autoimmune disease, particularly systemic lupus erythematosus or scleroderma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/64\">",
"     64",
"    </a>",
"    ]. The presence of anticentromere or antitopoisomerase (Scl-70) antibodies predicts the presence of scleroderma; however, these antibodies will also be detected by the ANA screen and do not need to be obtained if the screen is negative [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43095?source=see_link&amp;anchor=H4#H4\">",
"     \"Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults\", section on 'Laboratory tests'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/61/42968?source=see_link\">",
"     \"Undifferentiated systemic rheumatic (connective tissue) diseases and overlap syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One six-year study evaluated the efficacy of ANA and anticentromere and antitopoisomerase antibody testing in predicting the subsequent development of a connective tissue disorder among 85 patients initially referred for RP [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/65\">",
"     65",
"    </a>",
"    ]. Upon initial examination, 30 and 18 of these patients were considered to have primary RP and possible connective tissue disease (defined as one suggestive symptom), respectively. Patients were subsequently examined every two years, with blood drawn and the sera stored. Among these individuals, the presence of an ANA was significantly associated with the eventual development of a connective tissue disorder over the six-year follow-up period. In addition, the prognostic value of a positive anticentromere antibody was 60 percent sensitive and 98 percent specific for the development of the CREST or limited skin variant of scleroderma, while a positive antitopoisomerase antibody was less predictive of the evolution to scleroderma or probable scleroderma (38 and 90 percent sensitive and specific, respectively).",
"   </p>",
"   <p>",
"    The combination of autoantibodies and nailfold capillary microscopy may be more informative than either test alone. This was illustrated in a prospective study of 586 patients with Raynaud phenomenon who had no known connective tissue disease initially [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/67\">",
"     67",
"    </a>",
"    ]. The overall incidence of limited (CREST variant) or diffuse systemic sclerosis was 13 percent. In those with one or more autoantibodies (anticentromere [anti-CENP-B],",
"    <span class=\"nowrap\">",
"     anti-Th/To,",
"    </span>",
"    antitopoisomerase I, and anti-RNA polymerase III [anti-RNAP III]) or abnormal nailfold capillary microscopy, the incidence of SSc was 47 percent, while in those with both an autoantibody and abnormal nailfold capillary microscopy, the incidence of definite SSc was nearly 80 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/4/35905?source=see_link\">",
"       \"Patient information: Raynaud disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/49/30481?source=see_link\">",
"       \"Patient information: Raynaud phenomenon (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Raynaud phenomenon (RP) is an exaggerated vasoconstrictive response to various stimuli, including cold temperature and emotional stress. The phenomenon is manifested clinically by sharply demarcated color changes of the skin of the digits (",
"    <a class=\"graphic graphic_picture graphicRef66438 \" href=\"UTD.htm?15/41/16018\">",
"     picture 1",
"    </a>",
"    ). Abnormal vasoconstriction of digital arteries and cutaneous arterioles due to a local defect in normal vascular responses is thought to underlie the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6921/abstract/1\">",
"     1",
"    </a>",
"    ]. RP is considered primary if these symptoms occur in the absence of any associated disorder. By comparison, secondary RP refers to the presence of the disorder in association with a related illness, such as systemic lupus erythematosus or scleroderma.",
"   </p>",
"   <p>",
"    In addition to the color changes in affected digits or other sites, other symptoms due to ischemia include paresthesia, numbness, clumsiness of the hand, and, in more severe cases or those associated with an underlying connective tissue disease, ulceration of the skin.",
"   </p>",
"   <p>",
"    The diagnosis of the RP is based on the history alone since there is no simple office test to confirm the presence of cold- or emotion-induced vasospasm and since provocative testing is not recommended.",
"   </p>",
"   <p>",
"    Useful criteria for primary RP include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Symmetric episodic attacks",
"     </li>",
"     <li>",
"      No evidence of peripheral vascular disease",
"     </li>",
"     <li>",
"      No tissue gangrene, digital pitting, or tissue injury",
"     </li>",
"     <li>",
"      Negative nailfold capillary examination",
"     </li>",
"     <li>",
"      Negative antinuclear antibody test and normal ESR",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are many diseases and disorders that are associated with RP (",
"    <a class=\"graphic graphic_table graphicRef77253 \" href=\"UTD.htm?30/50/31532\">",
"     table 1",
"    </a>",
"    ), and, before concluding that a patient has primary RP, an evaluation should be performed to exclude an underlying cause (",
"    <a class=\"graphic graphic_algorithm graphicRef62965 \" href=\"UTD.htm?21/28/21952\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The presence of one or more of the following features increases the likelihood of secondary RP:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Later age of onset (greater than 40 years)",
"     </li>",
"     <li>",
"      Male gender",
"     </li>",
"     <li>",
"      Painful severe events with tissue sign of ischemia (ulceration)",
"     </li>",
"     <li>",
"      Asymmetric attacks",
"     </li>",
"     <li>",
"      RP associated with signs or symptoms of another disease",
"     </li>",
"     <li>",
"      Abnormal laboratory parameters suggesting vascular disease or an autoimmune disorder",
"     </li>",
"     <li>",
"      RP associated with ischemic signs or symptoms proximal to the fingers (such as the hand or arm) or toes (foot or limb)",
"     </li>",
"     <li>",
"      Abnormal capillary nailfold microscopy with enlarged or distorted capillary loops",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If, after a thorough history and a physical examination that includes capillary nailfold microscopy, there is a low suspicion of an underlying disease, then there is no need for further specialized testing, and a diagnosis of primary RP is appropriately made.",
"   </p>",
"   <p>",
"    However, if there is a moderate or high suspicion that the patient has secondary RP (",
"    <a class=\"graphic graphic_algorithm graphicRef62965 \" href=\"UTD.htm?21/28/21952\">",
"     algorithm 1",
"    </a>",
"    ), then further evaluation is needed. Recommended laboratory testing includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count",
"     </li>",
"     <li>",
"      General blood chemical analysis with tests of renal and liver function",
"     </li>",
"     <li>",
"      Urinalysis",
"     </li>",
"     <li>",
"      Rheumatoid factor",
"     </li>",
"     <li>",
"      Complement (C3 and C4)",
"     </li>",
"     <li>",
"      ANA (if positive ANA, then test for antitopoisomerase I, anti-RNA polymerase III, and anticentromere antibodies)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the laboratory testing suggests the presence of a connective tissue disorder (eg, scleroderma or systemic lupus erythematosus) or if there is still a strong suspicion of secondary RP despite normal laboratory results, referral to a rheumatologist for consultation may be appropriate.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/1\">",
"      Wigley FM. Clinical practice. Raynaud's Phenomenon. N Engl J Med 2002; 347:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/2\">",
"      Maricq HR, Carpentier PH, Weinrich MC, et al. Geographic variation in the prevalence of Raynaud's phenomenon: Charleston, SC, USA, vs Tarentaise, Savoie, France. J Rheumatol 1993; 20:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/3\">",
"      Cakir N, Pamuk ON, D&ouml;nmez S, et al. Prevalence of Raynaud's phenomenon in healthy Turkish medical students and hospital personnel. Rheumatol Int 2008; 29:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/4\">",
"      Voulgari PV, Alamanos Y, Papazisi D, et al. Prevalence of Raynaud's phenomenon in a healthy Greek population. Ann Rheum Dis 2000; 59:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/5\">",
"      Harada N, Ueda A, Takegata S. Prevalence of Raynaud's phenomenon in Japanese males and females. J Clin Epidemiol 1991; 44:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/6\">",
"      Purdie G, Harrison A, Purdie D. Prevalence of Raynaud's phenomenon in the adult New Zealand population. N Z Med J 2009; 122:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/7\">",
"      Czirj&aacute;k L, Kiss CG, L&ouml;vei C, et al. Survey of Raynaud's phenomenon and systemic sclerosis based on a representative study of 10,000 south-Transdanubian Hungarian inhabitants. Clin Exp Rheumatol 2005; 23:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/8\">",
"      Gelber AC, Wigley FM, Stallings RY, et al. Symptoms of Raynaud's phenomenon in an inner-city African-American community: prevalence and self-reported cardiovascular comorbidity. J Clin Epidemiol 1999; 52:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/9\">",
"      Jones GT, Herrick AL, Woodham SE, et al. Occurrence of Raynaud's phenomenon in children ages 12-15 years: prevalence and association with other common symptoms. Arthritis Rheum 2003; 48:3518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/10\">",
"      Nigrovic PA, Fuhlbrigge RC, Sundel RP. Raynaud's phenomenon in children: a retrospective review of 123 patients. Pediatrics 2003; 111:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/11\">",
"      Freedman RR, Mayes MD. Familial aggregation of primary Raynaud's disease. Arthritis Rheum 1996; 39:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/12\">",
"      Ling SM, Wigley FM. Raynaud's phenomenon in older adults: diagnostic considerations and management. Drugs Aging 1999; 15:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/13\">",
"      Silman A, Holligan S, Brennan P, Maddison P. Prevalence of symptoms of Raynaud's phenomenon in general practice. BMJ 1990; 301:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/14\">",
"      Maricq HR, Carpentier PH, Weinrich MC, et al. Geographic variation in the prevalence of Raynaud's phenomenon: a 5 region comparison. J Rheumatol 1997; 24:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/15\">",
"      Chikura B, Moore TL, Manning JB, et al. Sparing of the thumb in Raynaud's phenomenon. Rheumatology (Oxford) 2008; 47:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/16\">",
"      Chikura B, Moore T, Manning J, et al. Thumb involvement in Raynaud's phenomenon as an indicator of underlying connective tissue disease. J Rheumatol 2010; 37:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/17\">",
"      Uthman IW, Khamashta MA. Livedo racemosa: a striking dermatological sign for the antiphospholipid syndrome. J Rheumatol 2006; 33:2379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/18\">",
"      Maricq HR, Weinrich MC, Valter I, et al. Digital vascular responses to cooling in subjects with cold sensitivity, primary Raynaud's phenomenon, or scleroderma spectrum disorders. J Rheumatol 1996; 23:2068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/19\">",
"      Herrick A. Diagnosis and management of scleroderma peripheral vascular disease. Rheum Dis Clin North Am 2008; 34:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/20\">",
"      Murray AK, Moore TL, Manning JB, et al. Noninvasive imaging techniques in the assessment of scleroderma spectrum disorders. Arthritis Rheum 2009; 61:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/21\">",
"      Maricq HR, Jennings JR, Valter I, et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vasc Med 2000; 5:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/22\">",
"      Khanna PP, Maranian P, Gregory J, Khanna D. The minimally important difference and patient acceptable symptom state for the Raynaud's condition score in patients with Raynaud's phenomenon in a large randomised controlled clinical trial. Ann Rheum Dis 2010; 69:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/23\">",
"      Merkel PA, Herlyn K, Martin RW, et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002; 46:2410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/24\">",
"      Nielsen SL. Raynaud phenomena and finger systolic pressure during cooling. Scand J Clin Lab Invest 1978; 38:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/25\">",
"      Maricq HR, Weinrich MC. Diagnosis of Raynaud's phenomenon assisted by color charts. J Rheumatol 1988; 15:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/26\">",
"      O'Keeffe ST, Tsapatsaris NP, Beetham WP Jr. Color chart assisted diagnosis of Raynaud's phenomenon in an unselected hospital employee population. J Rheumatol 1992; 19:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/27\">",
"      LeRoy EC, Medsger TA Jr. Raynaud's phenomenon: a proposal for classification. Clin Exp Rheumatol 1992; 10:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/28\">",
"      Brennan P, Silman A, Black C, et al. Validity and reliability of three methods used in the diagnosis of Raynaud's phenomenon. The UK Scleroderma Study Group. Br J Rheumatol 1993; 32:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/29\">",
"      Maricq HR, Weinrich MC, Keil JE, LeRoy EC. Prevalence of Raynaud phenomenon in the general population. A preliminary study by questionnaire. J Chronic Dis 1986; 39:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/30\">",
"      Hur YM, Chae JH, Chung KW, et al. Feeling of Cold Hands and Feet is a Highly Heritable Phenotype. Twin Res Hum Genet 2012; 15:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/31\">",
"      Blatteis CM. Age-dependent changes in temperature regulation - a mini review. Gerontology 2012; 58:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/32\">",
"      Irwin MS, Gilbert SE, Terenghi G, et al. Cold intolerance following peripheral nerve injury. Natural history and factors predicting severity of symptoms. J Hand Surg Br 1997; 22:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/33\">",
"      Vinik AI, Erbas T, Stansberry KB, Pittenger GL. Small fiber neuropathy and neurovascular disturbances in diabetes mellitus. Exp Clin Endocrinol Diabetes 2001; 109 Suppl 2:S451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/34\">",
"      Wasner G. Vasomotor disturbances in complex regional pain syndrome--a review. Pain Med 2010; 11:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/35\">",
"      Kurklinsky AK, Miller VM, Rooke TW. Acrocyanosis: the Flying Dutchman. Vasc Med 2011; 16:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/36\">",
"      Khaira HS, Rittoo D, Vohra RK, Smith SR. The non-ischaemic blue finger. Ann R Coll Surg Engl 2001; 83:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/37\">",
"      Cohen JS. Erythromelalgia: new theories and new therapies. J Am Acad Dermatol 2000; 43:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/38\">",
"      Porter JM, Bardana EJ Jr, Baur GM, et al. The clinical significance of Raynaud's syndrome. Surgery 1976; 80:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/39\">",
"      Allen EV, Brown GE. Raynaud's disease: A critical review of minimal requisites for diagnosis. Am J Med Sci 1932; 183:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/40\">",
"      Suter LG, Murabito JM, Felson DT, Fraenkel L. The incidence and natural history of Raynaud's phenomenon in the community. Arthritis Rheum 2005; 52:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/41\">",
"      No&euml;l B. Pathophysiology and classification of the vibration white finger. Int Arch Occup Environ Health 2000; 73:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/42\">",
"      Heaver C, Goonetilleke KS, Ferguson H, Shiralkar S. Hand-arm vibration syndrome: a common occupational hazard in industrialized countries. J Hand Surg Eur Vol 2011; 36:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/43\">",
"      Andr&eacute;u JL, Ot&oacute;n T, Silva-Fern&aacute;ndez L, Sanz J. Hand pain other than carpal tunnel syndrome (CTS): the role of occupational factors. Best Pract Res Clin Rheumatol 2011; 25:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/44\">",
"      Spencer-Green G, Morgan GJ, Brown L, FitzGerald O. Hypothenar hammer syndrome: an occupational cause of Raynaud's phenomenon. J Rheumatol 1987; 14:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/45\">",
"      Yuen JC, Wright E, Johnson LA, Culp WC. Hypothenar hammer syndrome: an update with algorithms for diagnosis and treatment. Ann Plast Surg 2011; 67:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/46\">",
"      Cooke RA. Hypothenar hammer syndrome: a discrete syndrome to be distinguished from hand-arm vibration syndrome. Occup Med (Lond) 2003; 53:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/47\">",
"      Marie I, Herv&eacute; F, Primard E, et al. Long-term follow-up of hypothenar hammer syndrome: a series of 47 patients. Medicine (Baltimore) 2007; 86:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/48\">",
"      Ervasti O, Hassi J, Rintam&auml;ki H, et al. Sequelae of moderate finger frostbite as assessed by subjective sensations, clinical signs, and thermophysiological responses. Int J Circumpolar Health 2000; 59:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/49\">",
"      Carroll GJ, Withers K, Bayliss CE. The prevalence of Raynaud's syndrome in rheumatoid arthritis. Ann Rheum Dis 1981; 40:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/50\">",
"      Grassi W, Blasetti P, Core P, Cervini C. Raynaud's phenomenon in rheumatoid arthritis. Br J Rheumatol 1994; 33:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/51\">",
"      Saraux A, Allain J, Guedes C, et al. Raynaud's phenomenon in rheumatoid arthritis. Br J Rheumatol 1996; 35:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/52\">",
"      Pope JE, Al-Bishri J, Al-Azem H, Ouimet JM. The temporal relationship of Raynaud's phenomenon and features of connective tissue disease in rheumatoid arthritis. J Rheumatol 2008; 35:2329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/53\">",
"      Landry GJ, Edwards JM, McLafferty RB, et al. Long-term outcome of Raynaud's syndrome in a prospectively analyzed patient cohort. J Vasc Surg 1996; 23:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/54\">",
"      Block JA, Sequeira W. Raynaud's phenomenon. Lancet 2001; 357:2042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/55\">",
"      Carpentier PH, Maricq HR. Microvasculature in systemic sclerosis. Rheum Dis Clin North Am 1990; 16:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/56\">",
"      Spencer-Green G. Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases. Arch Intern Med 1998; 158:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/57\">",
"      Ingegnoli F, Boracchi P, Gualtierotti R, et al. Prognostic model based on nailfold capillaroscopy for identifying Raynaud's phenomenon patients at high risk for the development of a scleroderma spectrum disorder: PRINCE (prognostic index for nailfold capillaroscopic examination). Arthritis Rheum 2008; 58:2174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/58\">",
"      Lambova SN, M&uuml;ller-Ladner U. The role of capillaroscopy in differentiation of primary and secondary Raynaud's phenomenon in rheumatic diseases: a review of the literature and two case reports. Rheumatol Int 2009; 29:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/59\">",
"      Cutolo M, Pizzorni C, Secchi ME, Sulli A. Capillaroscopy. Best Pract Res Clin Rheumatol 2008; 22:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/60\">",
"      ter Borg EJ, Piersma-Wichers G, Smit AJ, et al. Serial nailfold capillary microscopy in primary Raynaud's phenomenon and scleroderma. Semin Arthritis Rheum 1994; 24:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/61\">",
"      Herrick AL, Cutolo M. Clinical implications from capillaroscopic analysis in patients with Raynaud's phenomenon and systemic sclerosis. Arthritis Rheum 2010; 62:2595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/62\">",
"      Anderson ME, Allen PD, Moore T, et al. Computerized nailfold video capillaroscopy--a new tool for assessment of Raynaud's phenomenon. J Rheumatol 2005; 32:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/63\">",
"      Hirschl M, Hirschl K, Lenz M, et al. Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance. Arthritis Rheum 2006; 54:1974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/64\">",
"      Wollersheim H, Thien T, Hoet MH, Van Venrooy WJ. The diagnostic value of several immunological tests for anti-nuclear antibody in predicting the development of connective tissue disease in patients presenting with Raynaud's phenomenon. Eur J Clin Invest 1989; 19:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/65\">",
"      Kallenberg CG, Wouda AA, Hoet MH, van Venrooij WJ. Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. Ann Rheum Dis 1988; 47:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/66\">",
"      Weiner ES, Hildebrandt S, Sen&eacute;cal JL, et al. Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease. A prospective study. Arthritis Rheum 1991; 34:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6921/abstract/67\">",
"      Koenig M, Joyal F, Fritzler MJ, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008; 58:3902.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7543 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-DCF38A056D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_48_6921=[""].join("\n");
var outline_f6_48_6921=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Symptoms of low blood flow and ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Livedo reticularis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Provoking factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H342907650\">",
"      Clinical criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H357333852\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PRIMARY AND SECONDARY RAYNAUD PHENOMENON",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Primary RP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Secondary RP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Nailfold capillary microscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Primary Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Secondary Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7543\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7543|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?21/28/21952\" title=\"algorithm 1\">",
"      Approach to dx of Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7543|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/41/16018\" title=\"picture 1\">",
"      Acute Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/15/19701\" title=\"picture 2\">",
"      Nailfold capillaroscopy - Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7543|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/50/31532\" title=\"table 1\">",
"      Factors associated with Raynauds",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17658?source=related_link\">",
"      Common problems of breastfeeding and weaning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43095?source=related_link\">",
"      Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28200?source=related_link\">",
"      Initial treatment of the Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=related_link\">",
"      Mucocutaneous manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29224?source=related_link\">",
"      Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23719?source=related_link\">",
"      Pathogenesis of the Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/4/35905?source=related_link\">",
"      Patient information: Raynaud disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/49/30481?source=related_link\">",
"      Patient information: Raynaud phenomenon (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/62/8170?source=related_link\">",
"      Thromboangiitis obliterans (Buerger's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28138?source=related_link\">",
"      Treatment of the Raynaud phenomenon resistant to initial therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20250?source=related_link\">",
"      Treatment-related toxicity in men with testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/61/42968?source=related_link\">",
"      Undifferentiated systemic rheumatic (connective tissue) diseases and overlap syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_48_6922="Palliative care: Overview of fatigue, weakness, and asthenia";
var content_f6_48_6922=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Palliative care: Overview of fatigue, weakness, and asthenia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/48/6922/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/48/6922/contributors\">",
"     Eduardo Bruera, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/48/6922/contributors\">",
"     Sriram Yennurajalingam, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/48/6922/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/48/6922/contributors\">",
"     J  Andrew Billings, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/48/6922/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/48/6922/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/48/6922/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H29611029\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatigue is the most common symptom in palliative care patients who have advanced cancer or other serious",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    life-threatening illnesses [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/1\">",
"     1",
"    </a>",
"    ]. It is also one of the most under-reported and undertreated symptoms in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Fatigue has substantial adverse physical, psychosocial, and economic consequences for both patients and caregivers [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. However, due to its subjective nature and multi-dimensional causes, assessment and treatment of fatigue in the palliative settings can be complex.",
"   </p>",
"   <p>",
"    This topic review will provide an overview of the clinical evaluation and treatment of fatigue in palliative care. Although the focus is on fatigue in cancer patients receiving palliative care, the principles of assessment and management are similar in other end stage disease states. A more extensive discussion of fatigue in patients with cancer and of the assessment and management of chronic fatigue syndrome are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11242?source=see_link\">",
"     \"Cancer-related fatigue: Prevalence, screening and clinical assessment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27098?source=see_link\">",
"     \"Cancer-related fatigue: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30825?source=see_link\">",
"     \"Clinical features and diagnosis of chronic fatigue syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/21/4440?source=see_link\">",
"     \"Treatment of chronic fatigue syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29611044\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to distinguish fatigue from other common presentations in palliative care including depression, delirium, drowsiness, and weakness.",
"   </p>",
"   <p>",
"    Fatigue in palliative care settings can be broadly defined as &ldquo;a subjective state characterized by feelings of tiredness and a perception of decreased capacity for physical or mental work&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/4\">",
"     4",
"    </a>",
"    ]. The",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    defines cancer related fatigue as a &ldquo;distressing, persistent, subjective sense of physical, emotional,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportional to activity and that interferes with usual functioning&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11242?source=see_link&amp;anchor=H2#H2\">",
"     \"Cancer-related fatigue: Prevalence, screening and clinical assessment\", section on 'Definition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the past, the terms &ldquo;asthenia&rdquo; and &ldquo;weakness&rdquo; were used to describe a subjective sensation of tiredness, while the specific term &ldquo;fatigue&rdquo; was used to describe a symptom of tiredness precipitated by effort. However, the terms are currently often used in the same context. The term &ldquo;fatigue&rdquo; has gained widespread acceptance in the medical literature and is preferentially used in the National Cancer Institute toxicity grading scale that covers fatigue, asthenia, and malaise (",
"    <a class=\"graphic graphic_table graphicRef60072 \" href=\"UTD.htm?10/32/10763\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    It is important to distinguish fatigue from other common presentations in palliative care including delirium, drowsiness or sleepiness, breathlessness, psychomotor retardation, and weakness. Psychomotor retardation involves a slowing-down of thought and a reduction of physical movements in an individual while weakness is a term commonly used to describe a state of lack of physical or muscle or motor strength.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29611051\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of fatigue in patients with cancer ranges from 48 to 75 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/5\">",
"     5",
"    </a>",
"    ]. The prevalence increases to 85 percent in patients with serious",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    life-threatening illnesses at the end of life (",
"    <a class=\"graphic graphic_table graphicRef73729 \" href=\"UTD.htm?5/57/6046\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4310459\">",
"    <span class=\"h1\">",
"     CAUSES AND PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with serious",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    life-threatening illness, fatigue can be distinguished as acute, and caused by an acute illness such as infection or cardiac decompensation, or more chronic, as in most of the cancer-related causes. Possible contributors to fatigue in patients with advanced cancer are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef86222 \" href=\"UTD.htm?17/51/18235\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In the palliative care patients, fatigue is most often a multi-dimensional symptom, often with multiple causes. Among these patients, correlative studies have shown an association of fatigue with pain, dyspnea, anorexia, psychological symptoms, gastroparesis symptoms (such as upper abdominal discomfort, bloating, and abdominal distension), and constipation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. The intensity of the individual symptom in a given patient may determine the ultimate contribution of that symptom to causation of fatigue. Other major contributors are anemia and medications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11242?source=see_link&amp;anchor=H5#H5\">",
"     \"Cancer-related fatigue: Prevalence, screening and clinical assessment\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29611072\">",
"    <span class=\"h2\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia is a particularly important contributor to fatigue, especially in patients undergoing cancer treatment. In a study of 4382 anemic cancer patients receiving chemotherapy, there was a positive correlation between hemoglobin levels and fatigue and quality of life across the range of clinically relevant hemoglobin levels of 8 to 14",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link&amp;anchor=H14#H14\">",
"     \"Approach to the adult patient with anemia\", section on 'Fatigue'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11242?source=see_link&amp;anchor=H11#H11\">",
"     \"Cancer-related fatigue: Prevalence, screening and clinical assessment\", section on 'Contribution of anemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27098?source=see_link&amp;anchor=H3#H3\">",
"     \"Cancer-related fatigue: Treatment\", section on 'Management of anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, towards the end of life for patients with cancer and for patients with non-malignant serious",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    life-threatening illnesses (ie, terminally-ill and largely bedbound patients), the importance of anemia as a contributor to fatigue is diminished. In such patients, fatigue is typically multi-dimensional and the main contributors are psychological symptoms such as anxiety and depression, pain, cachexia, medications, physical inactivity, infection, and hypogonadism. As the severity of these factors increases progressively at the end of life, the relative contribution of anemia to the causation of fatigue diminishes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/8,13\">",
"     8,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29611086\">",
"    <span class=\"h2\">",
"     Polypharmacy including opioids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications (side effects, cumulative effects of multiple drugs, and drug-drug interactions) are an often-overlooked contributor to fatigue. As examples, coadministration of opioids with other sedating medications, or drug-drug interactions between classes of medications such as anticholinergics, antihistamines, anticonvulsants, neuroleptics, opioids, central-antagonists, beta-blockers, diuretics, antidepressants, muscle relaxants, and benzodiazepines may contribute to drowsiness and fatigue. In some cases, altering the dose or dosing interval of a medication may substantially improve fatigue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9290?source=see_link&amp;anchor=H6#H6\">",
"     \"Cancer pain management with opioids: Prevention and management of side effects\", section on 'Somnolence and mental clouding'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/51/30521?source=see_link\">",
"     \"Prevention of adverse drug events in hospitals\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10228603\">",
"    <span class=\"h2\">",
"     Autonomic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autonomic dysfunction is a common complication of advanced cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/14\">",
"     14",
"    </a>",
"    ]. This syndrome includes postural hypotension, occasional syncope, fixed heart rate, and gastroparesis and is associated with gastrointestinal symptoms such as nausea, anorexia, diarrhea or constipation, and generalized weakness. While an association between fatigue and autonomic dysfunction has been established in neurological dysautonomic syndromes, and chronic fatigue syndrome, the relationship between autonomic dysfunction and fatigue in patients with advanced cancer remains unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/11,15,16\">",
"     11,15,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/41/12951?source=see_link&amp;anchor=H5756013#H5756013\">",
"     \"Mechanisms, causes, and evaluation of orthostatic and postprandial hypotension\", section on 'Symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10229820\">",
"    <span class=\"h2\">",
"     Hypogonadism in men with advanced cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypogonadism affects two-thirds of men with advanced cancer. Previous studies have shown that low testosterone levels in men with cancer are associated with fatigue, anorexia, depression, and insomnia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12824?source=see_link\">",
"     \"Clinical features and diagnosis of male hypogonadism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=see_link\">",
"     \"Causes of secondary hypogonadism in males\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4310935\">",
"    <span class=\"h2\">",
"     Role of inflammatory cytokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammatory cytokines may have a role in the pathophysiology of fatigue, based upon several lines of evidence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased levels in non-oncologic conditions that are characterized by fatigue, such as Chronic Fatigue Syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30825?source=see_link&amp;anchor=H7#H7\">",
"       \"Clinical features and diagnosis of chronic fatigue syndrome\", section on 'Immune dysfunction'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11242?source=see_link&amp;anchor=H7#H7\">",
"       \"Cancer-related fatigue: Prevalence, screening and clinical assessment\", section on 'Biologic response modifiers'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The occurrence of fatigue as a major side effect of therapeutic cytokines including interleukins, tumor necrosis factor (TNF)-alpha, and interferon, that are used in the treatment of certain cancer patients [",
"      <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/20-22\">",
"       20-22",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44711?source=see_link&amp;anchor=H2#H2\">",
"       \"Adjuvant immunotherapy for melanoma\", section on 'Clinical trials'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Up-regulation of pro-inflammatory cytokines and their correlation with fatigue in cancer patients [",
"      <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/23-25\">",
"       23-25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11242?source=see_link\">",
"       \"Cancer-related fatigue: Prevalence, screening and clinical assessment\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11242?source=see_link&amp;anchor=H5#H5\">",
"       \"Cancer-related fatigue: Prevalence, screening and clinical assessment\", section on 'Pathogenesis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Proinflammatory cytokines can act on mood, muscle mass, cognition, and metabolic status to induce fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. The inflammatory cytokines may also induce disturbance in the hypothalamic pituitary axis, affecting the levels of corticotrophin stimulating hormone and ACTH. These hormones, in turn, may influence adrenocorticoid hormone secretion by the adrenals [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29611093\">",
"    <span class=\"h1\">",
"     CLINICAL ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The assessment of fatigue in palliative care patients can be complex, given its multidimensional nature. In general, in cases of acute onset of fatigue in patients with a serious life-threatening illness, identification of the cause (eg, infection, cardiac decompensation), and treatment for the specific underlying condition may successfully reverse fatigue. In more chronic causes of fatigue such as that seen in patients with advanced cancer, fatigue is often multifactorial, so a multidimensional interdisciplinary approach is preferable. This is due to the multifactorial nature of fatigue in this population.",
"   </p>",
"   <p>",
"    A comprehensive history and physical examination should be undertaken to ascertain the various organ systems affected by the underlying disease and the impact of fatigue on activities of daily living and quality of life, to search for potentially reversible or treatable contributory factors, and to direct the diagnostic work-up. Review of all medications (both prescribed and over the counter, including",
"    <span class=\"nowrap\">",
"     complementary/alternative",
"    </span>",
"    therapies) is important and may reveal potential side effects, cumulative effect of multiple drugs, or drug-drug interactions that may be contributing to fatigue. If a medication is identified as being a potential contributor to fatigue, simply altering the dose or dosing interval may substantially improve fatigue. (See",
"    <a class=\"local\" href=\"#H29611086\">",
"     'Polypharmacy including opioids'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In patients with cancer, accurate assessment of the patient's current disease status, type of treatment, and response to treatment is an important component of the initial evaluation. Factors that are often causally related to cancer-related fatigue should be specifically assessed, including anemia, uncontrolled pain, emotional distress, sleep disturbance, nutrition and electrolyte disturbances (",
"    <a class=\"graphic graphic_table graphicRef64018 \" href=\"UTD.htm?4/38/4715\">",
"     table 4",
"    </a>",
"    ), and the presence of other comorbidities. Comorbidities that are unrelated to the cancer or its treatment (eg, infection, cardiopulmonary, renal, hepatic, neurologic, or endocrine dysfunction) may contribute significantly to symptoms of fatigue. Optimizing treatment for conditions that have been previously unrecognized (eg, hypothyroidism in a patient who previously had neck irradiation or who is receiving therapy with certain tyrosine kinase inhibitors targeting vascular endothelial growth factor such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    ) or suboptimally treated (eg, recurrent heart failure because of doxorubicin-induced cardiomyopathy) may improve fatigue.",
"   </p>",
"   <p>",
"    For patients with a non-cancer diagnosis, in addition to a thorough assessment of comorbidities, medications, and other potentially contributory causes, as with patients with cancer, diagnostic testing such as blood tests and radiographic imaging, may be needed, and should be based upon clinical suspicion. For patients with obvious findings due to end organ failure (eg, cardiac, respiratory, hepatic, or renal disease), the diagnostic work-up for fatigue should focus on assessment of the specific underlying cause. For cases where there are no obvious findings, physicians may evaluate for anemia, metabolic abnormalities, malnutrition, and infections.",
"   </p>",
"   <p>",
"    A more in depth discussion of clinical assessment of fatigue in patients with cancer is provided elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11242?source=see_link&amp;anchor=H15#H15\">",
"     \"Cancer-related fatigue: Prevalence, screening and clinical assessment\", section on 'Moderate to severe fatigue'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fatigue can be quantified by using the 0 to 10 visual analog scale, and instruments such as the Brief Fatigue Inventory, which measure not only intensity of fatigue but also functional impact (",
"    <a class=\"graphic graphic_table graphicRef54810 \" href=\"UTD.htm?9/29/9692\">",
"     table 5",
"    </a>",
"    ). However, scales such as these are not useful to sort out causality. From a clinical perspective, a patient presenting with a fatigue score of &ldquo;9 out of 10&rdquo; on a 0 to 10 scale may have anemia and cachexia as the main cause, while another patient with the same intensity of fatigue may have depression as the main cause. Use of the simple Edmonton symptom assessment scale (",
"    <a class=\"graphic graphic_figure graphicRef65702 \" href=\"UTD.htm?3/30/3567\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/28,29\">",
"     28,29",
"    </a>",
"    ] or other multi-dimensional tools may be helpful for a more comprehensive assessment of fatigue in both clinical and research settings (",
"    <a class=\"graphic graphic_table graphicRef86228 \" href=\"UTD.htm?17/13/17627\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29611100\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal management of fatigue involves aggressive treatment of reversible causes, if any are identified during the initial assessment. If a cause is not reversible or apparent, symptomatic treatment is appropriate (",
"    <a class=\"graphic graphic_table graphicRef86231 \" href=\"UTD.htm?32/30/33259\">",
"     table 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The treatment of fatigue should ideally involve an interdisciplinary team approach with active participation by the clinician, nurse, psychiatric counselor, social worker, chaplain, physical therapist, and occupational therapist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29611107\">",
"    <span class=\"h2\">",
"     Treatment of anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal management of symptomatic anemia requires an accurate diagnosis to identify potentially remediable causes (eg, ongoing blood loss, hemolysis, or deficiency of iron,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    , or vitamin B12). If a potentially treatable cause cannot be identified, treatment options include red blood cell (RBC) transfusion, or for selected patients, an erythropoiesis stimulating agent (ESA).",
"   </p>",
"   <p>",
"    Transfusions of packed red blood cells can improve fatigue that is due to anemia, at least in the short-term. In a prospective study of 61 patients receiving treatment in the palliative care unit, blood transfusions in patients with hemoglobin of 8 &plusmn;0.5",
"    <span class=\"nowrap\">",
"     g/dl",
"    </span>",
"    improved fatigue, dyspnea, and well-being for a short term (approximately 15 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/31\">",
"     31",
"    </a>",
"    ]. However, higher-quality studies are needed to determine which patients are most likely to respond, which are not, and the duration of any response [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/32\">",
"     32",
"    </a>",
"    ]. Furthermore, for those patients requiring repeated transfusions, there are potential harms, including blood-borne infection, acute transfusion reaction, transfusion-associated graft-versus-host disease, subtle immune modulation, and iron overload. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37766?source=see_link\">",
"     \"Transfusion-associated immune and non immune-mediated hemolysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=see_link\">",
"     \"Immunologic blood transfusion reactions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42214?source=see_link\">",
"     \"Transfusion reactions caused by chemical and physical agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10471?source=see_link\">",
"     \"Transfusion transmitted bacterial infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31175?source=see_link\">",
"     \"Transfusion transmitted HIV infection and AIDS\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=see_link&amp;anchor=H11#H11\">",
"     \"Iron overload syndromes other than hereditary hemochromatosis\", section on 'Transfusional iron overload'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment with ESAs can be beneficial in relieving fatigue and improving quality of life in patients with chronic anemia that is related to cancer chemotherapy. In one study of 4382 anemic cancer patients receiving chemotherapy, improvement of hemoglobin &ge;2",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    after treatment with an ESA was significantly correlated with improvement of fatigue, with maximum benefit occurring when the hemoglobin improved to12",
"    <span class=\"nowrap\">",
"     g/dl",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/12\">",
"     12",
"    </a>",
"    ]. In the United States, use of these agents is approved for patients who are receiving treatment for HIV infection or are undergoing palliative myelosuppressive cancer chemotherapy. ESAs are also indicated to reduce the need for blood transfusion in patients with chronic kidney disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=see_link\">",
"     \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23896?source=see_link\">",
"     \"Darbepoetin alfa for the management of anemia in chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/1/3098?source=see_link&amp;anchor=H30#H30\">",
"     \"Hematologic manifestations of HIV infection: Anemia\", section on 'Recombinant human erythropoietin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although treatment of anemia has been shown to decrease fatigue in patients receiving ESAs for these indications, this has not been demonstrated in other groups [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. Furthermore, use of these agents has become controversial in certain patients with cancer, in particular those with anemia unrelated to chemotherapy and in those receiving myelosuppressive chemotherapy with the intent of cure, because of concerns about thromboembolic side effects, higher mortality rates, and the possibility of adverse cancer outcomes. This subject is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=see_link&amp;anchor=H7#H7\">",
"     \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\", section on 'ESAs: efficacy, side effects, and clinical use'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27098?source=see_link&amp;anchor=H4#H4\">",
"     \"Cancer-related fatigue: Treatment\", section on 'ESAs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, use of ESAs for palliative care patients with fatigue related to anemia should be restricted to those with chronic kidney disease, and to those patients with anemia who are being treated for HIV infection, or receiving palliative myelosuppressive chemotherapy for cancer. In other groups, use of ESAs is considered \"unlabeled or investigational\" in the United States, and may not be reimbursed by insurance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link&amp;anchor=H19#H19\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\", section on 'Erythropoietin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29611114\">",
"    <span class=\"h2\">",
"     Symptom management",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10228376\">",
"    <span class=\"h3\">",
"     Pharmacologic approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a limited number of pharmacologic agents that have demonstrated efficacy in the treatment of fatigue in palliative care populations. The lack of good studies is related to the complex nature of fatigue in this population, and the paucity of randomized controlled studies in the palliative care setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29611129\">",
"    <span class=\"h4\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids decrease fatigue, and the proposed mechanisms include 1) a decrease of the cytokines IL-1, IL-6, and TNF-alpha that are associated with fatigue and 2) an effect on hypothalamic-pituitary axis function. As noted above, disturbances in hypothalamic-pituitary axis function have been observed in other chronic inflammatory and fatigue-related disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/36-41\">",
"     36-41",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4310935\">",
"     'Role of inflammatory cytokines'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Preliminary studies have found that glucocorticoids reduce symptoms such as fatigue, pain, and nausea, and improve appetite and overall quality of life in patients with advanced cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/42-47\">",
"     42-47",
"    </a>",
"    ]. It is not evident that there is any difference between different types of glucocorticoids; however,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    appears to be the most intensively investigated. In the only randomized placebo controlled trial of 84 evaluable patients with advanced cancer, oral dexamethasone (8 mg per day for 14 days) significantly improved fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/48\">",
"     48",
"    </a>",
"    ]. The mean (standard deviation) improvement in the FACIT-F fatigue subscale at day 15 was significantly higher in the dexamethasone group than in the placebo (mean and standard deviation were 9 [10.3] versus 3.1 [9.59] for dexamethasone and placebo, respectively, p = 0.008). The numbers of grade &ge;3 adverse effects did not differ between groups (17 out of 62 versus 11 out of 58, p = 0.27).",
"   </p>",
"   <p>",
"    Unfortunately, side effects limit the long-term use of glucocorticoids. The severity of most toxicities is dose-dependent. Side effects observed in some patients include infection, oral thrush, insomnia, mood swings, myalgia, and elevation of blood glucose. Prolonged use (for more than a month) of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    may cause gastritis (especially with concurrent use of NSAIDS), hiccups, edema, muscle weakness, easy bruising, dizziness, unusual hair growth on the face and body, bone loss, and decreased wound healing in some patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hiccups are an indirect side-effect of corticosteroids. At least one report suggests that rotation of steroids from one class to another (eg, a change from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) may result in improvement in hiccups [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Glucocorticoids may be most helpful for patients with fatigue who are in the terminal phases of advanced cancer or another serious",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    life-threatening illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29611136\">",
"    <span class=\"h4\">",
"     Megestrol acetate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anorexia-cachexia is an important contributory factor to fatigue in palliative care patients. Loss of more than 5 percent of premorbid body weight results in significant physical and psychological morbidity and is an independent risk factor for early mortality. In randomized placebo-controlled trials conducted in patients with advanced cancer and anorexia,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    significantly improved appetite, fatigue (activity), and overall well-being. The best balance between effectiveness and toxicity is between 480 to 800",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5113?source=see_link&amp;anchor=H4#H4\">",
"     \"Pharmacologic management of cancer anorexia/cachexia\", section on 'Progesterone analogs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Megestrol is dosed orally, once daily. There is an increasing",
"    <span class=\"nowrap\">",
"     dose/response",
"    </span>",
"    curve from 160 to 800",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    Side effects include thromboembolic events (use with caution in patients with history thromboembolism), adrenal suppression with insufficiency upon abrupt discontinuation, hypertension, hyperglycemia, breakthrough uterine bleeding, and skin photosensitivity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29611151\">",
"    <span class=\"h4\">",
"     Psychostimulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both fatigue and depression in patients receiving palliative care can be treated with the psychostimulants such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/44/32454?source=see_link\">",
"     dextroamphetamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    , pemoline (not available in the US), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"     modafinil",
"    </a>",
"    . Psychostimulants act rapidly, and are generally well tolerated and safe. However, they should be used with caution in patients with heart disease or cognitive disturbances (eg, delirium).",
"   </p>",
"   <p>",
"    All of the available data addressing the role of psychostimulants in management of fatigue patients with serious",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    life-threatening illness are in cancer patients, in whom, the benefit has been best shown for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"     modafinil",
"    </a>",
"    in patients with severe fatigue; benefit is less certain in patients with mild to moderate fatigue. The role of psychostimulants in the management of fatigue in terminally ill patients with diseases other than cancer needs to be defined by randomized controlled trials, and in these setting, these are considered investigational approaches. However, a trial of psychostimulants such as methylphenidate or modafinil is reasonable for patients with opioid-related sedation, for patients with severe fatigue who do not respond to a glucocorticoid or megestrol, or who have a contraindication to the use of either of these classes of drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29611158\">",
"    <span class=\"h5\">",
"     Methylphenidate",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with cancer,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    has been used to manage fatigue as well as opioid-induced sedation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/50,51\">",
"     50,51",
"    </a>",
"    ], cognitive dysfunction associated with brain tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/52\">",
"     52",
"    </a>",
"    ], and depression [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/53\">",
"     53",
"    </a>",
"    ]. Its mechanism of action is stimulation of the central nervous system by blockade of presynaptic norepinephrine and dopamine reuptake [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27098?source=see_link&amp;anchor=H11#H11\">",
"     \"Cancer-related fatigue: Treatment\", section on 'Methylphenidate and dexmethylphenidate'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9290?source=see_link&amp;anchor=H8#H8\">",
"     \"Cancer pain management with opioids: Prevention and management of side effects\", section on 'Psychostimulants'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     Methylphenidate",
"    </a>",
"    is usually administered twice a day at breakfast and lunch in order to minimize nighttime insomnia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29611165\">",
"    <span class=\"h5\">",
"     Modafinil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"     Modafinil",
"    </a>",
"    is effective and well tolerated for the treatment of excessive daytime sleepiness (EDS) in patients with narcolepsy, and for conditions such as Parkinson&rsquo;s disease and obstructive sleep apnea [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/56-59\">",
"     56-59",
"    </a>",
"    ]. As with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    , benefit in cancer-related fatigue is best established in patients with severe fatigue; benefit has not been shown for patients with mild to moderate fatigue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27098?source=see_link&amp;anchor=H13#H13\">",
"     \"Cancer-related fatigue: Treatment\", section on 'Modafinil'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The exact mechanism of action is unclear, although a murine study implicates non-noradrenergic, dopamine-dependent adrenergic signaling in the wake-promoting mechanism of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"     modafinil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/60\">",
"     60",
"    </a>",
"    ]. Modafinil is typically administered as a single daily dose of 200 mg in the morning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29612223\">",
"    <span class=\"h4\">",
"     Testosterone replacement in hypogonadic males",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, hypogonadism affects two-thirds of men with advanced cancer; low testosterone levels in men with cancer are associated with fatigue, anorexia, depression, and insomnia. (See",
"    <a class=\"local\" href=\"#H10229820\">",
"     'Hypogonadism in men with advanced cancer'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Testosterone replacement improves quality of life and diminishes fatigue in patients with noncancer conditions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=see_link&amp;anchor=H13#H13\">",
"     \"Testosterone treatment of male hypogonadism\", section on 'Outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The benefit of testosterone replacement for treatment of fatigue in hypogonadal men with advanced cancer was addressed in a small trial in which fourteen patients treated with placebo and 12 patients treated with testosterone (weight-based intramuscular testosterone administered every 14 days to achieve a bioavailable testosterone level 70 to 270",
"    <span class=\"nowrap\">",
"     ng/dL)",
"    </span>",
"    were evaluable for the primary outcome at day 29 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/61\">",
"     61",
"    </a>",
"    ]. In a preliminary report presented at the 2012 meeting of the American Society of Clinical Oncology, no statistically significant difference was found for fatigue (FACIT-F) scores between arms, but there was a trend for testosterone to improve fatigue scores (mean [SD] was -5.5 &plusmn; 19 for placebo and 3.9 &plusmn; 14 for testosterone, p = 0.09). Adverse events were similar between groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29612230\">",
"    <span class=\"h4\">",
"     Complementary medicines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preliminary studies have suggested efficacy for American Ginseng and Guarana for the treatment of cancer related fatigue. However, further long-term safety studies are needed, particularly in view of the potential for drug interactions with Ginseng. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27098?source=see_link&amp;anchor=H24908748#H24908748\">",
"     \"Cancer-related fatigue: Treatment\", section on 'Ginseng and guarana'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/13/40154?source=see_link&amp;anchor=H37#H37\">",
"     \"Complementary and alternative therapies for cancer\", section on 'Ginseng and guarana for fatigue'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no studies with fatigue as a primary outcome that confirm benefit from fish oil or melatonin, and these treatments should not be suggested for symptomatic therapy until further studies confirm their efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/62,63\">",
"     62,63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29611172\">",
"    <span class=\"h3\">",
"     Nonpharmacologic approaches",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29611180\">",
"    <span class=\"h4\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical activity is important to maintain a sense of well-being and to enhance quality of life (QOL) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/64\">",
"     64",
"    </a>",
"    ]. Most palliative care patients experience multiple symptoms, such as fatigue, pain, dyspnea, and nausea, which may all contribute to reduced physical activity, or even inactivity, and thereby reduced physical functioning. Exercise rehabilitation during or after curative or life prolonging treatment is considered as an effective means of restoring physical and psychological function [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefits of exercise in terms of improving physical performance have been shown in many trials conducted in patients with advanced cancer, although benefit in terms of fatigue has been more difficult to show. As an example, in a large randomized control study of 231 patients with incurable cancer and a life expectancy of three months to two years, physical exercise (60 minutes twice a week for eight weeks) provided significant improvement in physical performance as assessed by a hand grip strength test and the shuttle walk test, whereas fatigue, the predefined primary endpoint, was not significantly reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27098?source=see_link&amp;anchor=H7#H7\">",
"     \"Cancer-related fatigue: Treatment\", section on 'Exercise'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional randomized controlled trials are required in palliative care settings to assess the overall efficacy of exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/67\">",
"     67",
"    </a>",
"    ]. However, moderate exercise is a reasonable recommendation, if patients are able to tolerate it.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23013425\">",
"    <span class=\"h4\">",
"     Yoga",
"    </span>",
"    &nbsp;&mdash;&nbsp;A benefit for yoga in improving sleep quality and fatigue has been suggested in a randomized trial of 410 cancer survivors who reported sleep disruption after completing adjuvant chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27098?source=see_link&amp;anchor=H11096059#H11096059\">",
"     \"Cancer-related fatigue: Treatment\", section on 'Yoga'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are few data regarding the benefits of yoga in palliative care populations; although preliminary reports are encouraging [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/68,69\">",
"     68,69",
"    </a>",
"    ], randomized trials are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23013530\">",
"    <span class=\"h4\">",
"     Sleep hygiene",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with advanced cancer or other life limiting disease states, it is common to have multiple symptoms occurring simultaneously hence it is difficult to determine that sleep disturbance is the sole causative mechanism for fatigue, or if fatigue is contributing to sleep disturbance.",
"    <strong>",
"    </strong>",
"    Sleep disturbance may be influenced by numerous factors including daytime naps, pain, depression, anxiety, medication, sleep interruption because of sleep apnea, nocturia or hot flashes, and evening food",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    beverage intake.",
"   </p>",
"   <p>",
"    Few studies have evaluated sleep interventions to manage fatigue in advanced cancer and other life-limiting illnesses; the results are conflicting. Cognitive-behavioral therapy and stress reduction may help. Other suggestions for improving sleep patterns include taking a warm bath or drinking a glass of warm milk prior to bedtime, avoiding caffeinated beverages following dinner, emptying the bladder just before going to bed, and scheduling naps earlier in the day (",
"    <a class=\"graphic graphic_table graphicRef50224 \" href=\"UTD.htm?8/44/8908\">",
"     table 8",
"    </a>",
"    ). Some patients require medications to help them sleep. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=see_link\">",
"     \"Treatment of insomnia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27098?source=see_link&amp;anchor=H8#H8\">",
"     \"Cancer-related fatigue: Treatment\", section on 'Sleep therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29611187\">",
"    <span class=\"h4\">",
"     Behavioral and psychosocial interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive-behavioral and psychosocial interventions have also been found to be an effective modality for the treatment of cancer-related fatigue. Various randomized clinical trials have shown that supportive interventions (group and individual) such as education and stress management groups, coping strategies training, and behavioral interventions have been helpful for cancer patients with managing their fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/70\">",
"     70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27098?source=see_link&amp;anchor=H5#H5\">",
"     \"Cancer-related fatigue: Treatment\", section on 'Cognitive-behavioral and psychosocial interventions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29612237\">",
"    <span class=\"h3\">",
"     Multimodal interventions for refractory fatigue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic treatment should be considered in all cases in which fatigue is not effectively managed by treatment of reversible causes. In these cases, due to the complex, multi-dimensional nature of fatigue, it is unlikely that fatigue can be effectively mitigated using a single pharmacologic or non-pharmacologic intervention. Patients are likely to benefit from a combination of pharmacologic and non-pharmacologic interventions such as cognitive-behavioral therapy, increased physical activity, and pharmacologic therapy aimed at countering inflammation, changes in body composition, or brain function. In these cases, therapy must be individualized.",
"   </p>",
"   <p>",
"    Further studies are needed to investigate the efficacy of the multimodal intervention in patients with fatigue, particularly those with advanced cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management of fatigue in patients receiving palliative care for a non-cancer diagnosis such as end stage heart disease, COPD, and AIDS requires a multidimensional, interdisciplinary approach. In addition to measures to treat the causative mechanism of fatigue in these end stage disease states (such as optimization of ejection fraction in end stage heart disease and bronchodilators for end stage COPD), efforts to improve",
"    <span class=\"nowrap\">",
"     function/physical",
"    </span>",
"    condition and mobility (eg, the use of assistive devices such as walkers) should be considered so as to maintain independence. Pharmacologic interventions may include trials of psychostimulants and corticosteroids. Counseling techniques such as cognitive behavioral therapy and expressive supportive counseling to help patients adapt to progressive disease and physical decline, and for family support, should be considered. It is important to address fatigue as a subjective symptom and not as a physical syndrome and focus solely on strategies to increase",
"    <span class=\"nowrap\">",
"     function/physical",
"    </span>",
"    function. Lastly, patients suffer considerable distress if there is a gap between the patient&rsquo;s expectation for improved physical function through intervention and the reality of actual decline in function over time; ultimately most patients who are terminally ill will become bedridden. Measures that help adjust a patient&rsquo;s expectation may include changing the focus from physical functioning to other enjoyable, non-physical activities [",
"    <a class=\"abstract\" href=\"UTD.htm?6/48/6922/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29611194\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fatigue (asthenia, weakness) is the most common symptom in palliative care; it is also one of the most underdiagnosed and undertreated. Untreated or undertreated fatigue significantly affects quality of life of patients receiving palliative care; appropriate assessment and management of fatigue is essential. (See",
"      <a class=\"local\" href=\"#H29611051\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fatigue is a typically a multi-dimensional symptom. Among patients seen in a palliative care setting, acute fatigue may be due to an acute, potentially reversible medical condition (eg, cardiac decompensation, infection), while chronic fatigue, as typified by fatigue related to cancer, may have multiple contributing causes (",
"      <a class=\"graphic graphic_table graphicRef86231 \" href=\"UTD.htm?32/30/33259\">",
"       table 7",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4310459\">",
"       'Causes and pathophysiology'",
"      </a>",
"      above.) Some of the common treatable causes of fatigue in cancer patients at end of life including deconditioning, infection, dehydration, metabolic and endocrine disorders and cancer related symptoms such as pain, anorexia, insomnia and psychological symptoms. Anemia is a particularly important contributor in patients undergoing cancer treatment. Anemia is a less common contributor to fatigue in cancer patients nearing the end of life.",
"     </li>",
"     <li>",
"      The intensity of fatigue can be assessed using a &ldquo;0 to 10&rdquo; visual analog scale, or instruments, such as the Brief Fatigue Inventory, which measure not only intensity but also functional impact (",
"      <a class=\"graphic graphic_table graphicRef54810 \" href=\"UTD.htm?9/29/9692\">",
"       table 5",
"      </a>",
"      ). A comprehensive history and physical examination is indicated to identify potentially reversible etiologies. Review of all medications, both prescription and over the counter, is particularly important to identify side effects and potential drug-drug interactions that may be contributing to fatigue. Simply altering the dose or dosing interval may substantially improve fatigue. (See",
"      <a class=\"local\" href=\"#H29611086\">",
"       'Polypharmacy including opioids'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H29611093\">",
"       'Clinical assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When considering how to treat fatigue, a multidimensional approach is preferred. It is important to determine whether the etiology is reversible and treating these reversible causes as best as possible (",
"      <a class=\"graphic graphic_table graphicRef86231 \" href=\"UTD.htm?32/30/33259\">",
"       table 7",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Optimal management of symptomatic anemia requires an accurate diagnosis to identify potentially remediable causes (eg, ongoing blood loss, hemolysis, or deficiency of iron,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      , or vitamin B12). If a potentially treatable cause cannot be identified, treatment options include red blood cell (RBC) transfusion, or, for selected patients (chronic kidney disease, HIV infection, patients receiving palliative chemotherapy for cancer), an erythropoiesis stimulating agent (ESA). (See",
"      <a class=\"local\" href=\"#H29611107\">",
"       'Treatment of anemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a specific cause cannot be identified, we suggest symptomatic management:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      All patients should be counseled as to coping strategies that conserve energy (",
"      <a class=\"graphic graphic_table graphicRef73183 \" href=\"UTD.htm?16/47/17149\">",
"       table 9",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef53415 \" href=\"UTD.htm?6/16/6413\">",
"       table 10",
"      </a>",
"      ), and about good sleep hygiene (",
"      <a class=\"graphic graphic_table graphicRef50224 \" href=\"UTD.htm?8/44/8908\">",
"       table 8",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients who are in the terminal phase of their illness who have a high symptom burden that includes fatigue, we suggest a two week trial of a glucocorticoid (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      8 mg daily) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Another option for patients with fatigue related to",
"      <span class=\"nowrap\">",
"       anorexia/cachexia",
"      </span>",
"      is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"       megestrol acetate",
"      </a>",
"      (480 to 800 mg daily). (See",
"      <a class=\"local\" href=\"#H29611129\">",
"       'Glucocorticoids'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H29611136\">",
"       'Megestrol acetate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The role of psychostimulants is not well defined, particularly for patients with serious",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      life threatening illnesses other than cancer. However, a trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"       methylphenidate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"       modafinil",
"      </a>",
"      is reasonable for patients with opioid-related sedation, and for patients with severe fatigue who do not respond to a glucocorticoid or megestrol, or who have a contraindication to the use of these classes of drugs. (See",
"      <a class=\"local\" href=\"#H29611151\">",
"       'Psychostimulants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other nonpharmacologic approaches that may be helpful include moderate exercise, yoga, and cognitive-behavioral therapy.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/1\">",
"      Cella D, Davis K, Breitbart W, et al. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol 2001; 19:3385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/2\">",
"      Curt GA, Breitbart W, Cella D, et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 2000; 5:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/3\">",
"      Stone P, Richardson A, Ream E, et al. Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol 2000; 11:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/4\">",
"      Stone P, Richards M, Hardy J. Fatigue in patients with cancer. Eur J Cancer 1998; 34:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/5\">",
"      Piper BF, Cella D. Cancer-related fatigue: definitions and clinical subtypes. J Natl Compr Canc Netw 2010; 8:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/6\">",
"      Vogl D, Rosenfeld B, Breitbart W, et al. Symptom prevalence, characteristics, and distress in AIDS outpatients. J Pain Symptom Manage 1999; 18:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/7\">",
"      Kutner JS, Kassner CT, Nowels DE. Symptom burden at the end of life: hospice providers' perceptions. J Pain Symptom Manage 2001; 21:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/8\">",
"      Stone P, Richards M, A'Hern R, Hardy J. A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Ann Oncol 2000; 11:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/9\">",
"      Respini D, Jacobsen PB, Thors C, et al. The prevalence and correlates of fatigue in older cancer patients. Crit Rev Oncol Hematol 2003; 47:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/10\">",
"      Hwang SS, Chang VT, Rue M, Kasimis B. Multidimensional independent predictors of cancer-related fatigue. J Pain Symptom Manage 2003; 26:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/11\">",
"      Cherian D, Paladugu S, Pathikonda M, Parkman HP. Fatigue: a prevalent symptom in gastroparesis. Dig Dis Sci 2012; 57:2088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/12\">",
"      Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002; 95:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/13\">",
"      Munch TN, Zhang T, Willey J, et al. The association between anemia and fatigue in patients with advanced cancer receiving palliative care. J Palliat Med 2005; 8:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/14\">",
"      Walsh D, Nelson KA. Autonomic nervous system dysfunction in advanced cancer. Support Care Cancer 2002; 10:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/15\">",
"      Calkins H, Rowe PC. Relationship Between Chronic Fatigue Syndrome and Neurally Mediated Hypotension. Cardiol Rev 1998; 6:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/16\">",
"      Strasser F, Palmer JL, Schover LR, et al. The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer: a pilot study. Cancer 2006; 107:2949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/17\">",
"      Del Fabbro E, Hui D, Nooruddin ZI, et al. Associations among hypogonadism, C-reactive protein, symptom burden, and survival in male cancer patients with cachexia: a preliminary report. J Pain Symptom Manage 2010; 39:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/18\">",
"      Cannon JG, Angel JB, Abad LW, et al. Interleukin-1 beta, interleukin-1 receptor antagonist, and soluble interleukin-1 receptor type II secretion in chronic fatigue syndrome. J Clin Immunol 1997; 17:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/19\">",
"      Moss RB, Mercandetti A, Vojdani A. TNF-alpha and chronic fatigue syndrome. J Clin Immunol 1999; 19:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/20\">",
"      Sarna GP, Figlin RA, Pertcheck M, et al. Systemic administration of recombinant methionyl human interleukin-2 (Ala 125) to cancer patients: clinical results. J Biol Response Mod 1989; 8:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/21\">",
"      Eskander ED, Harvey HA, Givant E, Lipton A. Phase I study combining tumor necrosis factor with interferon-alpha and interleukin-2. Am J Clin Oncol 1997; 20:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/22\">",
"      Veldhuis GJ, Willemse PH, Sleijfer DT, et al. Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small-cell lung cancer. J Clin Oncol 1995; 13:2585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/23\">",
"      Inagaki M, Isono M, Okuyama T, et al. Plasma interleukin-6 and fatigue in terminally ill cancer patients. J Pain Symptom Manage 2008; 35:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/24\">",
"      Adler HL, McCurdy MA, Kattan MW, et al. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 1999; 161:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/25\">",
"      Collado-Hidalgo A, Bower JE, Ganz PA, et al. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res 2006; 12:2759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/26\">",
"      Ahlberg K, Ekman T, Gaston-Johansson F, Mock V. Assessment and management of cancer-related fatigue in adults. Lancet 2003; 362:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/27\">",
"      Lee BN, Dantzer R, Langley KE, et al. A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation 2004; 11:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/28\">",
"      Bruera E, Kuehn N, Miller MJ, et al. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 1991; 7:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/29\">",
"      Chang VT, Hwang SS, Feuerman M. Validation of the Edmonton Symptom Assessment Scale. Cancer 2000; 88:2164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/30\">",
"      Dittner AJ, Wessely SC, Brown RG. The assessment of fatigue: a practical guide for clinicians and researchers. J Psychosom Res 2004; 56:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/31\">",
"      Mercadante S, Ferrera P, Villari P, et al. Effects of red blood cell transfusion on anemia-related symptoms in patients with cancer. J Palliat Med 2009; 12:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/32\">",
"      Preston NJ, Hurlow A, Brine J, Bennett MI. Blood transfusions for anaemia in patients with advanced cancer. Cochrane Database Syst Rev 2012; 2:CD009007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/33\">",
"      Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997; 15:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/34\">",
"      Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998; 16:3412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/35\">",
"      Osterborg A, Brandberg Y, Molostova V, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol 2002; 20:2486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/36\">",
"      Agarwal SK, Marshall GD Jr. Dexamethasone promotes type 2 cytokine production primarily through inhibition of type 1 cytokines. J Interferon Cytokine Res 2001; 21:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/37\">",
"      Demitrack MA, Crofford LJ. Evidence for and pathophysiologic implications of hypothalamic-pituitary-adrenal axis dysregulation in fibromyalgia and chronic fatigue syndrome. Ann N Y Acad Sci 1998; 840:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/38\">",
"      Lundstr&ouml;m SH, F&uuml;rst CJ. The use of corticosteroids in Swedish palliative care. Acta Oncol 2006; 45:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/39\">",
"      Popiela T, Lucchi R, Giongo F. Methylprednisolone as palliative therapy for female terminal cancer patients. The Methylprednisolone Female Preterminal Cancer Study Group. Eur J Cancer Clin Oncol 1989; 25:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/40\">",
"      Della Cuna GR, Pellegrini A, Piazzi M. Effect of methylprednisolone sodium succinate on quality of life in preterminal cancer patients: a placebo-controlled, multicenter study. The Methylprednisolone Preterminal Cancer Study Group. Eur J Cancer Clin Oncol 1989; 25:1817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/41\">",
"      Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 1974; 33:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/42\">",
"      Bruera E, Roca E, Cedaro L, et al. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 1985; 69:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/43\">",
"      Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/44\">",
"      Fainsinger RL, Spachynski K, Hanson J, Bruera E. Symptom control in terminally ill patients with malignant bowel obstruction (MBO). J Pain Symptom Manage 1994; 9:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/45\">",
"      Ettinger AB, Portenoy RK. The use of corticosteroids in the treatment of symptoms associated with cancer. J Pain Symptom Manage 1988; 3:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/46\">",
"      Hardy JR, Rees E, Ling J, et al. A prospective survey of the use of dexamethasone on a palliative care unit. Palliat Med 2001; 15:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/47\">",
"      Bruera E, Moyano JR, Sala R, et al. Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: a randomized controlled trial. J Pain Symptom Manage 2004; 28:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/48\">",
"      Yennurajalingam S, Frisbee-Hume S, Delgado-Guay MO, et al. Dexamethasone (DM) for cancer-related fatigue: A double-blinded, randomized, placebo-controlled trial. J Clin Oncol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/49\">",
"      Kang JH, Hui D, Kim MJ, et al. Corticosteroid rotation to alleviate dexamethasone-induced hiccup: a case series at a single institution. J Pain Symptom Manage 2012; 43:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/50\">",
"      Bruera E, Chadwick S, Brenneis C, et al. Methylphenidate associated with narcotics for the treatment of cancer pain. Cancer Treat Rep 1987; 71:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/51\">",
"      Bruera E, Miller MJ, Macmillan K, Kuehn N. Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain. Pain 1992; 48:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/52\">",
"      Meyers CA, Weitzner MA, Valentine AD, Levin VA. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 1998; 16:2522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/53\">",
"      Homsi J, Nelson KA, Sarhill N, et al. A phase II study of methylphenidate for depression in advanced cancer. Am J Hosp Palliat Care 2001; 18:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/54\">",
"      Kimko HC, Cross JT, Abernethy DR. Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet 1999; 37:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/55\">",
"      Safer DJ, Zito JM, Fine EM. Increased methylphenidate usage for attention deficit disorder in the 1990s. Pediatrics 1996; 98:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/56\">",
"      Morrow GR, Shelke AR, Roscoe JA, et al. Management of cancer-related fatigue. Cancer Invest 2005; 23:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/57\">",
"      Broughton RJ, Fleming JA, George CF, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1997; 49:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/58\">",
"      Beusterien KM, Rogers AE, Walsleben JA, et al. Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep 1999; 22:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/59\">",
"      Schwartz JR, Feldman NT, Fry JM, Harsh J. Efficacy and safety of modafinil for improving daytime wakefulness in patients treated previously with psychostimulants. Sleep Med 2003; 4:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/60\">",
"      Wisor JP, Eriksson KS. Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil. Neuroscience 2005; 132:1027.",
"     </a>",
"    </li>",
"    <li>",
"     Pulivarthi K, Dev R, Garcia J, et al. Testosterone replacement for fatigue in male hypogonadic patients with advanced cancer: A preliminary double-blind placebo-controlled trial. J Clin Oncol 30, 2012 (suppl; abstr e19643) Abstract available online at   . file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=114&amp;abstractID=101245 (Accessed on August 17, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/62\">",
"      Wang YM, Jin BZ, Ai F, et al. The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials. Cancer Chemother Pharmacol 2012; 69:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/63\">",
"      Alfano CM, Imayama I, Neuhouser ML, et al. Fatigue, inflammation, and &omega;-3 and &omega;-6 fatty acid intake among breast cancer survivors. J Clin Oncol 2012; 30:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/64\">",
"      Cohen SR, Leis A. What determines the quality of life of terminally ill cancer patients from their own perspective? J Palliat Care 2002; 18:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/65\">",
"      Oldervoll LM, Loge JH, Paltiel H, et al. The effect of a physical exercise program in palliative care: A phase II study. J Pain Symptom Manage 2006; 31:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/66\">",
"      Oldervoll LM, Loge JH, Lydersen S, et al. Physical exercise for cancer patients with advanced disease: a randomized controlled trial. Oncologist 2011; 16:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/67\">",
"      Wagner LI, Cella D. Fatigue and cancer: causes, prevalence and treatment approaches. Br J Cancer 2004; 91:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/68\">",
"      Selman LE, Williams J, Simms V. A mixed-methods evaluation of complementary therapy services in palliative care: yoga and dance therapy. Eur J Cancer Care (Engl) 2012; 21:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/69\">",
"      McDonald A, Burjan E, Martin S. Yoga for patients and carers in a palliative day care setting. Int J Palliat Nurs 2006; 12:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/70\">",
"      Jacobsen PB, Donovan KA, Vadaparampil ST, Small BJ. Systematic review and meta-analysis of psychological and activity-based interventions for cancer-related fatigue. Health Psychol 2007; 26:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/71\">",
"      Bruera E, Yennurajalingam S. Challenge of managing cancer-related fatigue. J Clin Oncol 2010; 28:3671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/48/6922/abstract/72\">",
"      Yennurajalingam S, Bruera E. Palliative management of fatigue at the close of life: \"it feels like my body is just worn out\". JAMA 2007; 297:295.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14239 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-7DB0BEB7E6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_48_6922=[""].join("\n");
var outline_f6_48_6922=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29611194\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29611029\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29611044\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29611051\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4310459\">",
"      CAUSES AND PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29611072\">",
"      Anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29611086\">",
"      Polypharmacy including opioids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10228603\">",
"      Autonomic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10229820\">",
"      Hypogonadism in men with advanced cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4310935\">",
"      Role of inflammatory cytokines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29611093\">",
"      CLINICAL ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29611100\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29611107\">",
"      Treatment of anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29611114\">",
"      Symptom management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10228376\">",
"      - Pharmacologic approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H29611129\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H29611136\">",
"      Megestrol acetate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H29611151\">",
"      Psychostimulants",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H29611158\">",
"      - Methylphenidate",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H29611165\">",
"      - Modafinil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H29612223\">",
"      Testosterone replacement in hypogonadic males",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H29612230\">",
"      Complementary medicines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29611172\">",
"      - Nonpharmacologic approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H29611180\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H23013425\">",
"      Yoga",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H23013530\">",
"      Sleep hygiene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H29611187\">",
"      Behavioral and psychosocial interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29612237\">",
"      - Multimodal interventions for refractory fatigue",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29611194\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PALC/14239\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/14239|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/30/3567\" title=\"figure 1\">",
"      Edmonton symptom assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/14239|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/32/10763\" title=\"table 1\">",
"      NCI CTCAE grading scale for fatigue v4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/57/6046\" title=\"table 2\">",
"      Hospice provider rating of symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/51/18235\" title=\"table 3\">",
"      Contributors to fatigue in patients with advanced cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/38/4715\" title=\"table 4\">",
"      Cancer related fatigue initial workup",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/29/9692\" title=\"table 5\">",
"      Brief fatigue inventory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/13/17627\" title=\"table 6\">",
"      Assessment tools for fatigue in patients with serious illness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/30/33259\" title=\"table 7\">",
"      General approach to treatment of fatigue in palliative care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/44/8908\" title=\"table 8\">",
"      Good sleep hygiene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/47/17149\" title=\"table 9\">",
"      Energy conservation methods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/16/6413\" title=\"table 10\">",
"      Energy preservation methods",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44711?source=related_link\">",
"      Adjuvant immunotherapy for melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=related_link\">",
"      Anemia of chronic disease (anemia of chronic inflammation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9290?source=related_link\">",
"      Cancer pain management with opioids: Prevention and management of side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11242?source=related_link\">",
"      Cancer-related fatigue: Prevalence, screening and clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27098?source=related_link\">",
"      Cancer-related fatigue: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=related_link\">",
"      Causes of secondary hypogonadism in males",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30825?source=related_link\">",
"      Clinical features and diagnosis of chronic fatigue syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12824?source=related_link\">",
"      Clinical features and diagnosis of male hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/13/40154?source=related_link\">",
"      Complementary and alternative therapies for cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23896?source=related_link\">",
"      Darbepoetin alfa for the management of anemia in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/1/3098?source=related_link\">",
"      Hematologic manifestations of HIV infection: Anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=related_link\">",
"      Immunologic blood transfusion reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=related_link\">",
"      Iron overload syndromes other than hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/41/12951?source=related_link\">",
"      Mechanisms, causes, and evaluation of orthostatic and postprandial hypotension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5113?source=related_link\">",
"      Pharmacologic management of cancer anorexia/cachexia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/51/30521?source=related_link\">",
"      Prevention of adverse drug events in hospitals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=related_link\">",
"      Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=related_link\">",
"      Testosterone treatment of male hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42214?source=related_link\">",
"      Transfusion reactions caused by chemical and physical agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31175?source=related_link\">",
"      Transfusion transmitted HIV infection and AIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10471?source=related_link\">",
"      Transfusion transmitted bacterial infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37766?source=related_link\">",
"      Transfusion-associated immune and non immune-mediated hemolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/21/4440?source=related_link\">",
"      Treatment of chronic fatigue syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=related_link\">",
"      Treatment of insomnia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_48_6923="Environmental history of asthma";
var content_f6_48_6923=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59599&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59599&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Environmental history for the child with asthma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Passive tobacco smoke exposure (house, car, daycare)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Siblings and ages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wood-burning stoves and ventilation system",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Animals (dogs, cats, birds, furry pets); where animals reside and how often they are in the house or in the patient's bedroom",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leaky plumbing, recent flooding, obvious mold, mildew in any part of the house",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Method of heating, cooling; is there an evaporative cooler? window air conditioner?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patient's bedroom: type and age of mattress, bedding, window-coverings, flooring, dust-collecting items, stuffed animals and how often laundered",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_48_6923=[""].join("\n");
var outline_f6_48_6923=null;
var title_f6_48_6924="Differential diagnosis of FPIES";
var content_f6_48_6924=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F87565&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F87565&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of food protein-induced enterocolitis syndrome (FPIES)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Allergic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Food protein-induced proctocolitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Food protein-induced enteropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eosinophilic gastroenteropathies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anaphylaxis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Nonallergic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Infectious",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sepsis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Viral gastroenteritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bacterial enteritis (",
"        <em>",
"         Salmonella",
"        </em>",
"        ,",
"        <em>",
"         Shigella",
"        </em>",
"        ,",
"        <em>",
"         Campylobacter",
"        </em>",
"        ,",
"        <em>",
"         Yersinia",
"        </em>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Parasites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Gastrointestinal disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hirschsprung disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intussusception",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Volvulus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gastroesophageal reflux disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pyloric stenosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Metabolic disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neurologic disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Heart defects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Necrotizing enterocolitis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_48_6924=[""].join("\n");
var outline_f6_48_6924=null;
var title_f6_48_6925="Levels of IgG subclasses";
var content_f6_48_6925=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F50967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F50967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Levels of immunoglobulin G (IgG) subclasses in sera of normal subjects by age*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age, yr",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of subjects",
"       </td>",
"       <td class=\"subtitle1\">",
"        IgG",
"       </td>",
"       <td class=\"subtitle1\">",
"        IgG1",
"       </td>",
"       <td class=\"subtitle1\">",
"        IgG2",
"       </td>",
"       <td class=\"subtitle1\">",
"        IgG3",
"       </td>",
"       <td class=\"subtitle1\">",
"        IgG4",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0-1",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        420",
"        <sup>",
"         &Delta;",
"        </sup>",
"        (250-690)",
"       </td>",
"       <td>",
"        340 (190-620)",
"       </td>",
"       <td>",
"        59 (30-140)",
"       </td>",
"       <td>",
"        39 (9-62)",
"       </td>",
"       <td>",
"        19 (6-63)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1-2",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        470 (270-810)",
"       </td>",
"       <td>",
"        410 (230-710)",
"       </td>",
"       <td>",
"        68 (30-170)",
"       </td>",
"       <td>",
"        34 (11-98)",
"       </td>",
"       <td>",
"        13 (4-43)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2-3",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        540 (300-980)",
"       </td>",
"       <td>",
"        480 (280-830)",
"       </td>",
"       <td>",
"        98 (40-240)",
"       </td>",
"       <td>",
"        28 (6-130)",
"       </td>",
"       <td>",
"        18 (3-120)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3-4",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        600 (400-910)",
"       </td>",
"       <td>",
"        530 (350-790)",
"       </td>",
"       <td>",
"        120 (50-260)",
"       </td>",
"       <td>",
"        30 (9-98)",
"       </td>",
"       <td>",
"        32 (5-180)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4-6",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        660 (440-1000)",
"       </td>",
"       <td>",
"        540 (360-810)",
"       </td>",
"       <td>",
"        140 (60-310)",
"       </td>",
"       <td>",
"        39 (9-160)",
"       </td>",
"       <td>",
"        39 (9-160)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6-8",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        890 (560-1400)",
"       </td>",
"       <td>",
"        560 (280-1120)",
"       </td>",
"       <td>",
"        150 (30-630)",
"       </td>",
"       <td>",
"        48 (40-250)",
"       </td>",
"       <td>",
"        81 (11-620)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8-10",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        1000 (530-1900)",
"       </td>",
"       <td>",
"        690 (280-1740)",
"       </td>",
"       <td>",
"        210 (80-550)",
"       </td>",
"       <td>",
"        85 (22-320)",
"       </td>",
"       <td>",
"        42 (10-170)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10-13",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        910 (500-1660)",
"       </td>",
"       <td>",
"        590 (270-1290)",
"       </td>",
"       <td>",
"        240 (110-550)",
"       </td>",
"       <td>",
"        58 (13-250)",
"       </td>",
"       <td>",
"        60 (7-530)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13-16",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        910 (580-1450)",
"       </td>",
"       <td>",
"        540 (280-1020)",
"       </td>",
"       <td>",
"        210 (60-790)",
"       </td>",
"       <td>",
"        58 (14-240)",
"       </td>",
"       <td>",
"        60 (11-330)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Levels were determined by radial diffusion using monospecific antisera.",
"     <br>",
"      <sup>",
"       &bull;",
"      </sup>",
"      IgG4 levels appear to be absent in 10 percent of individuals.",
"      <br>",
"       <sup>",
"        &Delta;",
"       </sup>",
"       Geometric means are presented for each Ig at every age. The normal bounds, given in parentheses, are obtained by taking the mean logarithm, &plusmn; 2 standard deviations of the logarithms and then take the antilogs of the results.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Immunodeficiency Disorders- General Considerations. In: Immunologic disorders in infants and children, 5th edition, Stiehm, ER, Ochs, HD, Winkelstein, JA (Eds), Elsevier, Philadelphia 2004. Copyright &copy; 2004 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_48_6925=[""].join("\n");
var outline_f6_48_6925=null;
var title_f6_48_6926="Contents: Peds psychosocial emergencies";
var content_f6_48_6926=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Peds psychosocial emergencies",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Peds psychosocial emergencies",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/34/7718\">",
"           Child abuse: Anatomy and pathogenesis of retinal hemorrhages after abusive head trauma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/13/32985\">",
"           Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/19/40249\">",
"           Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/7/20602\">",
"           Child abuse: Eye findings in children with abusive head trauma (AHT)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/2/19497\">",
"           Child abuse: Injuries of the thorax; abdomen; retroperitoneum; and pelvis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/5/35927\">",
"           Child abuse: Social and medicolegal issues",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/62/18408\">",
"           Child neglect and emotional abuse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/27/23990\">",
"           Differential diagnosis of suspected child abuse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/23/11641\">",
"           Differential diagnosis of the orthopedic manifestations of child abuse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/11/38071\">",
"           Evaluation and management of suicidal behavior in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/27/35258\">",
"           Evaluation of sexual abuse in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/15/11510\">",
"           Management and sequelae of sexual abuse in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/16/36104\">",
"           Munchausen syndrome by proxy (medical child abuse)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/30/13802\">",
"           Orthopedic aspects of child abuse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/42/40617\">",
"           Peer violence and violence prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/19/24890\">",
"           Physical abuse in children: Diagnostic evaluation and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/54/26473\">",
"           Physical abuse in children: Epidemiology and clinical manifestations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/17/23834\">",
"           Suicidal behavior in children and adolescents: Epidemiology and risk factors",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-07B8947B9A-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f6_48_6926=[""].join("\n");
var outline_f6_48_6926=null;
var title_f6_48_6927="Contents: Lupus";
var content_f6_48_6927=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?3/39/3710\">",
"       Rheumatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Lupus",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Lupus",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Antiphospholipid antibody syndrome",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/29/35287\">",
"           Antiphospholipid syndrome and the kidney",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/31/23034\">",
"           Clinical manifestations of the antiphospholipid syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/29/27096\">",
"           Diagnosis of the antiphospholipid syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/0/44041\">",
"           Management of pregnant women with antiphospholipid antibodies or the antiphospholipid syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/2/41000\">",
"           Obstetrical manifestations of the antiphospholipid syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/16/35081\">",
"           Pathogenesis of the antiphospholipid syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/12/23754\">",
"           Treatment of the antiphospholipid syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Autoantibodies and diagnosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/10/1192\">",
"           Antibodies to double-stranded (ds)DNA, Sm, and U1 RNP",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/4/27718\">",
"           Antiribosomal P protein antibodies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/16/3338\">",
"           Diagnosis and differential diagnosis of systemic lupus erythematosus in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/29/27096\">",
"           Diagnosis of the antiphospholipid syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/43/5816\">",
"           Diagnostic approach to the neuropsychiatric manifestations of systemic lupus erythematosus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/54/28520\">",
"           Measurement and clinical significance of antinuclear antibodies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/44/42695\">",
"           Miscellaneous antinuclear antibodies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/2/41000\">",
"           Obstetrical manifestations of the antiphospholipid syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/23/8568\">",
"           The anti-Ro/SSA and anti-La/SSB antigen-antibody systems",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cutaneous manifestations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/61/6103\">",
"           Livedoid vasculopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/33/36378\">",
"           Mucocutaneous manifestations of systemic lupus erythematosus",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Drug-induced lupus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/32/28168\">",
"           Drug-induced lupus",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Miscellaneous manifestations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/23/37241\">",
"           Classification of and approach to the vasculitides in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/13/28889\">",
"           Coronary heart disease in systemic lupus erythematosus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/50/5928\">",
"           Gastrointestinal manifestations of systemic lupus erythematosus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/49/14106\">",
"           Hematologic manifestations of systemic lupus erythematosus in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/12/23753\">",
"           Musculoskeletal manifestations of systemic lupus erythematosus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/57/24474\">",
"           Neonatal lupus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/59/22456\">",
"           Non-coronary cardiac manifestations of systemic lupus erythematosus in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/31/41464\">",
"           Overview of the clinical manifestations of systemic lupus erythematosus in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/60/11210\">",
"           Pulmonary manifestations of systemic lupus erythematosus in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neuropsychiatric disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/43/5816\">",
"           Diagnostic approach to the neuropsychiatric manifestations of systemic lupus erythematosus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/11/33978\">",
"           Neurologic manifestations of systemic lupus erythematosus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/46/38631\">",
"           Neuropsychiatric manifestations of systemic lupus erythematosus",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Overlap syndromes",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/24/43401\">",
"           Clinical manifestations of mixed connective tissue disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/23/3447\">",
"           Definition and diagnosis of mixed connective tissue disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/61/42968\">",
"           Undifferentiated systemic rheumatic (connective tissue) diseases and overlap syndromes",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pathogenesis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/43/37562\">",
"           Epidemiology and pathogenesis of systemic lupus erythematosus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/16/35081\">",
"           Pathogenesis of the antiphospholipid syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pregnancy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/0/44041\">",
"           Management of pregnant women with antiphospholipid antibodies or the antiphospholipid syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/16/16646\">",
"           Menstrual function, menopause, and hormonal contraceptives in women with systemic lupus erythematosus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/57/24474\">",
"           Neonatal lupus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/2/41000\">",
"           Obstetrical manifestations of the antiphospholipid syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/45/39641\">",
"           Pregnancy in women with systemic lupus erythematosus",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Renal disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/29/35287\">",
"           Antiphospholipid syndrome and the kidney",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/12/44233\">",
"           Clinical features and therapy of membranous lupus nephritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/3/27706\">",
"           Diagnosis and classification of renal disease in systemic lupus erythematosus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/27/39352\">",
"           End-stage renal disease due to lupus nephritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/40/16008\">",
"           General principles of the use of cyclophosphamide in rheumatic and renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/37/37466\">",
"           Therapy of diffuse or focal proliferative lupus nephritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/3/12345\">",
"           Therapy of resistant or relapsing diffuse or focal proliferative lupus nephritis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/13/28889\">",
"           Coronary heart disease in systemic lupus erythematosus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/61/31703\">",
"           Determinants of glucocorticoid dosing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/40/16008\">",
"           General principles of the use of cyclophosphamide in rheumatic and renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/32/25098\">",
"           General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/47/27386\">",
"           Major side effects of systemic glucocorticoids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/0/44041\">",
"           Management of pregnant women with antiphospholipid antibodies or the antiphospholipid syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/50/2855\">",
"           Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/38/41578\">",
"           Overview of the therapy and prognosis of systemic lupus erythematosus in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/35/15929\">",
"           Preoperative evaluation and perioperative management of patients with rheumatic diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/37/37466\">",
"           Therapy of diffuse or focal proliferative lupus nephritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/12/23754\">",
"           Treatment of the antiphospholipid syndrome",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-DC2A45C7C4-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f6_48_6927=[""].join("\n");
var outline_f6_48_6927=null;
